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SUMMARY
Hepatic haem biosynthesis has been well characterised. The first 
enzyme of the haem biosynthetic pathway, 5-aminolaevulinic acid (ALA) 
synthase, is rate-limiting and under negative feedback control by 
haem. Liver is, however, a relatively minor site of haem synthesis as 
80% of haem is formed in the erythroid cells of the bone marrow.
Within developing erythroid cells haem is required both for its 
specific complexing with globin and for the coordinate regulation of 
erythroblast metabolism and differentiation. The study of erythroid 
haem synthesis has been hampered by the heterogeneous nature of the 
marrow cell population, the various differentiation stages of the 
erythroblast population, the small sample sizes available and the lack 
of sensitive enzyme assays. A variety of models and techniques have 
been used to study erythroid haem synthesis. Accordingly, the results 
have been inconclusive.
This work describes human bone marrow fractionation to provide 
four purified age-matched erythroblast cell populations. Myeloid 
(white) cells were removed from the sample by monoclonal antibody 
mediated cell lysis. The remaining cells were then fractionated by 
equilibrium density gradient centrifugation. These 'in vivo1 human 
erythroblasts were used to examine the effects of normal and abnormal 
erythroid differentiation on the first and last enzymes of the haem 
pathway, ALA synthase and ferrochelatase. A sensitive radiochemical 
assay for ALA synthase was adopted and improved. This was then used 
to examine the temperature-dependent inactivation of erythroid ALA 
synthase. A novel radiochemical assay for ferrochelatase was 
developed. Both assays utilise HPLC for isolation of the radioactive 
product and are capable of detecting picomoles of activity.
The pattern of ALA synthase and ferrochelatase activities during
(xxiii)
normoblastic erythropoiesis was established. ALA synthase activity 
was maximal in the most immature erythroid cells and diminished as the 
cells matured. Ferrochelatase activity was maximal in the 
intermediate erythroid cells. Hence, the development of enzyme 
activity appears to be sequential rather than simultaneous. On a 
quantitative basis, however, it is uncertain whether the development 
of ferrochelatase activity is limiting for haem formation.
The effects of iron and haem deficiency on haem enzyme activity 
were studied. In iron deficient erythroblasts ALA synthase activity 
was significantly reduced, particularly in the most immature erythroid 
cells. This enzyme reduction is likely to result from consequent haem 
deficiency rather than iron deficiency per se as an iron replete 
patient with haem deficiency associated with hepatoerythropoietic 
porphyria also showed reduced enzyme activity. This suggests that 
erythroid haem synthesis is controlled in a different manner to 
hepatic haem synthesis - a view compatible with the recent 
identification of specific genes and tissue-specific isoenzymes for 
ALA synthase.
ALA synthase and ferrochelatase activities were measured in 
patients with sideroblastic anaemia (SA). Haem synthesis is impaired 
in SA and ALA synthase is generally believed to be the site of the 
primary defect. ALA synthase activity was markedly impaired in 3 
patients with congenital SA (CSA) and 7 patients with primary acquired 
SA (PASA). One patient with secondary SA (SSA) demonstrated normal 
activity. Ferrochelatase activity was measured in six patients (1 
CSA, 5 PASA) and was found to be significantly reduced.
The latter 6 patients (1 CSA, 5 PASA) were treated with haem 
arginate in an attempt to correct the haem deficiency and to stimulate 
haem enzyme activity. Haem arginate was clinically ineffective (Hb
(xxiv)
levels did not change in any of the patients). However, the study 
demonstrated that exogenous haem is able to enter erythroblasts and 
influence haem enzyme activity. In two patients (1 CSA, 1 PASA), both 
ALA synthase and ferrochelatase activities returned to normal. This 
indicates a potential role for haem arginate in the treatment of 
haematological disorders other than SA which may respond to 
stimulated haem biosynthesis. The results also suggest that the 
primary abnormality in these cases of CSA and PASA is not ALA synthase 
(or ferrochelatase) deficiency. Furthermore, the stimulatory effect 
of exogenous haem on enzyme activity and the reduced ALA synthase 
activity in haem deficiency provide strong evidence of independent 
regulatory mechanisms for haem biosynthesis in erythroid and hepatic 
tissue.
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I INTRODUCTION
1.1 THE STRUCTURE AND PROPERTIES OF PORPHYRINS
The tetrapyrrolic porphyrin ring is a unique biological 
structure, the term "porphyrin" being taken from 
"haematoporphyrin" first used by Hoppe Seyler (1871) to 
describe the major constituent of an iron-free preparation of 
blood. Porphyrins and metalloporphyrins are found ubiquitously 
in nature and are used for many different biological functions.
Due to their complex ring structure and available ligand-
binding sites, porphyrins are capable of binding many metals. 
The most common metals bound are iron and magnesium to form 
haem and the chlorophylls respectively. Haem is central to all 
biological oxidations while chlorophylls are central to solar 
energy utilisation in the biosphere by harnessing the energy of 
the sun to the synthesis of carbohydrates and production of 
oxygen in green plants. The porphyrin structure of haem and 
chlorophyll was described by Hans Fischer who in 1930 was 
awarded the Nobel medal for unveiling the secrets of nature in 
showing that "despite her extravagant diversity she had been 
sufficiently economical to use the same building material when 
constructing two substances so greatly different in appearance 
and occurrence" (Soderbaum, 1930). This building material, 5- 
aminolaevulinic acid (ALA), a 5-carbon aminoketone, is the 
first intermediate in the porphyrin biosynthetic pathway.
The basic porphyrin nucleus consists of four pyrrole rings 
linked by four methylene bridges to form the macrocycle (Figure 
1). This represents a rigid planar structure to which eight 
side chains may be affixed at positions 1 to 8. It is the type 
of side chain which determines the physical characteristics of
1
the particular porphyrin in question. The four pyrrole rings 
are designated A, B, C and D and the four methylene bridges c < , 
)3 , 8  and 6 . The normal biological intermediate is not this 
highly conjugated biologically active compound, but the 
hexahydroporphyrin, the porphyrinogen, in which each methylene 
bridge is found in the reduced form. Porphyrinogens are 
colourless and unconjugated as compared with the conjugated and 
highly coloured porphyrins (for review of porphyrin chemistry 
see Smith, 1975).
Porphyrin nomenclature was developed by Fischer and the 
terminology employed has since been used widely (Figure 1). 
More recently the International Union of Pure and Applied 
Chemistry (IUPAC) and the International Union of Biochemistry 
(IUB) issued new recommendations concerning the nomenclature of 
tetrapyrroles (IUPAC-IUB Joint Commission of Biochemical 
Nomenclature, 1980) (Figure 1). Nevertheless, the traditional 
(Fischer) system remains the one used by principal workers in 
this field.
Porphyrins display a distinctive absorption spectrum 
allowing them to be readily identified in biological fluids or 
tissues. This spectrum consists of the Soret band, a major 
absorption band in the 400nm region, and four smaller 
absorption bands at longer wavelengths between 500nm and 630nm, 
with decreasing intensity towards the red. The Soret band 
generally has a 10-15 times greater absorption (molar 
extinction coefficient of 2-5x10^) than the next major band at 
500nm. With the formation of a porphyrin dication in aqueous 
HC1 or the formation of the metal complex of a porphyrin (Falk,
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1964; Williams, 1956) the four bands in the longer wavelength 
region are replaced by two bands known as c* and p  .
As metal-free porphyrins emit an intense red fluorescence 
upon excitation by long wavelength ultraviolet light (~400nm) 
spectrofluorometry provides a far more sensitive means of 
detecting porphyrins than visible light absorption 
spectrophotometry (Fuhrhop and Smith, 1975). Porphyrin 
chelates with those metals which have no unpaired electrons 
(e.g. Mg, Zn, Sn) also display strong fluorescence upon 
illumination with long wavelength ultraviolet light. Thus, 
while all free porphyrins and the porphyrin chelates with 
diamagnetic metals fluoresce, porphyrin chelates with 
paramagnetic metals do not fluoresce e.g. the Mg-porphyrin 
chelate chlorophyll, fluoresces, whereas iron-protoporphyrin IX 
i.e. haem, does not.
Although free porphyrins occur in nature in small 
quantities, no known function has been assigned to them. In 
contrast, haem, chlorophyll and corrin (which are Fe-, Mg- and 
Co- chelates of porphyrins or porphyrin derivatives 
respectively) carry out crucial biological functions.
THE BIOLOGICAL ROLE OF HAEM
Haem (ferroprotoporphyrin IX) (Figure 2) is the prosthetic 
group for many haemoproteins which serve important metabolic 
functions. These haemoproteins include myoglobin and 
haemoglobin (Hb) which carry out oxygen binding or transport; 
mitochondrial cytochromes a, a^, b, c and C3 , which are 
involved in electron transfer; microsomal cytochrome p450' 
which catalyzes mixed function oxidations; catalase, which
CH
4 4
CHCH
FIGURE 2
THE C Y C L I C A L  T E T R A P Y R R O L E  S T R U C T U R E  OF HAEM 
(FERROPROTOPORPHYRIN IX)
decomposes peroxidase, which activates and
tryptophan pyrrolase, which catalyzes the oxidation of 
tryptophan. Beyond its role in Hb production haem is also of 
central importance in erythropoiesis (i.e. red blood cell 
formation) by playing a major role in the regulation of 
erythroid cell metabolism (Sections 1.10, 1.11 and 1.12).
1.3 THE BIOSYNTHESIS OF HAEM
Haem biosynthesis occurs via an unbranched pathway 
consisting of a series of irreversible reactions (Figure 3). 
Each molecule of haem requires 8 moles of glycine and 8 moles 
of succinyl CoA and a total of 8 enzymes are involved in the 
biosynthetic process. The first enzyme, 5-aminolaevulinic acid 
(ALA) synthase, and the last three enzymes (coproporphyrinogen 
III oxidase, protoporphyrinogen III oxidase and ferrochelatase) 
are located within the mitochondria while the intermediate 
enzymes (ALA dehydratase, porphobilinogen deaminase, 
uroporphyrinogen III cosynthetase and uroporphyrinogen III 
decarboxylase) are located in the cytosol. The first 
intermediate of the pathway is 5-ALA, a 5-carbon aminoketone 
which is formed by the condensation of glycine activated by 
pyridoxal-5-phosphate (PLP) and succinyl CoA (Shemin and 
Russell, 1953). Two molecules of ALA are converted to 
porphobilinogen (PBG), which is a monopyrrole. PBG is, in 
turn, condensed to form porphyrins, consuming four PBG 
molecules per molecule of porphyrin. Uroporphyrinogen III is 
the first porphyrin formed, the side chains of which are then 
modified by a series of decarboxylation reactions to give
4
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FIGURE 3
THE PATHWAY OF HAEM BIOSYNTHESIS
protoporphyrinogen IX. Protoporphyrinogen IX is then rapidly
9+oxidised to protoporphyrin IX into which Fe is inserted to 
form haem.
The principal site of mammalian haem biosynthesis is in 
the erythroid cells of the bone marrow, with lesser sites of 
haem biosynthesis in the liver, spleen and lymph nodes. 
However, due to the biological importance of haem and its vital 
role in mitochondrial function, all cells must synthesise haem, 
the difference being only that of extent.
1.4 THE ENZYMES OF HAEM BIOSYNTHESIS
1.4.1 5-Aminolaevulinic Acid (ALA) Synthase (EC.2.3.1.37)
ALA synthase catalyzes the formation of ALA via the 
condensation of glycine and succinyl CoA in a reaction which 
requires PLP as cofactor (Shemin and Russell, 1953). Although 
this enzyme is known to be rate-controlling in hepatic haem 
biosynthesis (Section 1.8) its role in erythroid tissue is less 
certain. The study of this enzyme is of central importance to 
this work and as such, this step and ALA synthase measurement 
in erythroid tissue are discussed in depth in Chapter 3.
1.4.2 5-Aminolaevulinic Acid (ALA) Dehydratase (EC.4.2.1.24)
ALA dehydratase catalyzes the combination of two molecules 
of ALA to form porphobilinogen (PBG). This takes place in 
several stages (Shemin, 1976). Firstly, one molecule of ALA 
forms a Schiff base via combination of its keto group with an 
amino group of the enzyme. This ALA molecule then combines 
with a second ALA molecule as part of a Knorr reaction 
involving an intramolecular condensation of the carbanion of
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the Schiff base with the carboxyl group on the other ALA 
molecule with the loss of one water molecule (Nandi and Shemin, 
1968). The free amino grouping of the second ALA molecule 
displaces the amino group of the enzyme by transaldimination to 
form PBG. The ALA molecule initially bound to ALA dehydratase 
becomes the propionic acid substituent of PBG (Jordan and 
Seehra, 1980). The purified enzyme obtained from bovine liver 
and human erythrocytes is yellowish in colour and spectral 
analysis and kinetic studies suggest that PLP may be bound to 
the enzyme (Anderson and Desnick, 1979). PLP competitively 
inhibits human erythrocyte ALA dehydratase (Anderson and 
Desnick, 1979) but its precise role in the enzyme reaction is 
not known.
1.4.3 Porphobilinogen Deaminase (EC.4.3.1.8) and Uroporphyrinogen III 
Cosynthase (EC.4.2.1.75)
Although chemical condensation of four molecules of 
porphobilinogen (PBG) can yield four possible uroporphyrinogen 
isomers (Cookson and Rimington, 1954; Mauzerall, 1960) (Figure 
4), enzyme catalyzed reactions yield only type I and type III 
isomers of uroporphyrinogen. In the presence of PBG deaminase 
only uroporphyrinogen I is formed from PBG, whereas when both 
PBG deaminase and uroporphyrinogen III cosynthase are present 
uroporphyrinogen III is also formed. In the type III isomer 
one of the PBG molecules (ring D) is reversed (Figure 4) and it 
is only this structure that may proceed past the stage of 
coproporphyrinogen to form haem. PBG deaminase has frequently 
been referred to as uroporphyrinogen I synthase. However, the 
enzyme does not directly produce uroporphyrinogen, but first
6
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NOTE:
The only isomers found in nature are types I and III; and 
only isomer III can proceed to the formation of haem.
A = -CH2COOH; P = CH2 CH2 COOH.
FIGURE 4
TOE FOUR ISOMERS OF UROPORPHYRINOGEN
forms a s t r a i g h t  chain tetrapyrrole intermediate, 
hydroxymethylbilane (Battersby et al, 1979; 1979).
The way in which PBG deaminase and uroporphyrinogen III 
cosynthase interact in the assembly of uroporphyrinogens has 
been one of the most puzzling problems in the biochemistry of
1 o
this field. It has been shown using JC nuclear magnetic
l ^resonance spectroscopy and specifically labelled [-LJC]-PBG 
(Battersby et al, 1976) that PBG deaminase catalyzes the head 
to tail joining of four PBG molecules to create a linear 
tetrapyrrole with the release of four molecules of ammonia. In 
the absence of uroporphyrinogen III cosynthase this product is 
released from the enzyme as hydroxymethylbilane, which then 
cyclizes spontaneously to form uroporphyrinogen I. In the 
presence of the cosynthase as well as the deaminase, the 
h y d r o x y m e t h y l b i l a n e  is r a p i d l y  t r a n s f o r m e d  into 
uroporphyrinogen III (Levin, 1968). Rearrangement of ring D to 
form the asymmetrical uroporphyrinogen III occurs after 
formation of the linear tetrapyrrole just prior to closure of 
the macrocycle ring. A dipyrromethane resident at the enzyme 
active site provides the attachment site for the covalent 
binding of the substrate (Jordan and Warren, 1987; Warren and 
Jordan 1988a). An association or complex of the deaminase and 
cosynthase molecules accounts for the rapid enzymatic formation 
of uroporphyrinogen III (Frydman and Feinstein, 1974; Higuchi 
and Bogorad, 1975; Rossetti et al, 1980).
1.4.4 Uroporphyrinogen Decarboxylase (EC.4.1.1.37)
At this stage the basic porphyrin structure has been 
produced and all that remains prior to iron insertion is a
7
series of decarboxylations and oxidations to form the 
protoporphyrin nucleus. Uroporphyrin decarboxylase catalyzes 
the sequential removal of the four carboxyl groups of the 
acetic acid side chains in uroporphyrinogen to yield 
coproporphyrinogen (Granick and Mauzerall, 1958). The enzyme 
decar boxy lates all four isomers of uroporphyrinogen, but the 
naturally most abundant type III isomer is decarboxylated most 
rapidly, followed by types IV, II and I in decreasing order 
(Granick and Mauzerall, 1958; Cornford, 1964; Smith and 
Francis, 1979). There is no evidence that there is more than 
one enzyme for the four successive decarboxylation steps 
(Elder and Tovey, 1977; De Verneuil et al, 1978). In fact, the 
reaction catalyzed by uroporphyrinogen decarboxylase yields 
fro m  u r o p o r p h y r i n o g e n ,  hepta-, hexa-, p enta- and 
tetracarboxylate porphyrinogens.
1.4.5 Goproporphyrinogen Oxidase (EC.1.3.3.3)
Coproporphyrinogen oxidase removes the carboxyl group and 
two hydrogens from the propionic acid groups of pyrrole rings A 
and B of coproporphyrinogen to form vinyl groups at these 
positions. The reaction therefore yields a divinyl compound, 
protoporphyrinogen IX (Granick and Mauzerall, 1958). The 
enzyme requires molecular oxygen for activity and can act on 
isomers III and IV of coproporphyrinogen, but not on types I or 
II (Sano and Granick, 1961; Batlle et al, 1965; Porra and Falk, 
1964). Decarboxylation proceeds only at the jS-carbon atom of 
the propionate side chains, with a stereospecific loss of one 
hydrogen atom (Zaman et al, 1972; Battersby et al, 1972). The
8
reaction involves removal of a hydride ion with simultaneous 
decarboxylation, yielding yfi-hydroxypropionate as an 
intermediate (Sano, 1966). Studies using a chemically modified 
coproporphyrinogen oxidase or synthetic porphyrin substrates 
have suggested (Yoshinaga and Sano, 1980) the involvement of a 
tyrosine residue at the active site and that formation of a 
vinyl group from a /3-hydroxypropionate side chain is faster at 
position 2 than position 4. An intermediate 3-carboxylate 
porphyrinogen formed in the decarboxylation of hydroxypropionic 
porphyrin to protoporphyrin IX has been isolated by HPLC and 
characterised by mass spectroscopy as harderoporphyrinogen. 
The corresponding porphyrin was originally isolated from the 
Harderian gland of rodents (Jackson et al, 1980).
1.4.6 Protoporphyrinogen Oxidase (EC.1.3.3.4)
The penultimate step in the haem biosynthetic pathway is 
the oxidation of protoporphyrinogen IX. Although chemical 
oxidation of protoporphyrinogen to protoporphyrin occurs 
rapidly at neutral pH, this does not happen normally in cells. 
The existence of protoporphyrinogen oxidase was suggested from 
indirect observations, but it was the partial purification of 
this enzyme (Poulson and Polglase, 1975) that confirmed its 
existence.
In the conversion of protoporphyrinogen to protoporphyrin 
IX, six electrons are removed with molecular oxygen as the 
electron acceptor (Poulson and Polglase, 1975; Poulson, 1976). 
The enzyme exhibits relatively high substrate specificity since 
it will only use mesoporphyrinogen IX, protoporphyrinogen XIII 
and 2(4) vinyl-4 (2) hydroxyethyl deuteroporphyrinogen, although
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at lower rates than protoporphyrinogen IX (Jackson et al, 1978; 
Poulson and Polglase, 1975). Coproporphyrinogen I and III and 
uroporphyrinogen I and III are not substrates.
There is currently insufficient data to postulate a model 
for catalysis or substrate binding. Since the enzyme uses only 
protoporphyrinogen and mesoporphyrinogen IX, it is likely that 
the enzyme binding site for porphyrinogen recognises not only 
the vinyl groups at positions 2 and 4 on the A and B ring, but 
also the propionates at positions 6 and 7 on the C and D ring 
(Dailey, 1989). Those features involved in actual catalysis 
remain unknown, although the possibility of a protein tyrosyl 
residue involvement as with coproporphyrinogen oxidase has been 
proposed (Yoshinaga and Sano, 1980b).
1.4.7 Ferrochelatase (Protohaem Ferrolyase; Haem Synthetase) 
(EC.4.99.1.1)
Ferrochelatase catalyzes the final step in the haem 
biosynthetic pathway i.e. the insertion of iron into 
protoporphyrin IX to form haem with the loss of two protons 
(Goldberg et a l , 1956). The study of this enzyme is fraught 
with difficulties and constitutes one of the major topics of 
the work described in this thesis. Its role in haem 
biosynthesis is examined in depth in Chapter 4. Chapter 5 then 
describes the stepwise development of a novel highly sensitive 
radiochemical assay suitable for the measurement of erythroid 
ferrochelatase activity in the small sample sizes available 
from human erythroid tissue.
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1.5 AIA FORMATION VIA A  PATHWAY NOT INVOLVING GLYCINE AND SUCCINYL 
CoA
With few exceptions, ALA synthase activity has not been 
found in plant cells. Instead, the incorporation of [-*-4C]- 
glutamate or ©< -ketoglutarate into AIA has been shown to occur 
(Beale and Castelfranco, 1974). In this reaction C-l of 
glutamate becomes C-5 of ALA via the formation of an 
intermediate, 5 -6 -dioxovalerate (DOVA) (Beale et al, 1975). 
Transamination of DOVA to AIA then occurs as has been shown in 
Chlorella (Gassman et al, 1968), bean leaves (Gassman et al, 
1966) and R. spheroides (Neuberger and Turner, 1963). It is 
uncertain whether chlorophyll formation is exclusively 
associated with the DOVA pathway (Porra and Grimme, 1978) since 
in green algae both the classical AIA synthase reaction and the 
DOVA pathway have been demonstrated (Klein et al, 1980).
A reaction similar to that catalyzed by DOVA transaminase 
has also been found in mammalian cells (Varticovski et al, 
1980). Total DOVA transaminase activity was much greater than 
that of ALA synthase in bovine liver, suggesting that this 
enzyme may also have a role in ALA formation in mammalian 
cells. DOVA transaminase in mammalian liver and kidney is 
associated with alanine: glyoxylate transaminase activity 
(Noguchi and Mori, 1981). The activity of the latter is much 
greater than the former and the reaction favours glycine 
formation.
The role of DOVA transaminase in the regulation of haem 
formation in animal tissues remains to be elucidated but it is 
unlikely that this pathway has any direct role in mammalian 
haem biosynthesis.
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1.6 THE ENZYMES OF HAEM BIODEGRADATION
1.6.1 Haem Oxygenase (EC.1.14.99.3)
The catabolic sequence of haem degradation starts with the 
reductive breakdown of the haem macrocycle (Figure 5). The 
cycle is most open to oxidative attack at the carbon bridges 
linking the pyrrole rings, resulting in the formation of linear 
tetrapyrroles, referred to collectively as the bile pigments or 
biliverdins (Heirwegh and Brown, 1982). Since there are four 
different ring positions -cx, f t , and 6 - at which the haem 
ring may be cleaved, haem oxygenase can potentially produce 
four biliverdins (O'Carra, 1975; Tenhunen, 1976). However, 
the reaction is specific for one position i.e. cleavage 
between rings A and B to produce biliverdin IXcx (Frydman et 
al, 1981). The haem oxygenase reaction requires NADPH and 
oxygen and produces biliverdin and carbon monoxide. Either 
NADPH cytochrome c reductase or NADPH cytochrome P ^ q  reductase 
is also required and protohaem IX is the best enzyme substrate. 
In the intact cell, haem must be proteolytically split from its 
associated haemoproteins before it may be metabolised (Berk et 
al, 1974). Haem oxygenase is rate-controlling for haem 
degradation. Carbon monoxide inhibits the enzyme as does light 
of wavelength 450-470nm. Studies which have shown enzyme 
induction with cobalt and other metal ions suggest that the 
enzyme has a sulphydry 1-active regulatory component (Maines and 
Kappas, 1974; 1976; Maines, 1981; Maines et al, 1982).
1.6.2 Biliverdin Reductase (EC.1.3.1.24)
No biological role has been found for the biliverdin 
produced by haem oxygenase. Mammals transform this harmless
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compound, which is readily disposable, into the toxic and 
highly insoluble compound bilirubin by a reductive reaction 
requiring NADPH and catalyzed by biliverdin reductase. This 
compound is then conjugated with glucuronic acid to form more 
soluble bilirubin glucuronides. These are excreted in bile 
into the intestines and thereafter in the faeces, normally 
following transformation to mesobilirubinogen, stercobilinogen, 
stercobilin and urobilin (O'Carra, 1975). Bilirubin may also 
be oxidised to dipyrroles by a mitochondrial enzyme bilirubin 
oxidase, the importance of which remains to be assessed (Brown 
and Troxler, 1982).
1.7 DISORDERS OF PORPHYRIN METABOLISM 
The Porphyrias
The porphyrias are inherited and acquired disorders in 
which there are partial defects in the haem enzymes. They are 
classified as either hepatic or erythroid in origin depending 
on the principal site of expression of the gene defect (for 
review see Kappas et al, 1982). In all of the inherited human 
porphyrias, environmental factors play a vital role in 
determining clinical expression of the gene abnormality. The 
porphyrias are characterised by defects in specific haem 
enzymes; increased accumulation and excretion of chemical 
intermediates, and a variety of clinical manifestations among 
which neurological abnormalities and cutaneous photosensitivity 
dominate. There are certain naturally occurring animal 
porphyrias of genetic origin as well as experimental porphyrias 
that can be induced 'in vivo 1 by a variety of chemicals in 
normal animals and 'in vitro' in certain tissue preparations,
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such as cultured liver cells. These animals and experimental 
models of the porphyrias have provided important insights into 
the regulatory mechanisms by which cellular porphyrin and haem 
metabolism are controlled. Indeed, in few other categories of 
metabolic and genetic disorders has there been such a close 
parallel between the human condition and the laboratory model 
nor such direct relevance of information obtained from 
experimental systems to the pathogenesis and therapy of the 
human disease.
1.7.1 Congenital Erythropoietic Porphyria (CEP)
This autosomal recessive disorder is extremely rare. Ihe 
porphyrins which are overproduced are primarily of the type 1 
series with the genetic defect most probably being a deficiency 
of uroporphyrinogen III cosynthase.
CEP is the most striking of the porphyrias in terms of the 
marked severity of cutaneous photosensitivity and scarring 
which it may produce. Anaemia due to haemolysis may occur 
which serves as a further stimulus for increased porphyrin 
production in the bone marrow. Avoidance of sunlight, 
hypertransfusion (Piomelli et al, 1986) and treatment of 
secondary infections of the skin are important in the 
management of the disease.
1.7.2 Erythropoietic Protoporphyria (EPP)
EPP is an autosomal dominant disorder due to a deficiency 
of ferrochelatase. The disease is characterised by mild to 
moderate photosensitivity, but unlike CEP haemolytic anaemia is 
insignificant (Turnbull et al, 1973). Excess protoporphyrin is
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found in erythroid cells, plasma, bile and faeces. Progressive 
hepatic damage associated with marked protoporphyrin deposition 
in the liver is a severe and often fatal complication. Gene 
expression at the clinical level is highly variable, such that 
some carriers of the genetic defect have normal red cell 
porphyrin levels and no photosensitivity. Avoidance of 
sunlight is important in the prevention of cutaneous symptoms.
1.7.3 Acute Intermittent Porphyria (AIP)
This hepatic porphyria is inherited in an autosomal 
dominant fashion and is characterised by a deficiency of 
porphobilinogen (PBG) deaminase activity. PBG deaminase 
activity is approximately 50% of normal in all tissues examined 
(i.e. red blood cells, skin, cultured fibroblasts, mitogen- 
stimulated lymphocytes, amniotic cells and liver). Porphyrin 
overproduction is relatively minor and hence there is no 
photosensitivity. AIP is latent before puberty and the degree 
of clinical expression after puberty is variable despite the 
fact that PBG deaminase deficiency is the same in latent and 
expressed AIP. The clinical syndrome is most frequent in 
females. Hormonal, drug and nutritional factors predispose to 
full expression of the disease probably by inducing hepatic 
ALA synthase. Ninety per cent of individuals who inherit the 
gene defect for AIP remain clinically latent throughout adult 
life. Subtle endocrine abnormalities, including a demonstrated 
deficiency of hepatic steroid 5 cx-reductase activity in 
clinically expressed AIP, may underly disease expression in the 
10% of AIP gene carriers who develop clinical symptoms. The 
symptoms of AIP are largely neurovisceral in character and may
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be due to pharmacologic effects of porphyrin precursors on 
nervous tissue. Clinical management includes symptomatic 
therapy during acute attacks, a high carbohydrate intake, 
intravenous glucose, prevention of exposure to harmful drugs, 
and screening of family members to detect gene carriers of AIP. 
Haematin may be administered during the acute attack to reduce 
hepatic ALA synthase activity but there is no statistical 
evidence of its clinical efficacy in this disorder.
1.7.4 Hereditary Coproporphyria (HCP)
HCP is a milder disorder than AIP, but may cause similar 
neurovisceral symptoms. It is associated with overproduction 
of coproporphyrinogen III and excretion of the porphyrin 
precursors ALA and PBG. The genetic defect of HCP is reflected 
in a 50% deficiency of coproporphyrinogen III oxidase inherited 
as an autosomal dominant trait. Clinical expression of HCP as 
with AIP is dependent upon metabolic, chemical and 
environmental factors with clinical management similar to that 
for AIP. In HCP, coproporphyrinogen III accumulates in the 
liver and is also found in plasma and skin accounting for the 
photosensitivity observed in some patients.
1.7.5 Variegate Porphyria (VP)
VP has been recognised in many populations but is most 
common in South African whites. Inheritance is autosomal 
dominant and the underlying genetic defect causes a deficiency 
in the activity of either protoporphyrinogen oxidase or 
ferrochelatase. As is the case in AIP and HCP, hormones, drugs 
and metabolic factors influence clinical expression of the gene
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defect. C l i n i c a l l y  expressed VP is characterised by 
neurovisceral symptoms as in AIP. Photosensitivity due to the 
accumulation of porphyrins in plasma and skin is more common 
than in HCP. Clinical management is similar to that for AIP 
and HCP.
1.7.6 Porphyria Cutanea Tarda (PCT)
PCT is the most common form of porphyria. It usually 
begins in middle or late adult life with males affected most 
frequently. Patients with PCT have mild to severe 
photosensitivity and often liver disease. Alcohol, oestrogens 
and hepatic siderosis are predisposing factors. A deficiency 
of hepatic uroporphyrinogen (URO) decarboxylase activity 
characterises all cases of PCT. In PCT patients with the less 
common genetic (familial) form of this disease, the enzyme 
deficiency can also be demonstrated in erythrocytes, 
lymphocytes and cultured skin fibroblasts. This form of PCT is 
autosomal dominant. In most cases of PCT there is no family 
history of the disease (sporadic). Some studies have suggested 
that there is an inherited URO decarboxylase defect expressed 
in red cells as well as hepatic cells in all PCT patients, 
while others have reported that patients with sporadic PCT have 
abnormal enzyme activity only in the liver. The deficiency of 
hepatic URO decarboxylase in PCT results in a complex pattern 
of porphyrin excretion which includes excess production of the 
isocoproporphyrin series, a distinctive feature of this 
disease.
A second type of porphyria, believed to be related to PCT, 
has been termed "hepatoerythropoietic porphyria". Only 15
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cases have been reported in the world literature to date and 
HEP is thought to represent a homozygous form of familial PCT 
(see Chapter 7).
1.8 THE REGULATION OF HEPATIC HAEM BIOSYNTHESIS
Hepatic haem synthesis has been well characterised, 
facilitated by the homogeneous nature of hepatic tissue and the 
detailed study of the porphyrias. However, liver is a 
r e l a t i v e l y  minor site of haem biosynthesis producing 
approximately 15% of total body haem (Granick and Sassa, 1971; 
Hutton and Gross, 1970) with the remainder produced in the bone 
marrow (Jones et al, 1971; Berk et al, 1976). Hepatic haem is 
utilised as the prosthetic group for a number of apoproteins 
including mitochondrial cytochromes (16%), catalase (16%), 
cytochrome P 4 5 0  (50%), cytochrome B 5 (16%) and tryptophan 
pyrrolase (5%) (Badaway, 1979; Marver and Schmid, 1972). Many 
of these haemoproteins undergo rapid turnover thereby 
necessitating a continuous high rate of hepatic haem synthesis. 
The ability of the liver to rapidly synthesise haem is 
particularly dramatised by cytochrome P4 5 0 which is of critical 
importance in the detoxification and biotransformation of many 
drugs and chemicals. Thus, in liver cells, control of haem 
synthesis must be finely regulated in order to cope with 
insidious adverse changes in the environment.
Control of hepatic haem synthesis occurs at the first step 
of the haem biosynthetic pathway i.e. the condensation of 
succinyl CoA and glycine to form ALA catalyzed by ALA synthase 
(Granick and Urata, 1963; Granick and Beale, 1978; Meyer and
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Schmid, 1978; Tait, 1978). Under basal conditions, hepatocyte 
ALA synthase activity is low but sufficient to maintain an 
adequate supply of microsomal haem (Hutton and Gross, 1970; 
Sassa and Kappas, 1981). Many compounds can induce ALA 
synthase activity in avian and mammalian liver including 
various lipophilic chemicals and drugs and some natural and 
synthetic steroids (Granick, 1966). For example, certain 
chemicals such as 2-allyl-2-isopropylacetamide (AIA) (De 
Matteis, 1970; 1971; 1978) destroy cytochrome P 4 5 0 haem, 
leading to the accumulation of abnormal "green" pigments in the 
liver; 3,5-diethoxycarbonyl-l,4-dihydrocollidine (DDC) or 
griseofulvin cause a rapid inhibition of ferrochelatase (De 
Matteis et al, 1973; Rifkind, 1979; Anderson, 1978) leading to 
decreased haem formation; while phenobarbital reduces the 
concentration of regulatory "free" haem (in the range 
10“®-10“^M) by increased synthesis of apocytochrome (Baron
and Tephly, 1970; Rajamanickam et a l , 1975). Experimental 
depletion of haem by these methods causes ALA synthase 
induction, while conversely, excess cellular haem inhibits 
hepatic ALA synthase activity. Enzyme regulation by haem is 
achieved in several different ways:-
(1) Direct inhibition of ALA synthase activity (Tait, 1978)
(2) Inhibition of mRNA synthesis for ALA synthase (Whiting, 1976)
(3) Inhibition at a post-transcriptional step (Sassa and Granick, 
1970)
(4) Inhibition of the enzyme transfer from the cytosol to the 
mitochondrial inner membrane (Hayashi et al, 1972)
The concept of a regulatory haem pool (O.lpM) was first 
suggested by Granick et al (1975) and its existence is now
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generally accepted. This haem pool has two major regulatory 
effects, each of which results in a net decrease of its 
concentration. One effect is inhibition of functional 
mitochondrial ALA synthase and the other is induction of haem 
oxygenase. ALA synthase and haem oxygenase therefore exhibit a 
reciprocal relationship in hepatic tissue.
Haem synthesis may also be affected by other factors, for 
example, the rate of ALA formation may be limited by lack of 
substrate or cofactor. ALA synthase has a high Km value for 
glycine and experimental depletion of hepatic glycine reduces 
the effect of ALA synthase (Tephly et a l , 1973). Enzyme 
activity may also be decreased by pyridoxine deficiency or 
inhibitors of pyridoxine metabolism because PLP is an 
essential cofactor for ALA synthase activity (Shemin and 
Russell, 1953).
1.9 THE ROLE OF HAEM IN HAEM BIODEGRADATION
Multiple factors influence haem catabolism, including 
haem, Hb, sex steroids, heavy metals, hormones and drugs 
(Pimstone et al, 1971; Tenhunen et al, 1970? 1984; Gemsa et al, 
1973? Kikuchi and Yoshida, 1983; Bakken et al, 1972). Induction 
of haem oxygenase by haem or Hb has been reported in 
macrophages, the arachnoid and choroid plexes of the brain, the 
kidney and the liver. Spleen has the highest activity, 
followed by bone marrow then liver (Tenhunen et al, 1970).
The inter-relationship between hepatic haem synthesis and 
catabolism has never been fully elucidated, although studies 
have shown reciprocal oscillations in hepatic ALA synthase and
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haem oxygenase in vivo following intravenous haem 
administration (Schacter et al, 1976). This is explained as an 
initial repression of ALA synthase mRNA by haemin, then a 
succeeding induction of haem oxygenase followed by decreased 
cellular haem and derepression of ALA synthase (Bissell and 
Hammaker, 1976; Ibraham et al, 1979).
The effect of haem on haem oxygenase activity in other
tissues, such as haemopoietic bone marrow cells, remain 
uncertain.
1.10 ERYTHROPOIETIC HAEM BIOSYNTHESIS
Less extensive investigations have characterised haem 
biosynthesis in erythropoietic tissue as contrasted with the 
liver. Many mysteries therefore remain with regard to our 
understanding of bone marrow erythroid haem synthesis, yet it 
is the major haem-forming tissue (Berk et a l , 1976)
synthesising 80% of total body haem. The principal
difficulties which have hampered the study of haem biosynthetic 
and degradative pathways in the immature erythron are the 
association of bone marrow erythroid cells with a variety of 
other cells; the dynamic state of red cell precursors as a 
continuously developing tissue; the various stages of 
differentiation and the lack of sensitive specific enzyme 
assays. It is, however, thought that the regulation of haem 
synthesis is closely linked to erythropoiesis and may be 
different from that in liver.
1.10.1 Erythropoiesis
Mature erythrocytes arise from a series of differentiation
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and maturation steps starting from the pluripotent stem cell 
(Figure 6 ). The pluripotent stem cell has the capacity for 
self replication as well as for differentiation into 
granulocyte, monocyte, platelet or erythroid cell lines. The 
most striking molecular event during erythroid differentiation 
is the accumulation of Hb. While other proteins accumulate 
progressively, e.g. catalase, the haem enzymes accumulate 
during early maturation and diminish progressively (Freshney 
and Paul, 1972). The loss of nuclear material and mitochondria 
occurs late in the maturation sequence just prior to 
reticulocyte formation. The study of morphologically 
recognisable marrow erythroid progenitors has provided much 
information about the terminal steps of both normal and 
disordered erythropoiesis and the associated haem synthesis. 
However, early differentiation and maturation events occur in 
cells which are not morphologically identifiable and this has 
been a major limitation with regard to gaining a full 
understanding of the earliest events in erythropoiesis. We are 
still to a large extent in the dark regarding the control, 
organisation and sequence of biological change responsible for 
the conversion of the round nucleated haematopoietic stem cell 
to the mature anucleate disc-shaped erythrocyte.
1.10.2 Systems Available for the Study of Erythropoiesis
Workers have employed a variety of techniques and models 
to study erythropoietic haem synthesis. The range of cells and 
tissues is wide and includes chick blastoderm (Levere and 
Granick, 1965), foetal mouse liver (Freshney and Paul, 1971),
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Figure 6 depicts the erythron and maturation and 
amplification of the red cell series. Pluripotent stem 
cells are recruited into the pool of committed 
erythropoietin-responsive stem cells. Under the stimulus 
of erythropoietin and other factors (Section 1.11.1) 
committed cells differentiate into proerythroblasts. 
Normal maturation occurs by four mitotic divisions during 
which the proerythroblast matures to the reticulocyte, 
passing through three stages: the basophilic (early) 
erythroblast, polychromatophilic erythroblasts 1 and 2 
(intermediate), and the orthochromatic (late) erythroblast 
which by ejection of its nucleus emerges as a 
reticulocyte. Amplification results from maturational 
divisions with each e r y t h r o b l a s t  p r o d u c i n g  16 
reticulocytes in a process lasting 72 hours. In the 
ensuing 48 hours, the circulating reticulocyte matures 
into an erythrocyte. Ineffective erythropoiesis, with 
failure of erythroblast maturation and intramedullary cell 
destruction, and accelerated erythropoiesis, with skipped 
maturational divisions are also depicted.
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erythroid leukaemia cell lines, FEL (Sassa, 1976; Beaumont et 
al, 1984) and K562 cells (Hoffman et al, 1980), rabbit (Ponka 
and Schulman, 1985) and human reticulocytes (Gardner and Cox, 
1988) and 'in vitro' bone marrow cultures (Ibrahim et al, 
1982). However, techniques recently developed now allow the 
study of purified, age matched human bone marrow erythroid 
cells (Section VI).
Functional 'in vivo' and 'in vitro' progenitor cell 
assays, erythroid marrow cultures and established erythroid 
cell lines have permitted the study of early differentiation 
steps and have proved useful in the study of haem synthesis.
Progenitor Cell Assays 
(1) 'In Vivo' Systems
'In vivo' systems invo l v e  manipulation of intact 
experimental animals with drugs, radiation, bleeding or 
hyper transfusion. This is followed by 'in vitro' erythroid 
progenitor cell assays to assess the commitment of tripotent 
marrow stem cells to erythroid development. The erythroid 
burst forming units (BFU-E) develop from the stem cells and 
then mature further to cells from which the erythroid colony 
forming units (CFCJ-E) develop.
The original 'in vivo' assay for progenitors capable of 
giving rise to differentiated haematopoietic cells was the 
spleen colony-forming assay (Till and McCulloch, 1961). When 
normal mouse marrow cells were injected intravenously into 
lethal ly-irradiated syngeneic hosts, macroscopic colonies of 
haematopoietic cells appeared in the spleens of the recipients 
by 10-14 days. Irradiated animals, not rescued by marrow
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cells, died of haematopoietic failure. It was later 
demonstrated that these complex colonies, which contained all 
of the usual elements found in the blood, arose from a single 
multipotent progenitor termed the spleen colony-forming unit 
(CFU-S) (Becker et al, 1963). Successful 'in vitro1 growth of 
specific murine erythroid colonies (Stephenson et al, 1971) 
required the addition of various factors. This was later 
extended to human erythroid cultures to provide comparable 
information.
(ii) 'In Vitro1 Assays
'In vitro' assays are of two types. The usual assay 
involves cultures of haematopoietic tissues in semi-solid media 
containing methylcellulose (Iscove et al, 1974) or in plasma 
clots (McLeod et al, 1974). These assays provide conditions 
which allow terminal differentiation of cells already committed 
to differentiation rather than a l l o w  initiation of 
differentiation in the multipotent stem cell. The phenotype of 
the erythroid progenitor is "fixed" at the stage of maturation 
at which they existed in the marrow or peripheral blood when 
they were removed for culture.
A second type of 'in vitro' assay, a continuous liquid 
culture method, depends upon an adherent cell matrix (Eastment 
et al, 1982) and permits a measure of number, replication and 
maturation of even earlier progenitors. This system developed 
by Dexter and associates (Dexter and Lajtha, 1974; Testa and 
Dexter, 1977) is useful in studies of murine erythroid 
maturation.
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Erythroid Cell Lines/Cultures
(i) Friend Erythroleukaemia (FEL) Cells
Friend leukaemia virus-infected erythroid precursor (FEL) 
cells are an immortalised cell line of mouse origin which grow 
in suspension culture as undifferentiated haemocytoblasts, but 
undergo erythroid differentiation when treated with 
dime thy lsulphoxide, (DMSO) (Friend et al, 1971), other aprotic 
solvents (Sassa et al, 1975; Tanaka et al, 1975), butyric acid 
(Leder and Leder, 1975) or haem (Friend et a l , 1971). DMSO- 
treated FEL cells show the characteristics of erythroid cells 
as judged by the histochemical staining of Hb in the cytoplasm 
(Friend et al, 1971), the incorporation of -^Fe into haem 
(Friend et al, 1971), the fluorometric quantitation of haem 
(Sassa et al, 1975), the absorption spectra of the cell extract 
(Friend et a l , 1971) and the characteristic electrophoretic 
migration pattern of mouse Hb on polyacrylamide gels (Scher et 
al, 1971). DMSO-treated FEL cells form a mouse erythrocyte 
membrane antigen by the 4th day of culture (Sugano et al, 1973) 
and become agglutinable with phytohaemagglutin (Fujinami et al, 
1973). These murine erythroleukaemia cells thus represent a 
useful model of erythroid differentiation in tissue culture 
which cannot be achieved using cells of normal haematopoietic 
origin.
There is, however, a serious limitation to the use of FEL 
cells as a model of normal erythroid differentiation. In 
nonerythroid cells, transferrin receptors are correlated with 
cell proliferation (Larrick and Creswell, 1979; Sutherland et 
al, 1981; Trowbridge and Omary, 1981). Cultured transformed 
cells (Neckers, 1984) and malignant cells 'in vivo1 (Faulk et
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al, 1980; Aulbert et al, 1980) have high numbers of transferrin 
receptors. Furthermore, malignant cells contain high levels of 
ferritin (Drysdale et al, 1977) which probably results from an 
increase in transferrin-receptor-mediated iron uptake. 
Therefore, the basal level of iron transport and the amount of 
iron stored in uninduced FEL cells may be considerably higher 
than that found in the normal physiological equivalent.
(ii) K562 Cells
K562 cells are often referred to as the human equivalent 
of FEL cells (Schulman et al, 1981; Frazier et al, 1982; 
Klausner et al, 1983). Most of the iron taken up by these 
cells is incorporated into ferritin and only 1 0 % is recovered 
in haem (Schulman et al, 1981). Although K562 cells are 
inducible for Hb synthesis with haemin they are ill-defined 
cells originating from a patient with chronic myeloid leukaemia 
(Lozzio and Lozzio, 1975). Moreover, Hb production following 
haemin addition is entirely of embryonic or foetal types 
(Rutherford et al, 1979) and ALA dehydratase induced in K562 
cells is immunologically distinct from the enzyme of normal 
adult or foetal erythrocytes (Chang and Sassa, 1985). K562
cells are not therefore an ideal model of normal erythroid 
differentiation with regard to the regulation of haem 
synthesis.
(iii) Reticulocytes
Reticulocytes do not contain DNA, but may contain some 
mitochondrial fragments, ribosomes and Golgi bodies. They are
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the only system of pure erythroid cells readily available and 
easily obtained from peripheral blood. However, since they are 
anucleated they can only be used to investigate the 
posttranscriptional aspects of haem synthesis and iron 
transport. Nevertheless, reticulocytes have been extensively 
used to study erythroid haem regulation despite the fact that 
at the reticulocyte stage of development erythroid cells have 
all but stopped synthesising haem and Hb.
(iv) Isolated Bone Marrow Erythroblasts
A major obstacle to the study of human erythropoiesis has 
been an inability to achieve the physical separation of 
erythroid cells at different stages of development, both from 
one another and from cells of different types. Separation must 
also provide sufficient cell numbers to permit accurate 
biochemical analysis. To date, the most satisfactory method of 
cell separation is density sedimentation whereby separation 
depends on the continual decrease in cell size and 
corresponding increase in density during erythroid development. 
This has allowed the fractionation of tone marrow cells into 
distinct cell populations of similar differentiation status 
(Ali et al, 1982, 1983; May et al, 1982). However, this stage 
alone does not provide highly purified erythroid populations 
without white cell removal. Prior to fractionation, bone 
marrow cells may be treated with a monoclonal antibody (TG-1), 
cytotoxic for myeloid (white) cells (Beverely et al, 1980), 
which results in an increase in erythroid purity from 
approximately 20% to 80%. Fractionation of the remaining cells 
then produces erythroid subpopulations with erythroid purity of
27
up to 95% (Chapter 2).
1.11 THE REGULATION OF ERYTHROPOIESIS
Erythropoiesis is a complicated process which is 
influenced by hormones, metabolites, growth factors and 
cellular interactions. Erythroid development and haem 
biosynthesis are inextricably linked. To maintain a suitable 
perspective on the role of haem in erythropoiesis, the
regulation of erythropoiesis in a more general sense must first
be considered as it is unlikely that any one factor has an 
overiding effect on the development of erythroid cells.
The differentiation sequence of committed erythroid stem 
cells has been identified by 'in vitro1 culture techniques. 
Although CFU-E cells themselves are not morphologically 
identifiable, each class of progenitor can be separated by 
physical and functional properties (Ogawa et al, 1977a).
Stem cell primitive BFU-E mature BFU-E
CFU-E proerythroblast.
Further development then takes place producing the first 
morphologically i d e n t i f i a b l e  e r y t h r o i d  c e l l  (the 
proerythroblast).
Proerythroblast -> early erythroblast -> intermediate 
erythroblast late erythroblast reticulocyte -» 
erythrocyte.
One view of stem cell differentiation sees the 
microenvironment as having an instructive role in causing a 
stem cell to become committed to a particular blood cell
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lineage (Trentin, 1970; Wolf, 1978) through mechanisms such as 
cell-cell interactions or short range 'inducers'. Critics of 
this microenvironment theory have shown that the way in which a 
stem cell proliferates or becomes committed can be explained in 
terms of a purely random genetic process (Till et al, 1964; 
Humphries et a l , 1987). It has been argued that the various 
haematopoietic tissue environments influence blood cell 
production purely by facilitating the proliferation of 
particular kinds of committed precursor cells.
The q u e s t i o n  as to how the h a e m a t o p o i e t i c  
microenvironment facilitates the proliferation and/or 
differentiation of particular cell types remains open. Both 
the earliest precursor cells and the various intermediate cells 
however require growth factors to sustain their proliferation 
and differentiation. Such factors are often produced by other 
haematopoietic or stromal cells in the tissue environment and 
it is clear that the regulation of haematopoiesis involves 
complex interacting cell networks. Purified growth factors 
cannot mimic the local effects of the microenvironment 
indicating that cell-cell contact is necessary.
1.11.1 Factors Influencing Erythropoiesis
Erythropoiesis is influenced by systemic factors such as 
erythropoietin and by local factors such as burst promoting 
activity (BPA), colony stimulating factor (CSF) and cell-cell 
interaction.
The hormone erythropoietin (Epo), a glycoprotein produced 
in the juxtaglomerular cells of the kidney, has a major 
influence on erythropoiesis. It is essential to erythroid
development and differentiation and binds to specific cell 
surface receptors. Erythroid progenitors show increased 
sensitivity to Epo with increasing maturity (Ogawa et al, 
1977a). The haem enzymes in committed cells are also affected 
by Epo, in particular ALA synthase and PBG deaminase (Abraham 
et al, 1989), as are the globin genes (Sahr and Goldwasser,
1985). Expression of haem metabolic enzymes has been shown to 
be a prerequisite for erythroid cell development and 
differentiation in both FEL cells (Sassa, 1976) and human bone 
marrow (Brown et al, 1988). Burst promoting activity (BPA) 
acts with Epo to induce the maturation of tripotent stem cells 
to immature erythroid progenitors (Eliason, 1982; Iscove,
1978). Colony stimulating factor (CSF) has a suppressive 
effect on BFU-E and is competitive with respect to Epo (Van 
Zant and Goldwasser, 1977a; Van Zant and Goldwasser, 1979). A 
variety of hormones, including yfi-adrenergic agonists, thyroid 
hormones, growth hormone and androgenic/nonandrogenic steroids 
interact with Epo to enhance the cloning efficiency of BFU-E 
and CFU-E from a variety of species. Only the 5^-steroids may 
act independently of Epo. A common phenomenon of ^6-steroids 
on CFU-E formation in rodent (Singer et a l , 1976) and human 
(Urabe et al, 1979) bone marrow is the induction of ALA 
synthase with a subsequent increase in haem (Granick and 
Kappas, 1967; Levere and Gidari, 1974). On a molar basis 
steroid metabolites are 1 0 0  fold more active in stimulating 
erythroid colony formation from human bone marrow cells than 
they are in inducing ALA synthase or haem formation in avian 
liver cells. This sensitivity of bone marrow cells to steroids
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including glucocorticoids extends to rats (Singer et al, 1976), 
rabbits (Fischer et al, 1978) and man (Gold et al, 1976) 
suggesting an intrinsic biological characteristic of these 
cells not evident in hepatic cells. Differences of erythrocyte 
count, Hb concentration and haematocrit exist between men and 
women and may result from the effect of gonadal steroid 
hormones (Kappas and Palmer, 1963) as well as differences in 
body iron content. The presence of such hormones can reduce 
the requirement for Epo in culture by up to 90% (Udupa et al, 
1986).
The mechanism by which various hormones have their effect 
is mediated by mature accessory cells also present in the bone 
marrow such as T lymphocytes, monocytes and macrophages. 
Although an apparent effect of T cells on erythroid growth in 
culture can be demonstrated (Zanjani and Kaplan, 1979), further 
clarification is hampered by the lack of adequate techniques to 
remove other interacting cell populations. In addition to 
having a regulatory role in normal erythropoiesis, activated T 
cells (Nedwin et al, 1985) and T cell-derived lymphokines 
(Zoumbos et al, 1985; 1985) have been implicated in various 
types of bone marrow failure. T cells produce interleukins 
(Burdach and Levitt, 1987) and other lymphokines e.g. 
interferons (Broxmeyer et al, 1985) and tumour necrosis factor 
(Broxmeyer et al, 1985). Monocytes and macrophages are at 
least one source of CSF (MacVittie and Walker, 1978). BPA, 
humoral stimulating and humoral inhibitory activity (HSA/HIA) 
(Burke and Karp, 1987; Blackburn and Patt, 1980; Toksoz et al,
1980) and erythroblast enhancing factor (EEF) (Krystal, 1983) 
are derived from the stromal cell population. The role of such
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factors in erythropoiesis is currently under investigation. 
Lithium has been implicated in the control of erythrocyte 
production (Barr et al, 1987) and may act via inhibition of 
suppressor T lymphocytes (Bille et al, 1975; Chatelain et al,
1983).
Although animal models are useful in the study of 
mammalian erythropoiesis the further development of existing 
techniques for the study of human bone marrow erythropoiesis is 
necessary. Separation of erythroblasts into age-matched 
populations of equivalent differentiation status would permit 
such studies and allow analysis of haem enzyme activities, 
haem formation and iron incorporation. The regulation of 
erythropoiesis involves many complicated interactions and a 
multiplicity of factors. Deregulation of erythropoiesis may 
result from alterations in one or more of the components of the 
regulatory system. As haem synthetic activity is dependent 
upon the stage of erythroblast development, any factor that 
affects the control of erythropoiesis will then also affect 
haem synthesis. Conversely, while haem is known to have a 
regulatory role in erythropoiesis (Section L13), factors that 
influence haem synthesis then must also influence 
erythropoiesis.
1.12 THE REGULATION OF ERYTHROID HAEM BIOSYNTHESIS
Haem is produced by erythroid cells primarily to complex 
with globin as Hb. This process is finely coordinated such 
that free haem controls the initiation of globin gene 
expression (Harrison, 1984). Haem complexed with globin is 
preserved in circulating erythrocytes for 120 days. As such,
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it does not require the same sensitive control that regulates 
hepatic haem production with a T^ / 2 for haem of only a few days 
(Robinson, 1975). Haem synthesis in erythroid cells also 
differs from that in hepatic tissue in being inextricably 
linked to tissue differentiation (Fitzsimons et al, 1986, 
1988). During differentiation mitochondria and hence 
mitochondrial haem enzymes are lost. At the stage of 
reticulocyte formation few cells have intact mitochondria 
(Section 1.10). It must then be stressed that it is 
difficult to distinguish primary effects on haem biosynthesis 
from effects that are primarily linked to differentiation. Hb 
synthesis in erythroid cells is dependent on iron uptake (Ponka 
and Schulman, 1986) and the co-ordinate regulation of haem and 
globin biosynthesis. The very structure of haem as Fe- 
protoporphyrin demands close links between iron uptake, 
intracellular iron transfer and the haem biosynthetic pathway.
1.12.1 The Effect of Haem on Erythroid ALA Synthase
It would seem as if erythroid ALA synthase activity is 
controlled in a different manner to the hepatic enzyme. This 
control has two separate components : the development of enzyme 
activity as haem synthesis becomes established during 
differentiation and the short term regulation of activity in 
cells that are actively synthesising haem. Exogenous haem may 
have contradictory effects on two types of erythroid cells 
studied. In undifferentiated erythroid cells, haem has been 
shown to induce ALA synthase (Granick and Sassa, 1978; Elder, 
1981; Abraham and Levere, 1990) whereas in differentiated cells 
e.g. reticulocytes, haem appears to inhibit ALA synthase
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(Bruns and London, 1965; Ibrahim et al, 1978). The evidence is 
not yet however clear as even within the same cell type e.g. 
FEL cells, both positive and negative effects of haem on ALA 
synthase in early erythroid precursors have been demonstrated 
(Beaumont et al, 1984; Lu and Broxmeyer, 1983). Therefore, 
unlike liver cells, feedback inhibition of haem biosynthesis by 
haem at the level of ALA synthase may not be the major control 
mechanism in erythroid cells (Elferink et al, 1988).
This difference may in part be explained by the existence 
of specific liver and erythroid isoenzymes of ALA synthase as 
have been identified in guinea pig (Bishop et al, 1981), 
chicken (Watanabe et al, 1983) avian cells (Riddle et al, 1989) 
and man (Bishop, 1990). The concept of tissue-specific 
isoenzymes for ALA synthase had been disputed by various 
workers (Elferink et al, 1987; Schoenhaut and Curtis, 1986). 
They instead favoured the view that tissue specific regulation 
of a single gene could be achieved by use of a separate 
promoter in each cell type (Shaw et al, 1985) or that 
transcription could occur from two different but highly 
homologous genes differing only at the 5* end of the KNA or in 
untranscribed or untranslated regions. However, the recent 
publication of reliable genetic data has now confirmed the 
existence of tissue-specific isoenzymes in hepatic and 
erythroid tissues (Chapter 3, Section 3.3). The hepatic ALA 
synthase gene has been localised to chromosome 3 (Sutherland et 
al, 1988) and the erythroid ALA synthase gene to chromosome X 
(Cox et a l , 1990).
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1.12.2 The Role of Other Haem Enzymes in Erythroid Haem Control
It has been shown that during erythroid differentiation 
the activity of not only ALA synthase but also of the other 
enzymes in the haem biosynthetic pathway increases. It has 
been demonstrated in FEL cells treated with DMSO and in normal 
human bone marrow cells treated with Epo (Sassa, 1976; 1980) 
that a sequential induction of enzymes of the haem biosynthetic 
pathway occurs. It has therefore been suggested that 
ferrochelatase, the final enzyme of the pathway, may be rate 
limiting for haem formation. Whether ferrochelatase was truly 
rate-limiting in these circumstances remains debatable as an 
enzyme may only be considered to be rate limiting if the enzyme 
pathway is intact and fully developed. In this case, however, 
it was the late induction rather than regulation of 
ferrochelatase activity that was thought to limit haem 
production. A second group have also obtained similar results 
using FEL cells (Rutherford et al, 1979). Both these results 
have however been contradicted (Beaumont et al, 1984) by the 
demonstration of simultaneous rather than sequential induction 
of the haem enzymes in DMSO-treated FEL cells. This study 
suggested that iron availability rather than delayed appearance 
of ferrochelatase may limit haem synthesis. However, several 
workers have reported ferrochelatase inhibition by haemin in a 
variety of tissues including Rhodopseudomonas spheroides (Jones 
and Jones, 1970; Dailey, 1982), Spirillum itersonni (Dailey, 
1977) and mammalian liver (Roller and Romslo, 1977; Dailey and 
Fleming, 1983) indicating a possible regulatory function of 
this enzyme in haem biosynthesis. This theory is examined more 
fully in Chapter 4 of this thesis.
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Beru and Goldwasser (1985) demonstrated in rat bone marrow 
cells, Epo induced synthesis of PBG deaminase without any 
discernible effect on the other enzymes. Cells prior to the 
addition of Epo already contained levels of each haem enzyme 
sufficient to maintain haem synthesis in the subsequent few 
days. Activity of PBG deaminase increased linearly with Epo 
concentration and this increase was proportional to the 
increase in haem synthesis. The molecular biology of human PBG 
deaminase has since been investigated (Mignotte et al, 1988; 
1990; Chretien et al, 1988; Raich et al, 1989) leading to the 
discovery of two promoter sequences preceding the PBG deaminase 
gene. The additional promoter sequence is used only in 
erythroid tissue and has been shown to have sequence homology 
to the promoter sequence for the /$-globin chain gene (Mignotte 
et a l , 1990). This suggests that PBG deaminase and^S-globin 
chain production may be coordinated. It has also been shown 
that different isoforms of PBG deaminase are encoded by 
distinct tissue-specific mRNAs in human liver and erythroid 
tissue (Grandchamp et al, 1987). Both are, however, 
transcribed from the same gene (Raich et al, 1986). Hence, 
separate promoters of a single gene account for the tissue- 
specific and tissue-nonspecific mRNA transcripts and their 
respectively encoded enzymes. In erythroid tissue PBG 
deaminase and PBG oxygenase, which oxidises PBG to 5-oxo- 
pyrrolines, exhibit a reciprocal relationship (Frydman et al, 
1986). PBG oxygenase may therefore represent a counter­
regulation of PBG for haem synthesis. It is of interest that 
this enzyme contains one haem and two molecules of non-haem 
iron (Frydman et al, 1988).
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1.12.3 The Role of Haem on Iron Uptake
The relationships between intracellular haem, haem 
synthesis and iron uptake are also unclear. It has been 
suggested that the regulation of erythroid haem biosynthesis 
may be dependent upon the effects of haem on transferrin iron 
release (Ponka and Schulman, 1985) or on the development of 
transferrin receptors on the erythroid cell membrane 
(Wilczynska et al, 1984; Pelicci et al, 1982). Iron overload 
has also been shown to increase bone marrow ALA synthase, 
reduce ALA dehydratase and increase haem oxygenase activity 
(Abraham et al, 1985). Erythroid iron uptake is increased by 
inhibitors of haem synthesis such as isoniazid (INH), an 
antipyridoxal agent (Bottomley, 1982) and succinylacetone 
(Ponka et al, 1982), an inhibitor of ALA dehydratase (Tsudy et 
al, 1981; Sassa and Kappas, 1983). However, the theory that 
haem controls haem synthesis by regulating the release of iron 
from transferrin has not been completely accepted and has been 
challenged by several workers who have demonstrated normal iron 
uptake under conditions of reduced haem synthesis (Ibrahim et 
al, 1978; May et al, 1982a, 1982b). The proposed inhibition of 
iron uptake by haem also seems to occur only in erythroid 
cells. It has been observed in reticulocytes (Ponka and 
Neuwirt, 1969; 1971; Ponka et al, 1974; Schulman et al, 1974; 
Fielding and Speyer, 1975; Garrick et a l , 1978; Ponka and 
Schulman, 1986), foetal mouse liver erythroblasts (Malik et al, 
1979), human erythroblasts (May et al, 1982) and Hb- 
synthesising FEL cells (Granick and Sassa, 1978; Malik et al,
1979) but not with uninduced FEL cells (Malik et al, 1979),
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transformed lymphoblastoid cell lines of human origin (Schulman 
et al, 1981), uninduced K562 cells (Schulman et al, 1981) and 
rat hepatocytes.
It has also been argued that "free" intracellular haem 
(not complexed with globin) may limit haem synthesis by 
regulating the availability of iron to protoporphyrin (Neuwirt 
et al, 1972; Ponka et al, 1974). At present, however, we know 
little about the mechanisms within the cell which ensure that 
iron is presented to protoporphyrin as Fe^+ ions and not Fe^+ 
ions (Chapter 4, Section 4.5.4).
In summary, it would appear that the regulation of 
erythroid haem synthesis may be different from that known to 
operate in hepatic tissue. Hepatic ALA synthase is the rate 
controlling enzyme of the haem biosynthetic pathway and is 
under negative feedback control by haem. However, in erythroid 
tissue both positive and negative effects of haem on ALA 
synthase activity have been observed. Negative feedback by 
haem at ALA synthase may not therefore be the major control 
mechanism in erythroid haem synthesis. This may be explained 
by the existence of tissue specific isoenzymes for erythroid 
and hepatic ALA synthase. In erythroid cells other enzymes of 
the pathway apart from ALA synthase may be induced in response 
to factors which stimulate haem synthesis. Possible roles for 
the enzymes ferrochelatase and PBG deaminase in the regulation 
of erythroid haem biosynthesis have been suggested. Other 
workers have supported a role for haem in the regulation of its 
own synthesis via control over iron acquisition and not via any
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direct effect on haem enzymes.
It is apparent that further investigation into the 
mysteries of erythroid haem biosynthesis is required. For the 
moment, however, many questions must remain unanswered and 
open to speculation.
1.13 THE ROLE OF HAEM IN EKXTHROPOIESIS
Haem is known to affect the erythroid differentiation 
process and has been reported to accelerate haemoglobinisation 
of erythroblasts in bone marrow cell cultures (Bonanou-Tzedaki,
1981). Haem is necessary for globin synthesis in reticulocytes 
and erythroblasts (Bruns and London, 1965), for the binding of 
globin mRNA to ribosomes and for the initiation of globin 
synthesis in intact cells and cell-free systems (Zucker and 
Schulman, 1968; Adamson et al, 1969). It has been shown to 
decrease DNA synthesis and cell division in both mature and 
immature erythroblasts and to induce globin mRNA synthesis in 
the immature precursors. Haem has also been shown to enhance 
the 'in vitro1 growth of primitive erythroid progenitor cells. 
Several workers have reported the greatest effect on BFU-E 
(Monette and Holden, 1982; Lu and Broxmeyer, 1983) while others 
report the major effect to be on CFU-E (Porter et al, 1979; 
Ibrahim et a l , 1982). The conflicting results may however 
simply be a reflection of the different assay systems used.
A haemin-induced specific enhancement of both marrow BFU-E 
numbers and cell cycling within 6 hours of haemin 
administration has been demonstrated 'in vivo' (Monette et al,
1984). No effect was observed on CFU-E. Similar results have 
also been supported by other workers (Iscove, 1977; Suzuki and
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Axelrad, 1980; Adamson et al, 1978). It has been suggested 
that neither haernin, Epo nor BPA can substitute for each other 
and all appear necessary for optimal BFU-E derived colony 
formation (Lu and Broxmeyer, 1983). This view has, however, 
been disputed (Holden et al, 1982).
A haemin-controlled translational repressor (HCR) system 
is a well established process for the regulation of protein 
synthesis in reticulocytes (Gross, 1980) but has not been 
demonstrated in immature erythroid cells. The HCR inhibits the 
translation of globin protein. Haernin inactivates the HCR and 
thus permits Hb synthesis to occur and enhances the synthesis 
of other erythrocyte proteins (cytoplasmic and membrane) 
(Deutsch and Blumenfield, 1977). Likewise, protein synthesis 
in FEL cells is augmented by haernin as is the synthesis of 
globin mRNA (Dabney and Beaudet, 1978; Ross and Sautner, 1976; 
Hoffman and Ross, 1980). This suggests that haernin may act at 
both translational and transcriptional levels.
The role of haem biosynthetic and degradative enzymes in 
erythroid colony development and the effects of haernin have 
been examined (Ibrahim, 1982). The increase in haem enzymes 
induced by haernin was suppressed by the addition of 
cycloheximide suggesting that the translation of mRNA for the 
haem enzymes is necessary for erythroid differentiation. 
Furthermore, a reduction in haem oxygenase activity and hence 
increased availability of haem acts as a trigger for CFU-E 
development and differentiation. The well recognised 
reciprocal increase in ALA synthase activity in liver cells as 
a result of haem oxygenase induction (Ibrahim et al, 1974) is
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not applicable in bone marrow erythroid cells. T h e s e  r e s u l t s  
demonstrate that decreased haem oxygenase activity and 
increased intracellular haem are associated with the 
development and differentiation of erythroid-colony cultures. 
They also show that the mechanisms which control ALA synthase 
and haem oxygenase in marrow are different from those in liver.
1.14 HAEM BIOSYNTHESIS IN OTHER TISSUES
Further observations in other non-hepatic tissues have 
been limited, but so far imply that the control mechanism of 
haem biosynthesis may again be different from that in liver. 
For example, neither potent inducers of hepatic ALA synthase 
nor haernin influence ALA synthase activity in the harderian 
gland in mice (Margolis, 1971); heart (Briggs et al, 1976), 
adrenal gland (Condie et al, 1976), testis (Tofilon and Piper,
1980) and spleen (Wada et al, 1967) of rat or in cultured human 
haemin-treated amniotic cells (Sassa et a l ,  1974). 
Alternatively, however, specific hormones increase A L A  synthase 
activity in non-hepatic target tissues. For example,  
adrenocorticotropic hormone increases ALA synthase activity in 
the adrenal gland (Condie et al, 1976); human chorionic 
gonadotropin increases the enzyme activity in the testis 
(Tofilon and Piper, 1980); and erythropoietin increases A L A  
synthase in the spleen (Wada et al, 1967). In addition, cobalt 
chloride treatment produces a marked decrease in cardiac A L A  
synthase in rats that is of longer duration than that seen with 
liver (Maines and Kappas, 1977; Sedman and Tephly, 1980). 
Fasting increases ALA synthase in the adrenal gland, but 
decreases the enzyme activity in the heart (Condie e t al,
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1976). Special features of ALA synthase have also been 
reported in brain (Paterniti et al, 1978). Significantly, ALA 
synthase activity is normal in mitogen-stimulated acute 
intermittent porphyria (AIP) lymphocytes (Sassa et al, 1978) 
and skin fibroblasts (Meyer, 1973; Bonkowsky et al, 1975).
1.15 DISORDERS OF ERYTHROPOIESIS
Erythropoietic disorders are traditionally divided into 
two groups; (1) anaemia and (2) polycythaemia. Although this 
division is based on the presence of either too few or too many 
red cells, anaemia is functionally best characterised by a 
reduced Hb concentration and polycythaemia by a raised 
haematocrit. In anaemia the patient suffers from tissue 
hypoxia, the consequence of a low oxygen-carrying capacity of 
the blood. In polycythaemia the clinical manifestations are 
related to increased whole blood viscosity and increased blood 
volume, both consequences of a high haematocrit.
On the basis of determinations of the red cell mass, 
anaemia can be classified as:-
(i) Relative (i.e. dilutional)
Relative anaemia is characterised by a normal total red 
cell mass together with an increase in plasma volume.
(ii) Absolute
Absolute anaemia corresponds to a decreased red cell mass 
and may be divided as follows; (1 ) decreased red cell 
production; (2) increased red cell destruction; and (3) 
blood loss i.e. increased red cell loss.
Anaemia caused by decreased red cell production can be 
subdivided into (1) reduced erythropoiesis (hypoplasia); (2)
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ineffective erythropoiesis characterised by increased 
erythropoietic activity in the bone marrow but reduced release 
of mature erythrocytes and reticulocytes into the circulation.
For the work described in this thesis, two particular 
disorders of erythropoiesis were chosen for study and their 
effects on erythroid haem synthesis examined.
1.15.1 Iron Deficiency Anaemia
Severe iron-deficiency anaemia is characterised 
haematologically by a reduced Hb concentration and red cell 
count in peripheral blood. The erythrocytes are microcytic due 
to the reduced Hb content. Bone marrow examination shows a 
moderate degree of normoblastic hyperplasia while developing 
red cell precursors show poor haemoglobinisation. The anaemia 
is associated with minor degrees of ineffective erythropoiesis 
(Robinson, 1969) and reduced red cell life-span (McKee et al, 
1968).
Iron deficiency gives rise to defective synthesis of haem 
enzymes in many tissues and may result in impaired activity of 
other iron-dependent systems. As yet, no consistent pattern of 
depletion for specific enzymes or for particular tissues have 
emerged (Dagg et al, 1967; Beutler, 1964). In iron deficiency 
there is abnormal accumulation of both free coproporphyrin and 
protoporphyrin within erythrocytes (Pagliardi et al, 1959). 
The normal balance between haem and globin production is 
disturbed resulting in a relative excess of globin which is 
broken down by red cell protease activity (Barr et al, 1972).
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1.15.2 Sideroblastic Anaemia
Refractory anaemia, associated with hyperplastic bone 
marrow has been recognised for many years. These anaemias have 
been collectively grouped as Myelodysplastic Syndromes (MDS) 
(Bennett et al, 1981) in which marrow activity is increased but 
ineffective thereby leading to the association of hypercellular 
marrow with reduced formed elements in blood.
The sideroblastic anaemias (SA) are members of the MDS 
group in which the abnormality both in blood and marrow is 
predominantly erythroid in nature. Platelet and white cell 
formation are better preserved in SA than in the other MDS 
groups. SA is characterised by defective haemoglobinisation of 
red cells, ineffective erythropoiesis and an abnormal 
accumulation of iron in the maturing erythroblasts distributed 
in the form of a perinuclear ring (see photographic plate 6). 
This type of anaemia may be inherited or acquired. Acquired SA 
may either be primary or secondary, with primary acquired 
(PASA) the most frequent type. Secondary types of SA may be 
induced by drugs or alcohol or may be associated with various 
diseases. Anaemias of this type are similar in that the 
erythroblasts have an inability to utilise iron and to 
synthesise haem. It is widely thought that abnormal haem 
production is the primary abnormality in SA (Hines and Grasso, 
1970).
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Classification of SA:
X-linked
hereditary
pyridoxine responsive
non-pyridoxine responsive
primary
acquired
secondary
It has, however, been suggested from studies using age- 
matched human erythroblasts that the primary defect in SA may 
be an abnormality of mitochondrial iron metabolism resulting in 
reduced haem synthesis. Iron has been shown to accumulate in 
the cell stroma and mitochondria and has been found in the cell 
cytoplasm as ferritin aggregates. Further studies involving 
the incubation of sideroblastic human bone marrow cells with 
radioactive iron bound to purified human transferrin (May et 
al, 1982) have shown normal iron uptake per erythroblast, 
increased iron incorporation into stroma, normal iron 
incorporation into ferritin but decreased iron incorporation 
into haem.
Examination of human bone marrow erythroblasts in PASA by 
electron microscopy has revealed that the accumulation of iron 
is located within the erythroblast mitochondria and is 
frequently associated with (1) a depression of RNA synthesis 
and (2 ) a more marked depression of protein synthesis 
(Wickramasinghe and Hughes, 1978). Aoki (1980) in a study of 
69 patients with various types of PASA reported impaired
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mitochondrial enzyme function in both erythroblasts and 
granulocytes. Mitochondrial iron loading was, however, only 
seen in the erythroblasts. In patients with pyridoxine- 
responsive anaemia, ALA synthase was the only mitochondrial 
enzyme found to have diminished activity, but this was found in 
both erythroblasts and granulocytes.
It has been shown that virtually all cases of PASA have 
decreased ALA synthase activity and many workers believe that 
this is the primary defect which leads to the accumulation of 
iron in the mitochondria as a consequence of decreased haem 
synthesis (Cartwright and Deiss, 1975; Aoki et al, 1974). 
Genetic evidence has indicated that in cases of congenital SA 
(CSA), which follows x-linked inheritance (Lee et al, 1968; 
Bottomley, 1982; McKusick, 1986), the defect in ALA synthase 
activity may be due to a mutation of the ALA synthase gene now 
known to be located on chromosome X (Cox et al, 1990). 
Nevertheless, at present it remains unclear as to whether 
reduced ALA synthase activity is the primary cause of reduced 
haem synthesis in cases of CSA or whether it is secondary to 
some other haematological abnormality. However, the response 
of CSA to pyridoxine may be seen as strong evidence in favour 
of decreased ALA synthase activity contributing to the anaemia 
since PLP is the essential cofactor for ALA synthase. Aoki 
(1978) has suggested that pyridoxine may exert a stabilising 
effect on ALA synthase in CSA by preventing a temperature 
dependent susceptibility of the apoenzyme to a controlling 
protease in erythroid cells. Alternatively, he argues that 
whereas CSA may be caused by increased ALA synthase breakdown, 
PASA is due to reduced ALA synthase formation.
1.16 AIMS OF THE WORK
Little is known of erythroid haem synthesis in the bone 
marrow, yet it is the major haem synthesising tissue of the 
body. Thus, erythroid haem biosynthesis demands further 
examination to define the role that haem plays in erythroblast 
metabolism and differentiation and the role that impaired haem 
synthesis plays in the pathogenesis of sideroblastic and other 
anaemias.
Studies of human erythropoietic haem biosynthesis have 
been hampered by the heterogeneity of the bone marrow cell 
population, the small sample sizes available and the lack of 
suitably sensitive assays for the haem enzymes. Previous 
workers have employed a variety of cells and models to 
represent erythropoiesis and a variety of techniques to measure 
the enzymes of haem biosynthesis. Accordingly, the results 
have been inconclusive.
It is the aim of this work to employ recently described 
techniques or to develop new ones to study human erythroid 
haem synthesis "in vivo" in both normal and abnormal purified 
age-matched human erythroblasts in an attempt to gain insight 
into the control mechanisms which operate.
The work involves the study of the two haem enzymes 
perhaps most likely to be involved in the regulation of 
erythroid haem synthesis, ALA synthase and ferrochelatase. ALA 
synthase, the first enzyme of the haem biosynthetic pathway, is 
the rate controlling enzyme of haem biosynthesis in hepatic 
cells but its role in erythroid tissue remains to be 
established. Ferrochelatase, the terminal enzyme of the haem 
biosynthetic pathway, is examined as this too has been
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implicated in the control of erythroid haem synthesis (Sassa, 
1976; Jones and Jones, 1970; Dailey, 1982, 1977; Koller and 
Romslo, 1977; Dailey and Fleming, 1983).
The work presented three major technical challenges:
1 Methods of erythroblast separation had to be tested and a 
reproducible technique adopted for regular use.
2 Sensitive assays of haem enzyme activity were required for use
with isolated human erythroblasts. In particular, it was 
intended to adopt and further improve the sensitivity of the 
described radiochemical assay for ALA synthase activity 
(Fitzsimons et al, 1986) and to develop a novel highly 
sensitive radiochemical assay for ferrochelatase activity.
3 Bone marrow samples were required from a sufficient number of
suitable patients.
It was proposed to examine haem synthetic enzyme activity 
in isolated age-matched human erythroblasts obtained from 
patients with:
(a) normoblastic marrow
(b) iron deficiency
(c) sideroblastic anaemia
and then to use the information obtained:
(1) to establish the order in which ALA synthase and ferrochelatase
appear during erythroid differentiation and so resolve the 
conflict as to whether the enzyme activities appear 
simultaneously (Beaumont et al, 1984) or sequentially (Sassa, 
1976). Furthermore, to determine whether ALA synthase (Levere 
and Granick, 1965) or ferrochelatase (Sassa, 1976) is rate 
limiting for erythroid haem biosynthesis.
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(2 ) to examine the effects of iron deficiency on the activities of
these mitochondrial enzymes during erythroid differentiation. 
The effects of haem deficiency on erythroblast ALA synthase 
activity would be compared with the inducing effect that haem 
deficiency is known to have on hepatic ALA synthase.
(3) to examine the effect of erythroblast iron overload (ring
sideroblastic) on erythroid haem biosynthesis.
(4) to further examine ALA synthase in the hope of explaining the
temperature-dependent inactivation of the enzyme as has been 
observed in hepatic mitochondrial matrix fraction (Beattie et 
al, 1985) and intact human erythroblasts (Fitzsimons et al, 
1986).
(5) to examine the effect of haem therapy on ALA synthase and
ferrochelatase enzyme activities in individuals with 
sideroblastic (and hence haem deficient) erythropoiesis.
1.17 LAYOUT OF THESIS
The early chapters of the thesis describe and discuss the 
methodology involved in cell separation and the measurement of 
haem enzyme activity. The later chapters deal with the patient 
studies.
Chapter 2 details the preparation of human bone marrow 
samples into distinct highly purified age-matched erythroid 
subpopulations following the removal of the myeloid cell 
population.
Chapter 3 describes the further improvement of an existing 
highly sensitive specific radiochemical assay optimised for 
erythroid ALA synthase activity. The stability of ALA synthase 
is investigated and the role of PLP as cofactor examined in an
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attempt to prevent the consistently observed temperature- 
dependent inactivation (Beattie et al, 1985; Fitzsimons et al,
1986). The assay is applied for the first time to the 
measurement of ALA synthase in tissues other than 
erythroblasts.
Chapter 4 describes the structure and properties of 
ferrochelatase and discusses its possible regulatory role in 
erythroid haem synthesis. Chapter 5 describes in stepwise 
fashion the complete development of a novel highly sensitive 
specific radiochemical assay for the measurement of 
ferrochelatase activity in human erythroid cells. This work 
comprises the major experimental component of the thesis.
The latter chapters of the thesis are the more clinical 
and describe the application of these experimental techniques 
to the study of haem biosynthesis during normoblastic 
erythropoiesis and during various disease states associated 
with impaired haem biosynthesis.
Chapter 6 describes the pattern of ALA synthase and 
ferrochelatase activities during normoblastic erythropoiesis 
and examines the relationship between the two enzymes.
Chapter 7 describes the effects of iron and haem 
deficiency on ALA synthase activity in developing erythroid 
cells from individuals with iron deficiency. A unique 
opportunity arose during the time of study to examine a 
patient with hepatoerythropoietic porphyria (HEP). As such, 
the effects of haem deficiency caused by HEP on both erythroid 
and hepatic ALA synthase enzymes are reported in this chapter.
Chapter 8 examines ALA synthase activity during 
sideroblastic anaemia, a disease generally believed to be due
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to an abnormality of haem synthesis, but in which the primary 
abnormality is unknown.
Finally, Chapter 9 details a trial of haem arginate 
(Normosang) as possible therapy in sideroblastic anaemia. For 
the first time the effects of this drug on both ALA synthase 
and ferrochelatase activities are examined in developing 
erythroid cells in sideroblastic patients. This provides an 
opportunity to further examine the possible control mechanisms 
of erythroid haem biosynthesis as exogenous haem arginate 
behaves in the same manner as physiological haem (Tenhunen et 
al, 1987).
Each individual chapter contains a substantial 
introduction followed by experimental details and finally a 
discussion of the results. In the final chapters of the 
thesis (6-9) particular emphasis is paid to the enzymatic 
responses to haem deficiency/excess in erythroid cells and this 
is contrasted with the information which is currently available 
for hepatic tissue. Further studies are also suggested.
Chapter 10 highlights the conclusions from this work and 
discusses future perspectives for the study of erythroid haem 
synthesis.
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CHAPTER 2
PREPARATION OF HIGHLY PURIFIED AGE-MATCHED 
HUMAN ERYTHROBLASTS
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2 PREPARATION OF HIGHLY PURIFIED AGE-MATCHED HUMAN ERYTHROBLASTS
2.1 THE NATURE OF HUMAN BONE MARROW
Bone marrow is a dynamic and continuously developing 
tissue composed of cells from different lineages, at different 
stages of differentiation. The major cell lines are myeloid 
(white cells with cytoplasmic granules) and erythroid (red 
cells) with lesser numbers of lymphocytes, plasma cells, 
monocytes, histiocytes and megakaryocytes. The ratio of 
myeloid: nucleated erythroid cells is known as the M:E ratio 
and in normal bone marrow this ranges from 2.5 - 15:1 (Dacie 
and Lewis, 1975). In the presence of erythroid hyperplasia 
there is a reduction or a reversal of the normal M:E ratio.
In practice, bone marrow samples may be obtained by fine 
needle aspiration from the anterior/posterior iliac crests or 
from the sternum in relatively small volumes. Larger volumes 
are more difficult to obtain since aspiration of more than
0.3ml leads only to dilution of the sample with peripheral 
blood (Dacie and Lewis, 1984).
All mammalian cells apart from mature red blood cells 
synthesise haem, but bone marrow is by far the major iron 
utilising and haem producing tissue in the body (Berk et a l , 
1976). However, although the erythroid cells are responsible 
for the majority of haem synthesis, the myeloid cells in bone 
marrow are also rich in haem containing enzymes such as 
peroxidase, catalase and mitochondrial cytochromes.
2.2 HAEM SYNTHESIS IN WHOLE UNFRACTIONATED HUMAN BONE MARRCW
Techniques for human bone marrow fractionation and
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cellular isolation into distinct age matched erythroid cell 
populations were first described in 1983 (Ali et al, 1983). 
Until then most studies of human bone marrow haem biosynthetic 
activities had been confined to the detection of enzyme 
activity in unfractionated bone marrow in normal and 
pathological states. In these studies haem enzyme activities 
were assumed to reflect only that present in bone marrow 
erythroblasts and did not take into consideration the 
contribution made by the myeloid cell population. The enzyme 
activity was related to the sample erythroblast content and the 
activities detected in different samples were compared 
irrespective of any differences in their M:E ratios. 
Furthermore, in some pathological conditions the erythroblast 
population is more immature than that found in normal marrow
i.e. left shifted. Despite evidence from a variety of 
alternative erythroid systems of the effect of differentiation 
(i.e. maturity) on erythroblast haem enzyme activities this was 
not considered in those studies using unfractionated bone 
marrow samples (Bottomley et al, 1973; Aoki et al, 1974; 
Konopka and Hoffbrand, 1979; Manabe et al, 1982).
2.3 CONTRIBUTION OF THE MYELOID CELT. POPUIATION
Measurements of haem enzyme activities in unfractionated 
bone marrow are not a reliable index of erythroblast enzyme 
activity since myeloid cells in both normal and primary 
acquired sideroblastic anaemia (PASA) bone marrow samples 
contribute almost 50% of the ALA synthase activity found in 
unfractionated bone marrow (Fitzsimons et al, 1986).
Previous studies of ALA synthase activity had assumed that
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myeloid cells made no significant contribution towards 
unfractionated bone marrow enzyme activity (Takaku and Nakao, 
1971; Bottomley et al, 1973; Aoki et a l , 1974; 1979; Aoki, 
1980; Konopka and Hoffbrand, 1979; Fraser and Schacter, 1980; 
Tikerpae et al, 1981; Manabe et al, 1982). This assumption may 
have originated from the failure to detect ALA synthase 
activity in normal and leukaemic leucocytes (Walters et al, 
1967) and is of course further supported by the visual evidence 
from light microscopy that clearly shows erythroblasts to be 
the most active haem forming cells in bone marrow. However, 
the work of Walters et al (1967) was carried out prior to the 
development of a sensitive radiochemical assay for ALA synthase 
and subsequently other workers have produced contradictory 
evidence suggesting that myeloid cells may contribute 
significantly to the overall haem biosynthetic capacity of the 
bone mar row:-
(1) Immature, leukaemic myeloid cells can synthesise haem in 
significant quantities (Handler and Handler, 1972).
(2) Polymorphonuclear leucocytes contain haem-containing enzymes in 
particular myeloperoxidase which constitutes more than 5% of 
the dry weight of the cells (Suzuki et al, 1983).
As such, measurement of ALA synthase activity and other 
haem enzymes in whole unfractionated bone marrow may only be 
taken as a crude indicator of erythroblast enzyme activity. 
Such measurements are insensitive to the contribution made by 
myeloid cells and to differences in enzyme activity which occur 
in relation to erythroid cell differentiation.
In 1986 ALA synthase activity was measured in whole and
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fractionated human bone marrow (Fitzsimons et al, 1986). That 
study examined haem synthesis in highly purified age matched 
'in vivo' erythroblasts and now serves as the take off point 
from which this work has started.
In Summary
A critical feature to further progress in the study of 
human erythroid haem synthesis and its disorders is the ability 
to successfully isolate erythroid cells from the heterogeneous 
cell population of the bone marrow. Moreover, since the 
ability of erythroid cells to actively synthesise haem is 
chiefly dependent upon the differentiation status of the cell, 
it is further necessary to separate the erythroid population 
into smaller distinct subpopulations of similar differentiation 
status. Methods described to remove white cells and separate 
erythroblasts have now been adopted and optimised for use in 
this work. These methods are described in detail in this 
chapter and comprise of a combination of two techniques:
(1 ) myeloid cell lysis by monoclonal antibody
(2 ) separation of erythroblasts into four distinct age-matched cell 
populations by percoll equilibrium gradient density 
centrifugation.
2.4 PREPARATION OF BONE MARROW HFT.Tfi
Bone marrow cells were obtained (l-2ml) and placed 
directly into collecting medium (10ml, 4°C) (Appendix 1). Ihe 
cells were dispersed by sequential repeated aspiration through 
wide and fine gauge needles (microlance 19G2, 1.1 x 50;
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microlance 21G, 0.8 x 40) then washed (x 3) in cold culture 
medium (Appendix 1). Supernatant was removed at each wash 
following centrifugation at 4°C at 3000 rpm for 5 minutes 
(Mistral 4L refrigerated centrifuge). Accurate cell counts 
were made using a coulter counter with channelyzer attachment 
(Appendix 1).
2.5 MYELOID CELL LYSIS
Monoclonal antibody, TG-1 has been identified as an IgM 
complement fixing cytotoxic antibody specific for myeloid cells 
from promyelocytes to polymorphs (Beverley et al, 1980). It 
has been used as a myeloid cell lysing agent to produce highly 
purified preparations of erythroid cells from human bone marrow 
(Ali et al, 1983). The method for myeloid cell lysis requires 
incubation of the bone marrow cells with monoclonal antibody 
TG-1 for 30 minutes at 4°C to allow antibody fixation to the 
myeloid cell surface. Thereafter, samples are incubated at 
37°C in the presence of complement to allow cell lysis.
Hybridoma cells obtained from Dr. Peter Beverley, M.R.C. 
Tumour Immunology Group, University College Hospital, London, 
were cultured with the assistance of the Beatson Institute for 
Cancer Research, Glasgow. TG-1 released into the hybridoma 
supernatant was stable for several months at -80°C.
The lysis technique was modified (Fitzsimons et al, 1986) 
from the method described by Ali et al (1983). Bone marrow 
cell pellets (50 x 10^ cells) were suspended in TG-1 (2.5ml) by 
repeated aspiration through a fine gauge needle (microlance, 
21G, 0.8 x 40) then placed on ice for 30 minutes. Fresh 
autologous plasma (2.5ml) was added as a source of complement
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containing deoxyribonucleotidase (DNAse, EC 3.1.21.1) (DN-25, 
Sigma Chemical Company) to a final concentration of lmg per ml. 
The sample was then incubated in a shaking water bath (60 rpm) 
at 37°C for 30 minutes. DNAase was added to digest the DNA 
liberated from lysed cells and so prevent gel formation and 
aggregation of viable erythroid cells by the released DNA. The 
cells were washed (x 3) in culture medium (4°C) to remove 
myeloid cell debris. By this method the erythroid purity of 
the sample rose from approximately 2 0% to 80%.
2.6 BONE MARROW FRACTIONATION
The erythroid enriched cell population obtained following 
myeloid cell lysis was fractionated to produce four distinct 
age-matched highly purified erythroid cell populations. This 
was achieved using preformed percoll density gradients.
Between 1965 and 1970 the development of isopycnic 
(buoyant density) and velocity sedimentation methods resulted 
in numerous reports of useful cell separations. The theory of 
sedimentation has since been reviewed (Pretlow et al, 1975). 
Since density separation is effected on the basis of respective 
cell densities, and the densities of many cell types overlap 
broadly, the application of this method has some limitations 
(Pretlow et al, 1982). However, in the case of erythroid cells 
the increase in cell density as the proerythroblast 
sequentially matures through early, intermediate and late 
erythroblast stages of development is very marked, although 
some degree of overlap inevitably exists.
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2.6.1 Percoll Density Gradients
54ml of percoll (Pharmacia) was made isotonic by the 
addition of 6ml 8g/dl sodium chloride and was prepared to a 
specific density of 1.083g/l by the addition of 32ml culture 
medium (Appendix 1). Density gradients were prepared in 14ml 
capacity capped polycarbonate centrifugation tubes by spinning 
in a refrigerated ultracentrifuge (MSE superspeed 75) with the 
brake off in an angle-head rotor (MSE-25) for 45 minutes at 
2 0 0 0 0 rpm.
Bone marrow erythroblasts were washed (x 3) in culture 
medium (4°C) following TG-1 myeloid cell lysis. The cells were 
suspended in heat inactivated filtered (Gelman Acrodisc filter,
0.2 micron) foetal calf serum (1.0ml) to a concentration of 50 
x 10^ cells per ml. The erythroblast suspension was layered 
onto each preformed density gradient maintained at 4°C. The 
gradients were then spun in a refrigerated centrifuge (MSE, 
model 4L) at 2,400 rpm for 15 minutes at 4°C.
Percoll gradients were calibrated by the addition of 
percoll density marker beads (Pharmacia) added to a preformed 
percoll gradient which was then centrifuged as described 
(photographic plate 1). Erythroblasts were removed from four 
preset density fractions identified by the marker beads. The 
erythroblasts were then washed in culture medium (x 3) at 4°C 
to ensure complete removal of percoll. Cell counts were 
obtained and cytospin preparations made for each fraction.
2.6.2 The Erythroblasts in the Percoll Fractions
Each cytospin preparation was examined by light microscopy 
and erythroblast maturity assessed by differential cell
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&NOTE:
Gradients were calibrated by the addition of 10-15ul of 
density marker beads in distilled H 20 followed by 
centrifugation at 2400 rpm for 15 min.
Colour of bead 
Orange 
Blue/green 
Red
Blue/purple
Yellow
Green
Pink
density (g/ml) 
1.034 
1.048 
1.062 
1.076 
1.087 
1.100 
1.118
PLATE 1
PERCOLL DENSITY GRADIENT CALIBRATED BY DENSITY MARKER BEADS
counting of 400 cells. Each fraction was scored for its 
content of pro and basophilic early erythroblasts (E^), 
p o l y c h r o m a t i c  i n t e r m e d i a t e  erythroblasts (E2 ) and 
orthochromatic late erythroblasts (E^ ) (photographic plates 2- 
5).
Separation on the basis of density produced successful 
fractionation of the erythroid cell population into 
subpopulations of similar differentiation status. Those 
density steps which provided the most satisfactory separation 
of Ej cells from E2 cells from E3 cells were similar to those 
identified by Fitzsimons et al (1986).
Density (g/ml) Volume Removed (ml)
Fraction 1 1.062 - 1.070 1.0
Fraction 2 1.070 - 1.080 1.0
Fraction 3 1.080 - 1.100 1.5
Fraction 4 1.100 - 1.118 1.0
2.6.3 Haem Synthesis in Developing Erythroblasts
The progressive accumulation of Hb is clearly visible in 
the developing erythroid cells of the bone marrow and is 
inextricably linked to erythropoiesis itself. Hb is not 
evident in the early basophilic erythroblasts (percoll 
fractions 1 and 2 ), becomes evident in the intermediate 
polychromatic erythroblasts (percoll fraction 3), while by the 
stage of the late orthochromatic erythroblasts (percoll 
fraction 4) it packs the cytoplasm as if to squeeze the small 
densely packed nucleus from the cell.
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2.6.4 Erythroblast Differentials
Differential counting of erythroblasts is a subjective 
procedure liable to interobserver variation. All differential 
cell counting was performed by Dr. Edward Fitzsimons, project 
supervisor. Differential cell counts on the four percoll 
fractions were made on 400 cells. The stage of erythroid 
development was assessed by its content of E p  E 2 and E^ 
erythroblasts. In general, the intermediate erythroblasts of 
percoll fraction 2 were less mature than those of percoll 
fraction 3 (see photographic plates 2-5).
It has been shown with velocity centrifugation (Denton and 
Arnstein, 1973) that the most effective erythroblast separation 
was obtained from marrows showing pronounced erythroid 
hyperplasia. The work produced similar results for density 
centrifugation. Normal marrows lacking erythroid hyperplasia 
contained very few pro and early basophilic erythroblasts; as 
such?the least dense percoll fractions contained very few 
immature erythroid cells but large numbers of contaminating 
lymphocytes and monocytes. As a result, only marrows showing 
erythroid hyperplasia were suitable for study.
Within equivalent fractions from different bone marrows 
examined, the erythroblasts were found to be at a comparable 
level of maturity thus permitting the comparison of haem enzyme 
activity between age-matched erythroblasts from both normal and 
pathological bone marrow samples. The mean erythroblast 
differential counts in the percoll fractions were similar for 
the majority of bone marrows studied. Pro and early basophilic 
(E^) erythroblasts were most prominent in fraction 1. These 
immature cells were also present in fraction 2, but to a lesser
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extent and were outnumbered by intermediate (E2) polychromatic 
erythroblasts. Percoll fraction 3 contained more intermediate 
than late (E3 ) erythroblasts with the reverse being the 
situation in fraction 4 (see Table 1).
2.6.5 Other Methods of Bone Marrow Fractionation
Different methods have been used for fractionation of 
developing bone marrow erythroblasts to provide distinct age- 
matched populations of similar differentiation status. 
Erythroblasts may be synchronised in animals by injections of 
actinomycin D and harvested at intervals thereafter (Konijn et 
a l , 1979). The treatment is, however, toxic and few animals 
survive. Varying degrees of success have been achieved using 
the physical separation techniques of velocity (Denton and 
Arnstein, 1973) and density (Borsook et al, 1969) 
centrifugation for the fractionation of rabbit and mouse 
erythroblasts (Glass et al, 1975b).. Human erythroblast 
fractionation using monoclonal antibody TG-1 and percoll 
equilibrium density centrifugation has the advantages that the 
centrifugation step is short and refrigerated and that high 
percentage cell recoveries are achieved (Ali et al, 1983) so 
allowing its use with small cell numbers.
The density of developing erythroblasts is determined 
primarily by the nuclear size and Hb content (Borsook et al,
1969). As these characteristics do not change synchronously 
in every cell some erythroblast heterogeneity in the percoll 
fractions was unavoidable. However, the four fractions chosen 
for use produced reproducible erythroblast fractionation and
61
NORMOBLASTIC (n=io)
Sample e-j E2 E3
% % %
Percoll 1 45 45 10
Percoll 2 21 59 20
Percoll 3 10 63 27
Percoll 4 3 35 62
IRON DEFICIENT ( n ~ \ o )
Percoll 1 43 40 17
Percoll 2 43 45 12
Percoll 3 13 60 27
Percoll 4 _ 35 65
SIDEROBLASTIC ( f \ = \ o )
Percoll 1 33 46 21
Percoll 2 32 59 9
Percoll 3 19 62 19
Percoll 4 3 44 53
Note: The erythroblast differential cell counts were made
from the examination of 400 cells.
TABLE 1
MEAN ERYTHROBLAST DIFFERENTIAL CELL COUNTS FROM THE 
PERCOLL GRADIENTS
have provided clear information on the effects of normal and 
abnormal differentiation on haem enzyme activity. Improved 
fractionation may be achieved by increasing the number of 
percoll fractions sampled, but this would also reduce the cell 
numbers per fraction.
V. i
(b) x 1 2 0 0  
PLATE 2 (a)f (b)
PROERYTHROBLAST (PERCOLL FRACTION 1)
%x 800
PLATE 3
BASOPHILIC ERYTHRQBLAST (PERCOLL FRACTION 2) 
(Early and intermediate erythroblasts)
X  800
PLATE 4
POLYCHROMATOPHILIC ERYTHROBLAST (PERCOLL FRACTION 3) 
(Intermediate and late erythroblasts)
#(a) x 800
•2
1
©
■ ■
(b) x 600 (Note the small pyknotic nucleus about to be 
extruded from the cell)
PLATE 5 (a) (b)
ORTHOCHROMATIC ERYTHROBLAST (PERCOLL FRACTION 4)
(Late and intermediate erythroblasts)
x 1000 Iron granules (Perl's stain) are located in the 
perinuclear position
PLATE 6 (a)
RING SIDEROBLASTS
(b) Lower power electron micrograph depicts iron loaded 
mitochondria located alongside the nuclear membrane
I
(c) High power electron micrograph shows view of an 
iron-loaded mitochondrion.
PLATE 6 (b) , (c)
RING SIDEROBLASTS
CHAPTER 3
5-AMINOLAEVULINIC ACID SYNTHASE ACTIVITY 
IN HUMAN BONE MARROW
3 5-AMINOIAEVULINIC ACID SYNTHASE ACTIVITY IN HUMAN BONE MARROW
3.1 THE REACTION CATALYZED BY 5-AMINOLAEVULINIC ACID SYNTHASE (ALA
SYNTHASE) [SUCCINYL CoA: GLYCINE C-SUCCINYL TRANSFERASE,
(EC.2.3.1.37) ]
The first reaction in the haem biosynthetic pathway is the 
condensation of glycine and succinyl CoA to form ALA. This 
step is catalyzed by the mitochondrial enzyme, ALA synthase. 
The enzymatic reaction was first identified in the 
photosynthetic bacterium Rhodopseudomonas spheroides (Kikuchi 
et a l , 1958; Gibson et al, 1958) and requires PLP as enzyme 
cofactor. Subsequently, the enzymatic activity was 
demonstrated in a variety of species and tissues including 
microorganisms (Tait, 1972); yeast (Porra et al, 1972); avian 
(Granick, 1966) and mammalian liver cells (Granick and Urata, 
1963; Marver et al, 1966; 1966); mammalian erythroid cells 
(Takaku, 1968); mouse harderian gland (Margolis, 1971); rat 
kidney (Sardesai, 1972); heart (Condie and Tephly, 1978); brain 
(Paterniti, 1978) and insects (Brattsten and Wilkinson, 1975).
3.2 THE LOCATION AND MOLECULAR PROPERTIES OF ALA SYNTHASE
The purification of ALA synthase is difficult primarily 
because the enzyme is present in minute quantities and is very 
unstable. However, the dramatic induction of hepatic ALA 
synthase by drugs such as A1A and DDC has greatly facilitated 
the molecular and genetic characterisation of this enzyme. 
Drug-induced mitochondrial ALA synthase has been purified to 
apparent homogeneity from embryonic and adult chicken liver 
(Borthwick et al, 1983; Watanabe et al, 1984) and from adult 
rat liver (Srivastava et al, 1982). Glutaraldehyde cross- 
linking studies (Borthwick et a l , 1983) and direct electron
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microscopic analysis of enzyme preparations (Pirola et a l , 
1984) have indicated that the solubilised native enzyme exists 
as a homodimer. The estimated molecular weights (M.W) of the 
subunits as determined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) range from 65,000 
(adult chicken liver) to 70,000 (adult rat liver).
Electron microscopic localisation of ALA synthase in rat 
liver using gold-labelled antibodies has indicated that the 
enzyme is attached to the matrix surface of the inner 
mitochondrial membrane (IMM) (May et al, 1986). Most nuclear- 
encoded mitochondrial proteins are synthesised in the cytoplasm 
as a larger precursor and then posttranslationally imported to 
the mitochondria where they are processed to the mature form 
(Hay et a l , 1984). In general, precursors contain
amino terminal extensions of 20-70 amino acids which target the 
p r o t e i n  to the mito c h o n d r i a  and p a r t i c i p a t e  in 
intramitochondrial sorting (Schatz, 1987). The presequence is 
then removed by a protease. Both chicken and rat hepatic ALA 
synthase have been shown to be synthesised in the cytosol on 
membrane-free polyribosomes as larger precursors which undergo 
proteolytic maturation during transport to the mitochondria 
(Whiting, 1976; Brooker et al, 1980; Ades and Harpe, 1981; 
Srivastava et al, 1982; 1983a; Hayashi et al, 1983; Watanabe et 
al, 1983). Molecular weight estimates for the chicken 
precursor range from 70,000 (Whiting, 1976; Brooker et al, 
1980) to 75,000 (Ades and Harpe, 1981) and the rat precursor 
has been estimated at 76,000 (Srivastava et al, 1982). The 
relationship between the cytosolic and mitochondrial forms of
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the enzyme has been established both 'in vivo 1 by pulse- 
labelling experiments (Srivastava et al, 1982; 1983a) and 'in 
vitro' by demonstrating the direct posttranslational transfer 
and processing of the primary translation product into isolated 
mitochondria (Hayashi et al, 1983).
The cloning of ALA synthase from chicken liver has 
facilitated the isolation of homologous cDNA from rat 
(Srivastava et al, 1988; Yamamoto et al, 1988); human (Bawden 
et al, 1987; Bishop, 1990) and mouse liver (Young and Dierks, 
1990). The ALA synthase cDNA isolated from rat and human 
liver mRNA encode preproteins of identical length which exhibit 
a high degree of sequence homology with chicken liver ALA 
synthase. Alignment of the predicted amino acid sequences of 
these proteins with that of the chicken enzyme has suggested 
that each preprotein consists of a presequence containing 56 
amino acids followed by 586 amino acids of the mature enzyme. 
The amino acid homology of the mature proteins range from 78% 
(human to chicken) to 83% (human to rat).
3.3 GENE STRUCTURE AND EXPRESSION OF ALA SYNTHASE
It is now recognised that ALA synthase is encoded by two 
distinct genes: a housekeeping gene which is expressed in all 
tissues and cell types that have been examined (including 
erythroid cells), and an erythroid-specific gene which is 
dedicated to the management of ALA production during the 
terminal stages of erythroid cell differentiation. The genetic 
origin of erythroid ALA synthase has been one of the most 
controversial areas of research in recent years. Some 
investigators have favoured the view of separate genes encoding
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hepatic and erythroid ALA. synthase, while others have supported 
the concept of alternative promoters and/or splicing patterns 
within a single gene.
Several lines of evidence have led to the identification 
of two distinct genes for ALA synthase.
3.3.1 Evidence for a Housekeeping Gene
Borthwick et al (1984) cloned chick embryonic liver ALA 
synthase mRNA which was later demonstrated to be encoded by a 
single nuclear gene (Elferink et al, 1987). Northern blot 
hybridization analyses indicated that the gene encoded a single 
2.2kb mRNA which was found in all tissues examined, including 
liver, heart, brain and reticulocytes (Elferink et al, 1987). 
The structure of the reticulocyte transcript was identical to 
that found in liver; primer extension analyses indicated that 
it had the same 51 terminus as liver mRNA; and RNase protection 
experiments failed to detect any differences in internal 
sequence organisation. The size of the reticulocyte enzyme, as 
determined by SDS-PAGE was also identical to that of the liver 
(Elferink, 1987).
Srivastava et al (1988) reported similar results from a 
study in rat, using probes derived from rat liver cDNA. In 
agreement with the pattern in chicken, a single 2.3kb mRNA was 
detected in brain, heart, liver, kidney, testes and spleen with 
the structure of the transcripts identical in each tissue. 
Treatment of rats with AIA which selectively induces ALA 
synthase in liver, kidney and testes resulted in a 7-8 fold 
increase in steady-state transcript levels in each of these
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tissues, but not in any of the others.
These results appeared to demonstrate that a single 
"hepatic" ALA synthase gene was expressed at low levels in a 
variety of tissues, including those of erythroid origin. This 
gene responded in liver, kidney and testes to tissue-specific 
stimuli that induced ALA synthase expression. Thus, it seemed 
likely that this gene was active in all mammalian cells and was 
responsible for the maintenance of normal housekeeping 
function.
3.3.2 Evidence for an Erythroid-Specific Gene
Despite the convincing evidence that the "hepatic" ALA 
synthase gene encoded identical mENAs in a variety of tissues, 
including erythroid tissue, several workers maintained that 
different hepatic and erythroid ALA synthase isoenzymes were 
expressed in the two tissues. This was first suggested by 
Bishop et al (1981) from studies on guinea pig.
In contrast to the results of Elferink et al (1987), 
Watanabe et al (1983) had found that ALA synthase in chicken 
liver and reticulocytes differed in size both as mature 
proteins and as precursors when examined using polyclonal 
antibodies raised against purified hepatic ALA synthase. In 
liver mitochondrial extracts, the enzyme had a M.W. of 65,000 
which agreed well with M.W. estimates of the purified hepatic 
enzyme (63,000-68,000) and the calculated M.W. of the mature 
protein. However, the only cross-reacting proteins in 
erythroid mitochondrial extracts had a M.W. of 53,000. When 
the sizes of the preproteins were estimated for each cell type, 
liver polysomes synthesised a precursor of M.W. 73,000
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(calculated M.W. 70,209) while erythroid polysomes produced a 
protein of M.W. 55,000. Although the accuracy of the estimated 
M.W.'s for the hepatic forms of the enzyme were undisputed, the 
size estimates of the erythroid forms were the subject of 
debate. Since hepatic ALA synthase was known to be susceptible 
to proteolysis and easily converted to smaller polypeptides 
(M.W. 49,000, 51,000 in chicken and rat) which retained
enzymatic activity (May et al, 1986) Elferink et al (1987) 
suggested that the smaller erythroid forms detected by Watanabe 
et al (1983) resulted from proteolysis of the mature and 
precursor forms of the same protein that was expressed in 
liver. However, nucleic acid analyses suggested that this was 
not the case. Yamamoto et al (1985) used the polyclonal 
antiserum described by Watanabe et al (1983) to identify 
several putative ALA synthase cDNA clones in a reticulocyte 
cDNA expression library. One cDNA hybridized selectively to a 
reticulocyte mRNA encoding the expected preprotein (M.W. 
55,000). This cDNA hybridized to a unique 2kb mRNA and was 
expressed only in reticulocytes.
It was then concluded that the erythroid primary 
translation product (M.W. 55,000) detected by Watanabe et al 
(1983) was not encoded by the hepatic ALA synthase gene, but by 
a distinct gene which was differentially expressed only in 
erythroid cells. The protein encoded by this gene was later 
identified as an erythroid-specific form of ALA synthase 
following isolation and analysis of a cDNA copy of the 
erythroid ALA synthase mRNA (Riddle et al, 1989). Sequence 
analysis showed that it encoded a preprotein (M.W. 54,800, 518
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amino acids) which shared 56% amino acid sequence homology with 
hepatic ALA synthase. Genomic DNA blotting experiments and 
RNase protection assays further showed that this cDNA was 
encoded by a distinct ALA synthase gene expressed only in 
erythroid cells. In agreement with Elferink et al (1987) it 
was also shown that the hepatic ALA synthase gene is 
coexpressed in erythroid cells, but at a level that is only 1- 
2% of the erythroid gene.
Similar confusion existed concerning the number of mouse 
genes encoding ALA synthase. Schoenhaut and Curtis (1986) 
employed a novel genetic complementation technique to isolate 
cDNA encoding ALA synthase in BALB/c mouse. The results 
indicated that ALA synthase was encoded by a single gene. 
However, using a different approach to isolate ALA synthase 
cDNA from DBA/2 mouse Young and Dierks (1990) found that the 
enzyme was encoded by two distinct genes which were 
differentially regulated in erythroid and nonerythroid cells. 
This more recent data suggested that the approach used by 
Schoenhaut and Curtis (1986) introduced a strong bias for the 
recovery of clones encoding the erythroid-specific form of the 
enzyme, thereby creating the false impression that drug- 
inducible hepatic ALA synthase mRNA was the same as that 
expressed at high levels in differentiating erythroid cells.
The conflict has only recently been resolved with the 
localisation of housekeeping and erythroid ALA synthase genes 
to chromosome 3 (Sutherland et al, 1988) and chromosome X (Cox 
et al, 1990) respectively.
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3.4 REGULATORY MECHANISMS IN HEPATIC rRf.r.q
3.4.1 Induction and Repression of ALA Synthase in Hepatic Cells
As discussed in Chapter 1 (Section 1.8) the rate 
controlling enzyme of haem biosynthesis in hepatic tissue is 
ALA synthase. A large number of compounds are capable of 
inducing ALA synthase activity in liver including various 
lipophilic chemicals and drugs and some natural and synthetic 
steroids (Granick, 1966). Experimental depletion of haem 
induces ALA synthase while the presence of excess cellular haem 
inhibits ALA synthase in four possible ways:-
1. Direct inhibition of ALA synthase activity (Tait, 1978).
2. Inhibition of ALA synthase mRNA synthesis (Whiting, 1976).
3. Inhibition at a post transcriptional step (Sassa and Granick,
1970).
4. Inhibition of enzyme transfer from the cytosol to the inner 
mitochondrial membrane (Hayashi et al, 1972).
Granick (1975) proposed the now widely accepted concept of 
a regulatory haem pool suggesting that the rate of haem 
synthesis in hepatic tissue was regulated by the intracellular 
'free haem' concentration (O.lpM). Increases in 'free haem' 
concentration resulted in inhibition of functional ALA synthase 
and induction of haem oxygenase, while decreases in 
concentration had the opposite effect. A reciprocal 
relationship therefore exists between these two enzymes which 
is influenced by intracellular 'free haem' concentration.
Mitochondrial ALA synthase partially purified from rabbit, 
rat and guinea pig liver has Km values for glycine, succinyl 
CoA and PLP in the ranges 5 to 19 mM, 60 to 200 pM and 1 to 10
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pM respectively (Whiting and Elliot, 1972; Whiting and Granick, 
1976; Aoki et al, 1971; Scholnick et al, 1972; Woods and 
Murthy, 1975). The relatively high Km (i.e. low affinity) of 
the enzyme for glycine has raised the possibility that the 
enzyme activity may further be regulated by the physiological 
concentration of available glycine in liver (Sinclair and 
Granick, 1972).
3.4.2 Turnover of Hepatic ALA Synthase
The t V 2 of mitochondrial ALA synthase is short (i.e. 
70min in adult rat liver (Marver et al, 1966; Hayashi et al, 
1969; Tschudy et al, 1965)). ALA synthase has one of the most 
rapid turnover rates of the proteins in mitochondria as 
compared with the average t V 2 of mitochondrial proteins of 5 
days (Druyan et al, 1969). Control over the rate of enzyme 
synthesis in liver is believed to be the major regulator of 
enzyme activity and hence hepatic haem biosynthesis.
3.5 REGULATORY MECHANISMS IN ERYTHROID CELLS
3.5.1 Induction and Repression of ALA Synthase in EEL Cells
In DMSO-treated FEL cells (Chapter 1, Section 1.10.2(i) ) 
Hb accumulation begins during erythropoietic development and 
results in a 50-fold increase in cellular haem levels (Sassa,
1976). This is accompanied by relatively small increases in
the activities of most, if not all, of the haem enzymes (Sassa, 
1976; Rutherford et al, 1979; Beaumont et al, 1984). ALA 
synthase activity reaches a maximum of 3-5 times that of the 
preinduced level by 72-96 h. However, the extent of ALA 
synthase induction can be altered by manipulation of haem
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availability in differentiating cells (Beaumont et al, 1984). 
Addition of haemin (lOpM) prior to the induction procedure 
markedly inhibited the differentiation-dependent increase in 
ALA synthase activity. Conversely, the addition of 
succinylacetone (4,6-dioxoheptanoic acid), a potent inhibitor 
of ALA dehydratase, with DMSO led to a 6 fold increase in ALA 
synthase activity at 96 h compared with that achieved with 
DMSO alone. Haemin (lOpM) added at 72 hour after DMSO 
inhibited the 'superinduction1 of ALA synthase and reduced 
activity to the level achieved with DMSO alone. Thus, ALA 
synthase in differentiating FEL cells appeared to be sensitive 
to intracellular haem balance.
Two possible models are likely for the induction of 
erythroid gene expression.
A derepression model similar to that in hepatic cells whereby 
ALA synthase gene expression is regulated solely by haem. This 
would suggest that erythroid gene activation occurs during the 
differentiation process in response to the reduced haem levels 
which result from the rise in globin chain production and Hb 
formation.
Alternatively, ALA synthase may be induced by a developmental 
signal early in the differentiation sequence. In this case, 
the feedback mechanism(s) may act to coordinate the magnitude 
of this i n d u c t i o n  response with other aspects of 
differentiation.
These theories have been examined by manipulating haem 
availability in both undifferentiated and differentiated cells 
then assaying erythroid ALA synthase gene expression (Young and
Dierks, 1990).
While the level of housekeeping gene transcripts remained 
unchanged during differentiation, the number of erythroid ALA 
synthase mKNAs per cell increased dramatically to levels 50-75 
times above baseline by 96 h of induction with DMSO (Fraser and 
Curtis, 1987; Young and Dierks, 1990). Most of this increase 
could be attributed to higher rates of ALA synthase gene 
transcription (Fraser and Curtis, 1987). If erythroid ALA 
synthase was controlled by deregulation then erythroid gene 
expression would be activated in the absence of differentiation 
by cellular haem depletion. This was examined by culturing 
undifferentiated FEL cells in the presence of succinylacetone 
(Young and Dierks, 1990). Under these conditions, the cells 
entered a state of growth arrest which was both preventable and 
restorable by haemin addition (lOpM). The level of ALA 
synthase transcripts was identical to that in cells grown 
either in the absence or presence of succinylacetone and 
haemin (lOpM). Thus, expression of the erythroid gene cannot 
be activated in undifferentiated cells by haem depletion. 
Similar experiments in cells induced to differentiate with DMSO 
produced results in agreement with Beaumont et al (1984) 
whereby succinylacetone caused a haemin-reversible inhibition 
of Hb formation and super induction of ALA synthase activity. 
However, the kinetics of erythroid ALA synthase transcript 
accumulation were unaffected by succinylacetone or haemin.
It was therefore concluded that the induction of erythroid 
ALA synthase gene transcription is developmentally regulated 
and largely unaffected by intracellular haem balance.
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Furthermore, the extent of ALA synthase mRNA induction during 
differentiation (50-75 fold) was greater than the normal 5 fold 
increase in enzyme activity. Hence, it would appear that 
enzyme activity is influenced by post-transcriptional 
mechanisms sensitive to the presence of succinylacetone or 
haemin.
3.5.2 Possible Mechanisms of Post-tr anscr iptional Control
An explanation of the opposing effects of succinylacetone 
and haemin on ALA synthase activity in FEL cells may be that 
the rate of translation and/or transport of ALA synthase is 
under negative control by haem. However, the structure of 
erythroid ALA synthase mRNA suggests that more than one level 
of posttr anscr iptional control may be involved. Residues 6 to 
40 in the 51 untranslated region (UTR) have been shown to 
exhibit striking structural and sequence similarity to the cis- 
acting iron responsive elements (IRE) which coordinate 
production of ferritin subunits (Aziz and Munro, 1987; Hentze 
et al, 1987) and synthesis of the transferrin receptor (Casey 
et al, 1988) with the availability of iron. Casey et al (1988) 
have suggested that these elements are characterised by:
1. a 6-nucleotide loop containing the sequence CAGUGX;
2. an upper stem of five paired bases;
3. an unpaired 51 C residue separated from the loop by 5 bases;
4. a lower stem of variable length.
All of these elements are present in the putative IRE of 
the 5' UTR of mouse erythroid ALA synthase mRNA (Schoenhaut and 
Curtis, 1986) (Figure 7) while no such elements are present in
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FIGURE 7
THE 5' UNTRANSLATED REGION OF ERYTHROID ALA SYNTHASE mRNA 
SHOWS STRUCTURAL AND SEQUENCE SIMILARITY TO THE IRON 
RESPONSIVE ELEMENTS OF RAT AND HUMAN FERRITIN SUBUNIT mRNA
any of the housekeeping ALA synthase genes which have been 
examined to date.
Synthesis of the iron-storage protein ferritin is 
regulated at the translational level by the availability of 
iron. The mRNAs for both ferritin subunits (A and H) are 
stored as inactive ribonucleoprotein particles, which are 
translated when iron enters the cell (Rogers and Munro, 1987; 
Zahringer et al, 1976; Aziz and Munro, 1986). The 
redistribution of these mRNAs into polysomes in the presence of 
iron is mediated by cis-acting sequences (the IRE) found in the 
51 UTR of both subunit mRNAs. It has been proposed that when 
iron levels are low a cytoplasmic protein selectively binds to 
the 5'-IRE of ferritin mRNA and blocks translation (Liebold and 
Munro, 1988). The presence of iron disrupts these complexes 
allowing access of the 51 UTR to the ribosomes and mRNA 
translation then occurs. In contrast to ferritin, the 
synthesis of transferrin receptors is stimulated when 
intracellular iron levels are low (Casey et al, 1988) 
presumably as a means of increasing iron acquisition. It is 
believed that the same type of protein interactions which 
control the rate of ferritin mRNA translation may also occur 
with the IREs in the 3'UTR of transferrin receptor mRNA (Casey 
et al, 1988).
In view of these observations, it is also possible that 
translation of erythroid ALA synthase mRNA is coupled to iron 
availability. In addition to causing increased globin and haem 
biosynthesis, DMSO treatment of FEL cells produces a 6 -fold 
increase in the expression of erythroid transferrin receptors 
(Wilczynska et al, 1984). Furthermore, the induction of
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transferrin receptor expression in FEL cells is blocked by haem 
(Wilczynska et al, 1984). The effect of increasing the rate of 
iron transport during differentiation has been examined by 
circumventing the transferrin receptor-dependent iron transport 
system with a more effective iron delivery system using the 
synthetic iron chelator salicylaldehyde isonicotinoyl hydrazone 
(SIH) (Laskey et a l , 1986). With Fe-SIH as the iron source, 
the rate of incorporation of [2-1 4C]- glycine into haem in DMSO- 
treated FEL cells increased 3.6 fold (Laskey et a l , 1986). 
Addition of ALA to DMSO-treated FEL cells had no effect on the 
rate of ^ F e  incorporation into haem when ^ F e - t r a n s f e r r i n  w a s  
used as the iron donor. This then indicates that it is the 
rate of iron transport, rather than the synthesis of ALA which 
limits haem production in differentiating FEL cells. It has 
been suggested (Dailey, 1989) that the strong transcriptional 
response of erythroid ALA synthase may be attenuated at the 
level of translation by the availability of iron as a means of 
coordinating the rate of protoporphyrin IX synthesis with the 
rate of iron transport. This further suggests that the 
'superinduction1 of ALA synthase by succinylacetone may not 
reflect a reduction in haem levels, but rather increased levels 
of iron due to the inhibition of protoporphyrin IX production. 
This iron-sensitive feedback loop at the level of translation 
may account for the effects of succinylacetone. It is more 
difficult to explain the inhibition of ALA synthase expression 
by haem. There is currently no data to indicate the function 
of this feedback control or how it may operate.
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3.6 REACTION MECHANISM FOR ALA SYOTBASE
The following mechanism has been elucidated for the 
reaction catalyzed by ALA synthase purified from R. spheroides 
(Zaman et al, 1973; Akhtar et al, 1976; Abboud et al, 1974) 
(see figure 8 ) ) -
1. Glycine forms a Schiff base with PLP which is bound to the 
enzyme yielding a stable carbanion.
2. A proton (R-configuration) is removed from the methylene carbon 
atom of glycine.
3. Succinyl CoA condenses to the carbanion to formcx-amino-j3- 
ketoadipic acid with the loss of CoA.
4. c* -amino-/3-ketoadipic acid is decarboxyl a ted to yield ALA.
The proton on the methylene carbon atom of glycine lost 
at step 1 is specifically that of the R configuration while the 
one having the S-configuration is incorporated into ALA (Zaman 
et al, 1973). Succinyl CoA is not required for the proton 
removal reaction (Laghai and Jordan, 1976). Haem, an 
allosteric effector of the enzyme activity, has, however, no 
effect on the loss of the proton from glycine (Laghai and 
Jordan, 1976). Decarboxylation of cx-amino-jS-ketoadipic acid 
to ALA occurs on the enzyme and then ALA is released into the 
medium from the pyridoxal-enzyme complex (Abboud et al, 1974).
3.7 THE ASSAY OF ALA SYNTHASE ACTIVITY
3.7.1 Colourimetrie Assay of ALA Synthase Activity
ALA synthase activity is generally determined in tissue 
homogenates or in isolated mitochondrial fractions by the use 
of a colourimetric method (Granick and Urata, 1963; Marver et
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THE REACTION MECHANISM FOR ALA FORMATION
al, 1966; Hayashi et al, 1969; Sassa et al, 1979). The 
original colo rimetric assay (Mauzerall and Granick, 1956) 
involved the conversion of ALA to a pyrrole by adding either 
acetylacetone or ethylacetoacetate. ALA pyrrole may then be 
reacted with modified Ehrlich reagent and quantified by 
spectrophotometry at 555nm. In this reaction a coloured salt 
is formed by the reaction of the free ex-hydrogen on the pyrrole 
with the dimethylamino-benzaldehyde (DMAB) in the Ehrlich 
reagent (Lien and Beattie, 1982) (Figure 9). The colour is not 
stable and must be read at 15 minutes to avoid the reaction of 
the coloured salt with a second molecule of pyrrole to form a 
colourless compound.
The major limitation of this assay method for ALA 
formation is the lack of sensitivity. The limit of detection 
with colo rimetric assays is approximately 3 nmoles ALA/ml 
(Falk, 1964). Such assays are not then suitable for use with 
tissues containing low levels of ALA synthase activity, or with 
tissues which are only available in very small quantities such 
as bone marrow.
The formation of aminoacetone pyrrole which also reacts 
with Ehrlich reagent may present a significant problem. 
Aminoacetone is formed by the condensation of glycine with 
acetyl CoA, catalyzed by aminoacetone synthase, or by the 
oxidation of threonine (Lien and Beattie, 1982). Separation of 
ALA pyrrole and aminoacetone pyrrole can be achieved by Dowex 
ion exchange chromatography (Mauzerall and Granick, 1956; 
Marver et al, 1966) or alternatively by solvent extraction 
(Granick, 1966; Sassa et al, 1979).
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3.7.2 Fluorometric Assay of ALA Synthase Activity
A highly sensitive fluorometric assay for ALA synthase 
activity has been described (Bishop et al, 1982). Although 
this assay was capable of detecting ALA synthase activity in 
the pmole/ml range it was not able to detect enzyme activity in 
bone marrow lysates (Bottomley and Moore, 1982).
3.7.3 Radiochemical Assay of ALA Synthase Activity
Radiochemical assays of ALA synthase activity have been 
shown to be the most sensitive means of detection and are 
sensitive to the level of 10-100 pmoles ALA/ml (Irving and 
Elliot, 1969). Such methods have been favoured in the 
detection of ALA synthase activity in liver (Irving and Elliot,
1969), human bone marrow (Bottomley et al, 1973), 'in vitro1 
cultured cell lines (Ebert and Ikawa, 1974), 'in vitro' bone 
marrow cultures (Ibrahim et al, 1982), peripheral blood 
leucocytes (Brodie et al, 1977) fractionated human bone marrow 
erythroblasts (Fitzsimons et al, 1986), adrenal gland (Condie 
et al, 1976), heart (Briggs et al, 1976; Israelis et al, 1974), 
kidney (Barnes et al, 1971), brain (Barnes et al, 1971) and 
testes (Tofilon and Piper, 1980).
For the purposes of the work described here a highly 
sensitive specific radiochemical assay suitable for the 
measurement of ALA synthase activity in the small cell numbers 
available from human bone marrow was required. Such a method 
(Fitzsimons et al, 1986) was adopted and modified to further 
optimise the conditions for the measurement of erythroid ALA 
synthase activity.
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3.8 MEASUREMENT OF ALA SYOTHASE ACTIVITY IN HUMAN BONE MARROW
ALA synthase activity in human bone marrow was measured by 
the radiochemical method described by Fitzsimons et al (1986). 
This method utilises [^C]-succinate and glycine as enzyme 
substrates and employs a means for the isolation of the 
radioactive product [^C]-ALA which is more sensitive and 
specific than that offered by other assays. The method 
involves firstly the conversion of [-^C]-ALA product to the 
more stable compound [^C]-ALA pyrrole . The pyrrole is then 
partially isolated by sorbent extraction prior to complete 
isolation from radioactive contaminants by reversed phase high 
performance liquid chromatography (RPHPLC). The RPHPLC 
isolation of ALA pyrrole was based on the method first 
described in the assay of rat liver ALA synthase activity 
(Tikerpae et al, 1981) and when combined with a radiochemical 
assay offers sensitivity double that of the next most sensitive 
assay.
3.8.1 Problems with Radiochemical Assays of ALA Synthase Activity
There are three major difficulties with regard to 
radiochemical assays of ALA synthase activity in human bone 
marrow.
1. Choice of suitable radioactive substrate (Section 3.8.2).
2. Isolation of radioactive ALA (Section 3.8.3).
3. Loss of radioactive ALA during enzyme incubation known as ALA
utilisation (Section 3.8.10(iv)).
3.8.2 Choice of Suitable Radioactive Substrate
The direct substrates of ALA synthase are succinyl CoA and
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glycine. The assay described by Fitzsimons et al (1986) 
utilises [^C]-succinyl CoA as substrate as opposed to [^C]- 
glycine (Freshney and Paul, 1970) because the Km of ALA 
synthase for glycine is high at 4.2 mmol/1 (Freshney and Paul,
1970), 2.5-7.5 mmol/1 (Nakakuki et al, 1980) and approximately 
160 times the Km for succinyl CoA (Aoki et al, 1974). Thus, 
[^C]-glycine is not a practical substrate (Bishop and Wood, 
1977).
The Km for succinyl CoA is low at 11 pmol/1 (Nakakuki et 
al, 1980). Succinyl CoA is unstable both at -20°C and during 
incubation at 37°C (Aoki et al, 1974). It is unavailable 
commercially and is normally prepared from [^C]-ketoglutarate 
or [l^c]-succinate. [-^-^C]-succinate provides higher 
sensitivity than [1 4C]-ketoglutarate in both assays of hepatic 
(Ebert et al, 1970) and erythroid (Fitzsimons et al 1986) ALA 
synthase and was therefore chosen for use in conjunction with a 
succinyl CoA generating system in the work described here.
3.8.3 Isolation of Radioactive ALA
A major problem in the assay of ALA synthase activity is 
the specific isolation of [-*-^C]-ALA from other radioactive 
compounds found in the reaction mixture (Patton and Beattie, 
1973). Most radiochemical methods to date have employed 
solvent extraction of ALA pyrrole by ethylacetate followed by 
single column ion-exchange chromatography (Irving and Elliot, 
1969). This method was later simplified (Ebert et al, 1970) 
resulting in a rapid and sensitive radiochemical assay capable 
of detecting low levels of activity. The subsequent
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development of a sequential multicolumn ion exchange procedure 
(Strand et al, 1972) improved specificity, but resulted in a 
laborious procedure which produced significant variability in 
ALA recoveries from duplicate samples (Schacter et al, 1976). 
In addition, complete separation of [1 4 C]-ALA from other 
radioactive compounds has never been achieved by this means in 
assays using mitochondria or crude liver homogenates (Bishop 
and Wood, 1977; Managa et al, 1978; Wolfson et al, 1980). 
Separation has, however, been marginally improved using a 
Beckman amino acid analyser (Bishop and Wood, 1977). Methods 
have also been developed to extract impurities from [^4C]- 
succinate which may contaminate [^4C]-ALA (Condie et al, 1976; 
Bishop and Wood, 1977; Brooker et al, 1982). Sodium dodecyl 
sulphate (SDS) has been used to replace TCA at reaction 
termination to inhibit the extraction of contaminants along 
with ALA. However, the presence of SDS resulted in decreased 
enzyme activity and variable recovery of the internal standard 
(Scotto et al, 1983). When [1 4C]-glycine is used as substrate 
(Freshney and Paul, 1971) in place of [1 4 C]-succinate high 
voltage paper electrophoresis can effect separation of [ 4^C]- 
ALA from [1 4C]-glycine (Rutherford et al, 1979), although this 
is incomplete. This method is not suitable for the separation 
of [1 4C]-ALA from [1 4C]-succinate.
The use of RPHPLC for the specific isolation of ALA 
pyrrole was first described by Tikerpae et al (1981). This 
method has since been modified (Fitzsimons et al, 1986) to 
enable the specific isolation of [^4C]-ALA pyrrole from [^4C]- 
succinate.
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3.8.4 Principles of HPLC
Liquid chromatography is a chemical separation method 
based on the interactions between solutes, liquid mobile phase 
and solid stationary phase. Separation takes place in a column 
containing the chromatographic material (the stationary phase) 
in the form of small particles. The solvent (i.e. eluent or 
mobile phase) is pumped through the particle bed enabling 
sample components dissolved in the mobile phase to reversibly 
interact with the stationary phase in a continuous manner. 
Separation is achieved on the basis of the relative affinities 
of the sample components for the stationary and mobile phases. 
Components with a strong affinity for the stationary phase 
elute later than those with a greater affinity for the mobile 
phase.
The HPLC system consists of a pump and a solvent 
reservoir, with an injection valve for applying a precise 
volume of sample prior to the column. A solvent delivery 
system is connected to the column in order to feed it with 
mobile phase. The pump is capable of operating under high 
pressure (6000 psi) and the system is optimised to increase 
speed, resolution and sensitivity. After passing through the 
column the separated sample components are monitored by a 
detector then fractionated in a fraction collector.
The Detector
Samples may be detected using a variable wavelength 
spectrophotometer sensitive to the nanogram level of detection.
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3.8.5 Principles of RPHPLC
Reversed-phase HPLC (RPHPLC) utilises solubility 
properties of the sample. Partitioning of the sample 
components between a hydrophilic and a lipophilic solvent 
depends on their respective solubility characteristics. Less 
hydrophobic components attach to the hydrophilic phase and more 
hydrophobic ones to the lipophilic phase. In RPHPLC, silica 
particles with chemically bonded hydrocarbon chains represent 
the lipophilic phase while an aqueous mixture of an organic 
solvent (surrounding the particles) represents the hydrophilic 
phase. The whole process, therefore, depends on the extractive 
power of the hydrophilic phase. This may be altered by the 
addition of an organic solvent to the hydrophilic phase. A 
high concentration of organic solvent will increase the 
extractive power for hydrophobic compounds.
The ability of a stationary phase to discriminate between 
two components i.e. the selectivity can be influenced in 
three different ways -
1 The choice of stationary phase
2 The addition of an organic solvent to the mobile phase
3(a) Changing the pH to alter the hydrophobicity of components 
containing acid and/or basic groups 
(b) By the addition of an ion-pairing agent to render ionic 
components hydrophobic.
(i) The Stationary Phase
The retention of hydrophobic components is influenced by the 
thickness of the lipid layer. A C18 layer is more hydrophobic 
than a C 8 layer which in turn is more hydrophobic than a C2
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layer. HPLC columns are available prepacked with silica 
particles chemically bonded with these hydrocarbon chain 
lengths. C18 packing provides maximum resolving power for 
hydrophobic compounds.
(ii) The Mobile Phase
The mobile phase is an aqueous solution of an organic solvent, 
the type and concentration of which determines the extractive 
power.
(iii) Hydrophobicity of the Sample
The hydrophobicity of the sample may be increased by 
neutralising charged groups on the molecule by the 
incorporation of an ion-pairing substance in the mobile phase. 
The ion-pairing molecule is a bulky molecule which forms a 
complex with a charged sample component due to electrostatic 
interaction. The ion-ion bond is shielded by the rest of the 
molecule. Similarly, hydrophobic molecules may be made less so 
by the addition of a hydrophilic ion-pairing agent.
ALA pyrrole may be detected by HPLC/spectroscopy at a 
measuring wavelength of 252 nm. ALA pyrrole elutes from a C18 
column between 7 and 8 minutes using a mobile phase of methanol 
: water (37 : 63 v/v) containing heptanesulphonic acid (0.005M) 
as ion pairing agent and set at a flow rate of 1.5ml min ^ 
(Fitzsimons et al, 1986).
This experimental work describes the assay of ALA 
synthase activity in normal human bone marrow and details:
1* Improvements made to the assay with respect to the composition 
of the reaction mixture.
85
2. Marrow cell preparation prior to enzyme assay.
3. The choice of labelled enzyme substrate.
4. Further study of the temperature-dependent inactivation of ALA 
synthase (Beattie et al, 1985; Fitzsimons et al, 1986).
5. The suitability of the assay for use with non-erythroid tissue.
3.8.6 Materials
The following chemicals and enzymes were purchased from 
Sigma Chemical Company: succinic acid, disodium salt, 
hexahydrate; trizma base, reagent grade; 5-aminolaevulinic 
acid, hydrochloride; succinyl ace tone (4 ,6-dioxoheptanoic acid); 
succinic thiokinase (succinyl CoA synthetase, EC.6.2.1.4), 
partially purified lyophilized powder from porcine heart; 
coenzyme A, sodium salt; guanosine 5' triphosphate, sodium salt 
type III; pyridoxal 5-phosphate (codecarboxylase).
Radiochemicals were purchased from Amersham International: 
5-amino[4 -^^C]-laevulinic acid hydrochloride, freeze-dried, 
sealed under nitrogen; [2 ,3-^^C] succinic acid, freeze-dried, 
sealed under nitrogen.
All other chemicals were purchased from BDH Chemicals 
Limited (reagent grade): sucrose, hexahydrate; magnesium
chloride, hexahydrate; glycine (aminoacetic acid); 
ethylenediaminetetra-acetic acid, disodium salt; potassium 
dihydrogen orthophosphate; sodium acetate, trihydrate;
trichloroacetic acid.
HPLC grade chemicals were purchased from the following 
companies: acetonitrile and methanol (Rathburn Chemicals); PIC 
B7 (ion pairing agent, heptane sulphonic acid) (Waters
Associates)•
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3.8.7 HPLC EQUIPMENT
The following equipment was purchased from Waters 
Associates: dual piston pump (model M 6000 A); variable 
wavelength spectrophotometer (model 481); integrator (model 
740, data module); sep-pak sorbent extraction columns (C18).
The following equipment was purchased from Canberra 
Packard: liquid scintillation analyser 2000 CA (model A2020); 
scintillation vials (pony vials); scintillation fluid 
(picofluor 40).
All other materials were purchased from the following 
companies: sample injector (Rheodyne, model 7125); reversed 
phase HPLC column-Apex C18 0DS, 5jjM particle size (4.6 x 150mm) 
(Jones Chromatography); fraction collector (Gilson, model 203); 
sample concentrator (Techne dri block, model D8-3).
3.8.8 Preparation of Bone Marrow Cells
ALA synthase activity can be measured in mitochondrial 
fractions, partially purified preparations of the enzyme or in 
crude tissue homogenates. However, due to the loss of 
mitochondria that occurs during preparation of mitochondrial 
fractions from small amounts of tissue (as is the case for bone 
marrow samples), most workers have chosen to work on crude 
tissue preparations (De Matteis and Hollands, 1982).
The method of tissue preparation described and optimised 
for use in human bone marrow (Fitzsimons et al, 1986) was 
employed. Cell pellets were ice cooled then sonicated in 
incubation medium using an ultrasonic disintegrator (MSE, 
150KW) fitted with a V s "  titanium probe set to 15 microns in 
air (3 pulses of 5 seconds duration). In the work described
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here, the volume of incubation medium added to each cell pellet 
was reduced from 1.50ml to 0.85ml without loss of enzyme 
activity. As sonication was shown to reduce ferrochelatase 
activity (Chapter 5, Section 5.10.1) freeze-thawing was also 
examined as an alternative means of tissue preparation (Section 
3.9.3).
3.8.9 Enzyme Assay Incubation Medium
Initial experiments took place in incubation medium 
prepared from distilled deionised E^O containing sucrose 
(250mM), glycine (50mM), magnesium chloride, MgCl2 (20mM), tris 
base (40mM), ethylenediaminetetra-acetic acid, EDTA (5mM) pH'd 
to 7.4 with potassium dihydrogen orthophosphate (KH2PO4 ) 
(50mM). This was the basic incubation medium to which all 
other components required for the enzyme reaction were added 
fresh on the day of assay. This was stable at -20°C for 
several months.
3.8.10 Function of Incubation Medium Components
(i) Sucrose
Sucrose is commonly present in the incubation medium 
(Rutherford et al, 1979; Wolf son et al, 1980; Tikerpae et al, 
1981) and provides osmotic stability for ALA synthase during 
tissue preparation.
(ii) Glycine
Glycine is the immediate enzyme substrate and erythroid ALA 
synthase has been shown to be saturated with 25mM glycine 
(Bottomley et al, 1973). A concentration of 50mM glycine has
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been used in most studies (Irving and Elliot, 1969; Tikerpae et 
al, 1981; Ibrahim et al, 1982).
(iii) Magnesium
Magnesium ions, Mg^ , are required as cofactor for succinate 
thiokinase activity which catalyzes the activation of [1 4 C]- 
succinate to [1 4C]-succinyl CoA (Ramaley et al, 1967). [1 4C]-
Succinyl CoA is the direct substrate of ALA synthase. The 
optimum Mg2+ concentration was established (Section 3.9.2).
(iv) Ethylenediaminetetra-acetic Acid (EDTA, disodium salt)
EDTA inhibits ALA dehydratase, the second enzyme of the haem 
biosynthetic pathway, and so prevents the condensation of ALA 
formed during the enzyme incubation to the monopyrrole, 
porphobilinogen (i.e. ALA utilisation). Enzyme activity is 
inhibited by EDTA via the chelation of Zn2+ ions (Bevan et al,
1980). Failure to inhibit this enzyme leads to loss of ALA via 
ALA utilisation in assays of both liver and bone marrow ALA 
synthase. A concentration of 5mM EDTA was found to completely 
abolish ALA utilisation in the assay of erythroid ALA synthase 
only when used in conjunction with succinylacetone (Section 
viii) (Fitzsimons et al, 1986) while EDTA alone completely 
abolishes ALA utilisation in the assay of hepatic ALA synthase 
(Ebert et al, 1970; Strand et al, 1972)..
Incubation medium containing these stable components was 
prepared (Appendix I) and stored at -20°C. On the day of assay 
further, less stable components were added.
(v) Pyridoxal Phosphate (PLP)
PLP is an essential cofactor for ALA synthase (Section 3.6).
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However, exogenous PLP may not be necessary for the detection 
of maximum enzyme activity in normal human bone marrow 
(Bottomley et al, 1973). In tissues in which it has been 
required for maximum enzyme activity O.lmM PLP was saturating 
(Irving and Elliot, 1969; Bishop et al, 1982). For this study
0.4mM PLP was chosen for use.
(vi) Coenzyme A (CoA)
CoA is required as substrate by succinate thiokinase (STK) for 
the formation of succinyl CoA, the direct substrate of ALA 
synthase. The quantity of exogenous CoA required for maximum 
ALA synthase activity is dependent upon the nature of the 
tissue under study. For example, crude liver homogenate does 
not require exogenous CoA (Ebert et al, 1970) while crude deep 
frozen bone marrow sonicates require exogenous CoA at a 
concentration of 1.35mM (Fitzsimons et al, 1986).
(vii) Succinylacetone (4,6-dioxoheptanoic acid)
Succinyl acetone is a profound and specific inhibitor of hepatic 
and erythroid ALA dehydratase (Tschudy et al, 1981; Sassa and 
Kappas, 1983). In the assay of human bone marrow ALA synthase 
a combination of succinylacetone (2mM) and EDTA (5mM) 
completely inhibits ALA utilisation (Fitzsimons et al, 1986).
(viii) Succinic Thiokinase (STK) (Succinyl CoA Synthetase; EC 6.2J..4) 
STK catalyzes the reversible conversion of succinate to
o i
succinyl CoA in a reaction which requires both Mg ions and 
triphosphate as cofactors.
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COOH COOH
CH2 + CoA
GTP GDP ch2
COOH 0 = C - S - CoA
SUCCINATE SUCCINYL CoA
The optimum concentration in the assay of bone marrow ALA 
synthase activity is 1 unit per ml (Fitzsimons et al, 1986).
(ix) Guanosine Triphosphate (GTP)
Commercial STK is GTP dependent for maximal activity. In 
normal human bone marrow the optimum GTP concentration was 5mM 
(Fitzsimons et al, 1986).
(x) [ 4^C] Succinate
When [^4 C]-succinate is used as substrate for ALA synthase 
adequate quantities of [^ 4C]-succinyl CoA must be generated by 
the bone marrow cells themselves or alternatively by an 
exogenous succinyl CoA generating system. Such a system may be 
provided by the addition of STK, GTP, Mg^+ ions and CoA. 
Succinate (2mM, specific activity 3.0Ci/mol) is saturating for 
marrow AIA synthase and provides suitable sensitivity.
glycine to [1 4 C]-ALA at saturating concentrations. This
ALA formed during the reaction is preserved and its further 
metabolism to PBG by ALA dehydratase inhibited.
In summary, the incubation medium contains all the 
reagents required for the conversion of [^4C]-succinate and
ensures optimal ALA synthase activity. In addition, the [1 4C]
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3.8.11 Experimental Procedure for the Measurement of Erythroid ALA 
Synthase
The experimental procedure for ALA synthase measurement is 
described:
3.8.12 Incubation Conditions
On the day of assay coenzyme A (1.35mM), GTP (5.0mM) and 
PLP (0.4mM) were added to incubation medium (20ml). This 
complete incubation medium (0.85ml) was added to each cell 
pellet (approximately 20 x 1 0^ cells) prior to sonication.
The assay was carried out in duplicate in eppendorf tubes 
(1.5ml capacity) containing: [1 4 C]-succinate (0.05ml), 2mM
succinylacetone (0.025ml), sonicated sample (0.40ml) and 0.5 
units of succinate thiokinase (0.025ml)
The contents were mixed, then incubated at 37°C for 1 hour 
in a shaking water bath (60 rpm).
3.8.13 Enzyme Reaction Termination
The enzyme reaction was terminated by the addition of
0.25ml ice cold TCA (10% w/v). A known quantity (0.05ml) of 
ALA (4mM) was added as internal standard to enable ALA recovery 
to be calculated for each sample. An aliquot (0.5ml) of sodium 
acetate (1M) was added to bring the pH to 6.5 and so optimise 
pyrrole formation.
3.8.14 ALA Pyrrole Formation
Samples were then spun in a microcentrifuge at 1200g (3 
min) and the supernatant transferred to glass boiling tubes. 
Ethylacetoacetate (0.05ml) was added. Each tube was capped
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with a marble then heated to 100°C for 20 minutes. This 
resulted in 100% conversion of ALA to ALA pyrrole, (Section
3.8.20). Distilled water was added to 5.0 ml.
3.8.15 Partial Isolation of [^^C]-ALA Pyrrole by Sorbent Extraction
Sorbent extraction is commonly used for sample clean-up 
prior to HPI£. 'Sep-pak1 sorbent extraction columns containing 
packing material of C18 hydrocarbon chain length were used for 
the partial separation of [1 4C]-ALA from the remaining t1 4C]- 
succinate and other contaminants. The principles of sorbent 
extraction are broadly similar to that of RPHPLC and are 
discussed in Chapter 5, (Section 5.7.1).
(i) Activation of 'Sep-pak' Column
Columns were activated by the sequential addition of 
acetonitrile (10ml), H 2 O (5ml), MeOH (5ml) and H 2O (10ml) and 
were reusable up to five times when reactivated between 
samples.
(ii) Application of Sample
Samples containing ALA pyrrole were applied to each activated 
column at a flow rate of 1.5ml per minute. Retention of ALA 
pyrrole was determined at 100% (Section 3.8.20). Columns were 
then dried on a bench top vacuum pump.
(iii) Elution of ALA Pyrrole
ALA pyrrole was eluted by the sequential addition of three 
aliquots of MeOH (1.0ml) at a flow rate of 1ml min \
(iv) Sample Concentration
Samples were concentrated by solvent evaporation under N 2 at
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37°C in a sample concentrator.
(v) Sample Reconstruction
Samples were resuspended in 0.1ml of 50% aqueous methanol (v/v) 
and an aliquot taken for RPHPLC (0.05ml).
3.8.16 RPHPLC Isolation of [1 4C] ALA PYRROLE
The HPLC pump was set at a flow rate of 1.5ml per minute. 
Mobile phase, 37% aqueous methanol (v/v) containing 0.005M 
heptane sulphonic acid (PIC B7) as ion-pairing agent was 
filtered (micropore 0.45mm filter) before use. The HPLC column 
was an Apex C18 ODS column, 5pM particle size (4.6 x 150mm). A 
variable wavelength spectrophotometer detected ALA pyrrole at 
252nm and 1.0 AUFS. Column eluate was collected in 30 second 
fractions which were counted (dpm, j i scintillation counting, 10 
min) following the addition of picofluor 40 scintillant (3.0 
ml).
ALA pyrrole eluted between 7 and 8 minutes following 
sample injection as a single sharp peak (Figure 10). Any free 
[-^C] -succinate which had been nonspecifically retained on the 
sep-pak was eluted by 3 minutes with no radioactive 
contamination of the ALA pyrrole peak. Other unidentified 
radioactive peaks eluted within 5 minutes of sample injection 
but did not interfere with isolation of ALA pyrrole and were 
probably due to the presence of other radioactive cellular 
metabolites.
The peak area of ALA pyrrole was directly proportional to 
the pyrrole content and was used to calculate ALA recovery per 
sample (Section 3.8.17).
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Peak 1 = solvent front Peak 2
Peak 3 = cellular metabolite Peak 4
Peak 5 = cellular metabolite Peak 6
See text for further details
FIGURE 10
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['^C]-succinate 
P^cj-ALA pyrrole
THE ISOLATION OF [ 1 ] -ALA PYRROLE USING REVERSED-PHASE
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
3.8.17 ALA Recovery
To calculate the ALA pyrrole peak area equivalent to 100% 
ALA recovery a known number of [1 4 C]-ALA dpm's were added to 
recovery samples containing: 0.50ml fresh incubation medium
with [1 4 C]-ALA (0.025uCi).
These samples were treated in the same manner as those 
containing cells i.e. TCA, carrier ALA and sodium acetate 
were added prior to pyrrole formation and sep-pak application. 
From the recovery samples five aliquots (0.05, 0.04, 0.03, 0.02 
and 0.01ml) were injected into the HPLC and fractions 
collected. From the recorded dpm in the original 0.025uCi 
[14C]-ALA (corrected for the purity of the [ 4^C]-ALA, Section
3.8.20) recovery was calculated as the percentage dpm recovered 
in the ALA pyrrole peak. The graph relating percentage 
recovery to pyrrole peak area was linear and the peak area 
corresponding to 100% recovery could be read off. The average 
recovery of ALA pyrrole was 70%. The results for each sample 
were then corrected to 1 0 0% recovery.
3.8.18 Control T\ibes
The dpm in the ALA pyrrole peak resulting from 
contaminating [^4C]-succinate or radioactive metabolites were 
determined for each batch of samples. Control tubes contained 
[1 4 C]-succinate incubated with bone marrow cells either for 
zero time and then treated as previously described, or for 1 
hour at 37°C but without the subsequent addition of 
ethylacetoacetate required for pyrrole formation. Control dpm 
were always low (less than 100 dpm; background 80 dpm).
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3.8.19 Enzyme Activity Calculation
For each bone marrow sample assayed, the dpm in the ALA 
pyrrole peak was corrected for background and for 1 0 0 % 
recovery. The ALA synthase activity in each sample was then 
calculated from the formula:
pmol ALA/eppendorf tube/h = corrected dpm in ALA pyrrole
dpm/pmol [^-^C]-substrate
Enzyme activity was related to the erythroblast content 
of each sample.
3.8.20 Purity of Commercial [^C]-ALA
The purity of commercial [^4 C]-ALA was assessed at 4-6 
weekly intervals since [ 4^C]-ALA slowly degrades during storage 
at -20°C over a period of months. This enabled an accurate 
value for the recovery of [^4C]-ALA pyrrole to be calculated. 
The method used was first described by Fitzsimons (M.D. Thesis, 
1986).
Method
1.2 nmol [1 4 C]-ALA is added to 0.5ml incubation medium 
containing 200 nmol cold ALA (identical to that used as 
internal standard). ALA pyrrole is formed and the volume made 
to 5.0 ml with water. From this solution 0.5ml is diluted 1 in 
5 with water and reacted with an equal volume of modified 
Ehrlich reagent. The O.D. at 555 nm is then determined (0.32). 
From the formula:
O.D.
CONC(M) = _______  _______ _
Extinction coefficient (M)
it can be confirmed that 100% conversion of cold ALA to ALA
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pyrrole occurs under these conditions. 1.0 ml of this solution 
is taken for scintillation counting and the remainder injected 
through an activated C18 Sep-pak cartridge. No ALA. pyrrole can 
be detected in the sep-pak eluate by reaction with Ehrlichs 
reagent thereby indicating that all ALA pyrrole has been 
retained by the Sep-pak. 1.0ml of eluate is then taken for 
scintillation counting.
Despite the absence of detectable ALA pyrrole in the 
eluate, a significant proportion of the original dpm may be 
recovered in this fraction. 1 .0ml of this fraction was 
reheated to 100% for 20 min with 0.1 ml ethyl ace toace tat e. On 
cooling, no ALA pyrrole can be detected with Ehrlich reagent. 
Therefore, these dpm do not represent unconverted [^ 4C]-ALA but 
rather contaminating dpm from [ 4^C]-ALA degradation.
ALA pyrrole may be eluted from the Sep-pak with methanol 
(3.5ml). Complete ALA pyrrole recovery can be confirmed with 
modified Ehrlich's reagent and the purity of the dpm retained 
by the sep-pak as [-*-4C] -ALA confirmed by RPHPLC.
It was found that after 6 months storage at -20°C the 
purity of the [1 4C]-ALA was reduced from 98% to approximately 
90%. The purity of the [-^4C]-ALA was therefore monitored every 
4-6 weeks.
3.9 IMPROVEMENTS TO THE EXISTING ALA SYNTHASE ASSAY
Initial assays detected less ALA synthase activity in 
whole bone marrow than that reported by Fitzsimons et al 
(1986). The source of water used to prepare assay incubation 
medium was identified as the factor responsible for this 
reduced enzyme activity.
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3.9.1 Effect of Water Purity in Incubation Medium on ALA Synthase 
Activity
Initial assays took place in incubation medium prepared 
from distilled deionised H20 . The effect of the purity of the 
H2O on ALA synthase activity was tested using three batches of 
incubation medium prepared from different H20  sources:
1 . distilled, deionised
2 . distilled
3. sterilised, bottled.
Results
The results are expressed in Table 2 as dpm in the ALA pyrrole 
peak. Each value was corrected to 100% recovery.
Conclusions
1. ALA synthase activities in samples assayed in incubation medium 
prepared from sterilised bottled H 2 0  and from distilled 
deionised H20 were 83% and 58% respectively, relative to the 
enzyme activity in incubation medium prepared from distilled
h2o.
It was suspected that water deionisation may have removed 
an ion required for maximal enzyme activity. Ferrous ions in 
particular may be involved in the biosynthesis of ALA in 
chicken erythrocyte preparations (Brown, 1958; Morrow et al, 
1969) and were included (10~^M) in two of each of the 
triplicate assays.
2. The addition of Fe2+ ions (10"6 M) had the greatest effect on 
those samples suspended in incubation medium prepared from 
distilled deionised H20. The presence of Fe2+ ions at this 
concentration increased enzyme activity by 24%. Nevertheless,
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Source of H?0 for 
Incubation Medium
Fe2+ ions 
(10’6 M)
Corrected 
Average dpm 
in ALA-P
Increase in 
Activity (%) 
With Fe2+
Double distilled. 
Deionized E^O +
2051
2552
24
Distilled H2O 3550 N.S.
+ 3768
Sterilized, Bottled 2963 N.S.
b20 + 2934
Each point represents the mean of duplicate observations 
NS - not significant
TABLE 2
EFFECT OF THE SOURCE OF THE HoO IN INCUBATION MEDIUM ON ALA 
SYNTHASE ACTIVITY
enzyme activity remained 28% below that obtained in incubation 
medium prepared from distilled H20.
3. The addition of Fe2+ ions (10“^M) to samples incubated in
incubation medium prepared from distilled H 20  or sterilised, 
bottled H20  had no effect on enzyme activity.
The results indicate that deionisation of the incubation 
medium leads to a reduction in ALA synthase activity. The 
addition of Fe2+ ions at 10"6m  partially prevented the loss of 
enzyme activity. The reduction in enzyme activity resulting 
from the use of sterilised bottled water may relate to the 
presence of minute quantities of detergent remaining in these 
bottles. The assay is known to be sensitive to the presence of 
detergent during incubation (Fitzsimons et al, 1986) and the 
addition of Fe2+ ions (10“® M) did not improve enzyme activity.
Distilled H20 was used routinely to prepare ALA synthase 
assay incubation medium (as opposed to the distilled deionised 
H20 used previously). This almost doubled the sensitivity of 
the assay. The effects of altering the concentration of EDTA 
and MgCl2 in the incubation medium were then examined.
3.9.2 Effect of Altering the Concentration of Components of the
Incubation Medium
EDTA (lOmM) and MgCl2 (20mM) had previously been used in 
the assay of rat liver ALA synthase activity (Tikerpae et al,
1981) and were chosen without further experimentation in the 
assay of human bone marrow enzyme activity (Fitzsimons et al, 
1986). Since both EDTA and Mg2+ ions are essential components 
of the assay, EDTA as an inhibitor of ALA dehydratase and Mg2+ 
ions as cofactor for STK, the optimum concentrations of these
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components were determined. The need for an exogenous succinyl 
CoA generating system was also confirmed.
Results
The results are shown in Table 3. Corrected dpm in [^C]-~ 
ALA pyrrole was taken as a measure of ALA synthase activity.
Conclusions
1. A reduction in the concentrations of EDTA and MgCl2 from lOmM 
and 20mM to 2mM and 5mM respectively had no significant effect 
on ALA synthase activity.
2. In those assays which contained EDTA (lOmM) and MgCl2 (20mM) 
the addition of STK (1 unit/ml) to provide an external succinyl 
CoA generating system resulted in an increase in detectable ALA 
synthase activity of 29%.
3. In assays containing EDTA (2mM) and MgCl2 (5mM) the addition 
of STK (1 unit/ml) produced an increase in detectable ALA 
synthase activity of 59%.
It is unclear why the presence of STK should apparently 
produce a larger (x 2) increase in enzyme activity in the 
presence of lower concentrations of EDTA and M g C l 2. 
Nevertheless, it is obvious that an exogenous succinyl CoA 
generating system is required for the assay of bone marrow ALA 
synthase activity in cells which have been stored at -80°C 
prior to assay.
The conclusions from this work led to alterations in the 
incubation medium by reducing the concentration of EDTA and 
MgCl2 to 2mM and 5mM respectively. This is similar to the 
concentrations chosen in ALA synthase assays which utilise 2- 
ketoglutarate as substrate (Tikerpae et al, 1981). This
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[EDTA]
nM
[Mg2+]
nM
+ STK
1 unit/ml” ^
Mean Corrected 
dpm in [14C] AIA-P
10 20 - 1846
10 20 + 2389
10 20 - 1671
2 5 + 2982
2 5 - 1845
2 5 + 2940
2 5 - 1881
Each point represents the mean of duplicate observations 
TABLE 3
EFFECT OF ALTERING THE CONCENTRATION OF EDTA, Mg2+ IONS AND 
SUCCINATE THIOKINASE ON ALA SYNTHASE ACTIVITY
improved the sensitivity of the assay possibly via an effect on 
STK with increased availability of succinyl CoA.
3.9.3 Optimum Procedure for Sample Preparation Prior to Assay
The optimum procedure for bone marrow sample preparation 
prior to assay of ALA synthase activity (Fitzsimons et al, 
1986) was shown to be sonication of bone marrow cells in 
incubation medium using a Vg" titanium probe set to 15 microns 
in air (3 x 5'). Work described later in this thesis (Chapter 
5, Section 5.10.1) determined that optimum ferrochelatase 
activity is achieved by freeze-thawing (x 3) in incubation 
medium : glycerol (80:20, vol/vol). The effect of freeze 
thawing on ALA synthase activity was therefore determined. ALA 
synthase activity was determined following different sample 
preparation methods.
Sample Preparation p moles ALA/10^
erythroblasts/hr
Sonication (3 x 51) 612
Freeze thawed (x 3) 390
in incubation medium
Freeze thawed (x 3) 275
in incubation medium:
glycerol (80:20, vol/vol) 235
(Each point represents the mean of duplicate observations).
The results confirmed sonication (Fitzsimons et al, 1986) 
to be the best means of sample preparation prior to measurement 
of bone marrow ALA synthase activity.
3.9.4 Effect of Using [14C]-Glycine as Labelled Substrate
ALA synthase activity was assayed in human bone marrow 
using [^C]-glycine as labelled substrate as an alternative to
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[14C] -succinate.
Incubation medium was prepared with a reduced glycine 
concentration of ImM, as used by Freshney and Paul (1972). On 
the day of assay all other components of the incubation medium 
were added but with [^4C]-glycine (2.5pCi) in ImM glycine 
substituted for [^4C]-succinate. The assay was then carried 
out in the normal manner.
Several attempts to measure ALA synthase activity in bone 
marrow (10 x 10^ cells) by this method failed due to an 
inability to isolate [14C]-ALA using RPHPLC. Although most 
(80%) of the dpm in commercial [^4C] -glycine eluted at 4 mins 
following sample injection several additional radioactive peaks 
containing significant dpm were also detected between 0 and 10 
minutes and the dpm attributable to [^4C]-ALA alone could not 
then be determined. A known quantity of [^4C]-glycine was 
injected into the HPLC. The pattern of dpm elution was 
identical to that previously described indicating that the 
[^■4C]-glycine was impure and that these impurities rather than 
radioactive metabolites were the cause of contamination. The 
separation of [14C]-ALA and [*4C]-glycine by high voltage 
electrophoresis (Freshney and Paul, 1970) may therefore also 
be subject to error due to the presence of radioactive 
contaminants in [-*-4C] -glycine. In view of the high Km value 
for glycine and this clear evidence of contaminating impurities 
[^■4C]-glycine is not a suitable substrate for measurement of 
erythroid ALA synthase.
3.9.5 Stability of [14C] Succinate
The stability of [^4C]-succinate during storage at -20°C
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was examined.
Several identical bone marrow samples were assayed for ALA 
synthase activity using either freshly prepared [^C]-succinate 
solution or [^C]-succinate preparation which had been stored 
at -20°C for several months. The results were corrected for 
the specific activity of the [-^C] -succinate preparation and to 
100% recovery of ALA pyrrole. No deterioration in the 
effectiveness of the [^C]-succinate preparation as enzyme 
substrate was observed.
[•^Cj Succinate [^ C] Succinate
Preparation Stored at -20°C Preparation Freshly
Prepared
dpm in 14863 14649
[14C]-ALA
pyrrole
(x)
(S.D.) 52 158
(n) 3 3
3.9.6 Stability of Basic Incubation Medium
The stability of the basic incubation medium during 
storage at -20°C was examined.
Incubation medium was routinely prepared (Appendix I) 
then stored in 20ml aliquots at -20°C. At each fresh 
preparation of incubation medium an assay in stored incubation 
medium (-20°C, 6 months) was included alongside assays in 
freshly prepared incubation medium. This enabled the 
assessment of any inter-batch variation in the effectiveness of 
the incubation medium.
Incubation medium could be stored for up to 1 year without 
losing its effectiveness in the assay of ALA synthase activity.
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3.10 STABILITY OF EKYTHRQID ALA SYNTHASE
The stability of erythroid ALA synthase was investigated. 
Studies of hepatic ALA synthase have shown that incubation at 
37°C of the mitochondrial matrix fraction from either control 
or AIA-induced rats resulted in a significant loss of enzyme 
activity (50-70%) after 30 min (Beattie et al, 1985). However, 
addition of O.lmM PLP, to the preincubation medium completely 
prevented this loss. The loss was temperature dependent as a 
55% loss of ALA synthase activity occurred following incubation 
at 30°C (60 min) while the enzyme was completely stable at 
2 2 °C . ALA synthase inactivation did not involve proteolytic 
digestion since the addition of a wide range of protease 
inhibitors in the absence of PLP did not protect against 
inactivation. The theory has been put forward (Beattie et al,
1985) that the cofactor, PLP, may dissociate from the enzyme 
during preincubation resulting in irreversible inactivation of 
the apoenzyme at temperatures above 22°C.
A loss of enzyme activity during preincubation at 37°C 
would be particularly significant to the work described here 
because it was intended to study enzyme activity in 
fractionated erythroblasts (Chapter 2). This fractionation and 
white cell removal requires a 30 min period of incubation at 
37°C.
In this study of bone marrow erythroid ALA synthase 
activity a temperature-dependent inactivation was consistently 
observed. Attempts were made to prevent this loss of activity 
with PLP and associated metabolites.
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3.10.1 Pyridoxine Metabolism
Pyridoxine has several we 11-documented functions in normal 
cellular chemistry. In amino acid metabolism it is required as 
a coenzyme in such reactions as decarboxylation, deamination, 
transamination, transulphuration and desulphuration. It is 
also required for the normal cellular transport of amino acids 
and with regard to the biosynthesis of haem, it is essential as 
a coenzyme for the formation of 5-aminolaevulinic acid.
Pyridoxine exists in three biologically active forms; 
pyridoxine, pyridoxamine and pyridoxal. Anderson et al (1971) 
have partly clarified the mechanism for conversion of 
pyridoxine to the metabolically active form, pyridoxal, in 
mature red cells (Figure 11). The mature cell is the only 
major site for this conversion.
Nutritional pyridoxine deficiency is rare in man. It is 
manifest by glossitis, dermatitis and neurological 
abnormalities. Mice maintained on a pyridoxine-deficient diet 
develop a hypochromic anaemia and abnormal sideroblasts in the 
bone marrow after 6 weeks. Typical ring sideroblasts are 
usually absent, but can be produced if the animals are given 
additional iron or the pyridoxine antagonists cycloserine and 
isoniazid (Harris et al, 1965). In swine, experimental 
pyridoxine deficiency results in a microcytic, hypochromic 
anaemia, a raised serum iron and saturated TIBC (Harris et al, 
1965). The bone marrow shows an increase in sideroblasts, 
indicating that pyridoxine deficiency may have a role to play 
in sideroblastic anaemia (see Section 1.15.2). However, in 
man, the effects of pyridoxine deficiency vary between 
subjects. This is well illustrated by the reports of two pairs
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of brothers who were deficient in pyridoxine. While one 
brother developed neurological abnormalities, the other only 
became anaemic (Gehrmann, 1965; Snyderman et al, 1953).
3.10.2 Pyridoxal Phosphate as Cbfactor for ALA Synthase Activity
Almost all features of pyridoxine-responsive anaemia can 
be ascribed to the disturbance of erythroblast haem synthesis 
(Aoki et al, 1974; Heilmeyer, 1966; Hines and Grasso, 1970; 
Weintraub et al, 1966; Vogler and Mingioli, 1965). The main 
defect is believed to lie at ALA synthase. It is generally 
considered that decreased Hb synthesis and decreased 
erythrocyte production due to ineffective erythropoiesis are 
caused by reduced ALA synthase activity in erythroblasts, and 
that improvement of Hb synthesis and RBC production in the bone 
marrow by treatment with pyridoxine results from the increase 
in ALA synthase activity.
Erythroblast ALA synthase has also been shown to be 
subject to a temperature sensitive inactivation. ALA synthase 
activity was measured in bone marrow cells following 
preincubation with PLP and associated metabolites in an attempt 
to correct for this temperature-dependent inactivation.
Experimental
(i) Stability of Erythroid ALA Synthase at -80°C
Erythroid ALA synthase was found to be stable at -80°C for up 
to one year.
(ii) Stability of Erythroid ALA Synthase at 4°C
Erythroid ALA synthase was found to be stable in intact cells
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maintained at 4°C for up to eight hours.
(iii) Stability of Erythroid ALA Synthase at 37°C
A temperature-dependent inactivation of erythroid ALA synthase 
was consistently observed following a 30 min incubation at 37°C 
in culture medium. In a series of six experiments the average 
fall in ALA synthase activity in whole human bone marrow was 
45% (+ 14.8).
3.10.3 Hie Effect of Pyridoxal Phosphate, Pyridoxine and Pyridoxal on 
ALA Synthase Activity
The effects of pyridoxine metabolites were examined for 
their ability to protect ALA synthase activity in incubated 
(37°C) erythroid tissue.
Materials
Pyridoxal 5-phosphate (PLP), pyridoxine (PN) monohydrochloride 
and pyridoxal (PL) hydrochloride were purchased from Sigma 
Chemical Company.
3.10.4 The Effect of Pyridoxal Phosphate on the Temperature-Dependent 
Loss of ALA Synthase Activity
PLP (0-5mM) was added to intact normal human bone marrow 
cells suspended in 0.5ml serum, serumrculture medium (50% v/v) 
and incubation medium. The samples were mixed then 
preincubated at 37°C for 30 min. ALA synthase activity was 
measured in duplicate for each sample and the results were 
expressed as corrected dpm in ALA pyrrole (Tables 4 (a)-(d)). 
Each table represents results obtained using bone marrow from a 
different individual.
A large decrease in ALA synthase activity was observed
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(a) Incubation Serum (1ml) Average Change in
time
at 37°C (mins)
+ PLP (mM) corrected
dpm
ALA synthase 
activity (%)
0 0 4096 -
30 0 2477 -39.5
30 0.2 1783 -56.4
30 0.5 1952 -52.3
30 1.0 2688 -34.4
30 2.0 2789 -31.9
Incubation 
time (mins) 
at 37°C (mins)
Serum (1ml) 
+ PLP (mM)
Average
corrected
dpm
Change in 
ALA synthase 
activity (%)
0 0 7047 -
30 0 3673 -47.9
30 0.1 2862 -59.4
30 0.2 3776 -46.4
30 0.5 5296 -24.8
30 1.0 4325 -38.6
30 2.0 3776 -46.4
point represents the mean of duplicate observations.
TABLES 4 (a), (b)
THE EFFECT OF PLP (0-2mM) ON THE TEMPERATUREHDEPENDENT LOSS OF 
ALA SYNTHASE ACTIVITY IN INTACT CELLS
(c) Incubation Serum: Average Change in ALA
time (mins) culture corrected synthase activity
at 37dC (mins) medium dpm (%)
(50% v/v)
+ PLP (mM)
0 0 2398
30 0 1022 -57.4
30 1.0 965 -59.8
30 2.0 1132 -52.8
30 5.0 655 -72.7
(d) Incubation Incubation Average Change in
time (mins) Medium (1ml) corrected ALA synthase
at 37°C (mins) + PLP (mM) dpm activity (%)
0 0 2268
30 0 766 -66.2
30 0.5 1125 -50.4
30 1.0 1420 -37.4
30 2.0 1134 -50.0
30 5.0 973 -57.1
Each point represents the mean of duplicate observations.
TABLES 4 (c), (d)
THE EFFECT OF PLP (0-5nti) CN THE TEMPERATURE-DEPENDENT LOSS OF 
ALA SYNTHASE ACTIVITY IN INTACT CELLS
following preincubation which could not be prevented by PLP 
over the concentration range 0-5mM. The loss of activity was 
least in serum (39.5%) and greatest in incubation medium 
(66.2%). All incubations were carried out at pH 7.4.
Sonicated Cells
Sonication of cells prior to preincubation led to a 
greater temperature-dependent loss of ALA synthase activity 
than that observed in whole cells. This could however be 
prevented by 5-10mM PLP (Tables 5(a)-(c)).
The ability of 5mM PLP to prevent the temperature- 
dependent loss of enzyme activity in sonicated cells but not in 
intact cells suggests that extracellular PLP cannot reach 
intracellular ALA synthase. It would then appear that PLP 
either cannot traverse the erythroid cell membrane or the 
mitochondrial membrane. Since PLP is thought to freely pass 
through the erythrocyte membrane (Hamfelt, 1967) it is likely 
that PLP can enter the erythroblast but cannot penetrate the 
mitochondrial membrane to reach the site of the active enzyme.
3.10.5 The Effect of Pyridoxine on the Temperature-Dependent Loss of 
ALA Synthase Activity
Pyridoxine (PN) under normal circumstances in the mature 
erythrocyte is readily metabolised to the biologically active 
form, PLP (Anderson et al, 1971). The experiments described in 
Section 3.10.4 were repeated in triplicate with PN in place of 
PLP to d e t e r m i n e  whether PN could traverse the 
erythroid/mitochondrial cell membrane.
It was found that PN (0-5mM) could not protect against the
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(a) Incubation Incubation Average Change in ALA
time 
at 37°C 
(mins)
medium (1ml) 
+ PLP (mM)
corrected
dpn
synthase
(%)
0 0 436 -
0 0 456 -
30 0 193 -51.6
30 0 239 -45.2
30 1 337 -24.4
30 2 438 N.S.
Each point represents the mean of duplicate observations.
N.S. = not significant
TABLE 5 (a)
THE EFFECT OF PLP (0-2mM) ON TOE TEMPERATURE-DEPENDENT LOSS OF 
ALA SYNTHASE ACTIVITY IN SONICATED CELLS
(b) Incubation Incubation Average Change in ALA
time medium (1ml) corrected synthase activity
at 37°C + PLP (mM) dpm (%)
(mins)
0 0 2268
30 0 840 -62.9
30 0.5 735 -67.6
30 1.0 1135 -50.0
30 2.0 1536 -32.3
30 5.0 2149 N.S.
(c) Incubation 
time 
at 37° 
(mins)
0
30
30
30
30
30
Incubation Average 
medium (1ml) corrected 
+ PLP (mM) dpm
0
0
5
5
10
10
10778
1540
12247
13052
10529
12418
Change in ALA 
synthase activity 
(%)
-85.7
+13.6
+21.1
N.S.
+15.2
Each.point represents the mean of duplicate observations. 
N.S. - not significant.
TABLES 5 (b), (c)
THE EFFECT OF PLP (0-1 OmM) ON THE TEMPERAOTRE-DEPENDEWT IOSS 
OF ALA SYNTHASE ACTIVITY IN SONICATED CELLS
temperature-dependent inactivation of ALA synthase in either 
intact or sonicated cells (Tables 6(a),(b)).
3.10.6 The Effect of Inhibition of Haem Synthesis on the Temperature- 
Dependent Loss of ALA Synthase Activity
It was noted that the temperature-dependent loss of ALA 
synthase activity was greater in incubation medium than in 
serum or culture medium. Since incubation medium contained 
EDTA (2mM), an inhibitor of haem synthesis, it was speculated 
that the excessive loss in the presence of EDTA may have 
resulted from inhibition of haem synthesis. The effects of two 
inhibitors of haem synthesis i.e. EDTA and succinylacetone on 
ALA synthase activity during preincubation were examined. As 
previously discussed, both EDTA and succinylacetone are 
inhibitors of ALA dehydratase.
3.10.7 The Effects of EDTA on the Temperature-Dependent Loss of ALA 
Synthase Activity
Intact and sonicated bone marrow cells (10 x 10^ cells) 
were preincubated in incubation medium both in the presence and 
absence of EDTA (2mM).
The loss of enzyme activity was equally high in the 
presence or absence of EDTA (2mM) indicating that EDTA did not 
protect against the temperature-dependent loss of enzyme 
activity. The loss of activity observed in sonicated cells ( > 
90%) (Table 7(a)) was greater than that observed in intact 
cells (54%) (Table 7(b)) again suggesting that ALA synthase 
becomes less stable following sonication. In accordance with 
the earlier results (Section 3.10.4) the addition of PLP (5mM) 
abolished the loss of enzyme activity in sonicated cells, but 
not in intact cells.
109
(a) Incubation 
time 
at 37°C 
(mins)
Incubation 
PLP (5n#t)
median (1ml) 
EDTA (2mM)
Average
corrected
dpm
Change in ALA 
synthase 
activity (%)
0 - + 2351 -
30 - - 179 -92.4
30 - + 206 -91.2
30 + — 2162 -8.0
(b) Incubation 
time 
at 37°C 
(mins)
Incubation median (1ml) 
PLP (5nff) EDTA (2noM)
Average
corrected
dpm
Change in ALA 
synthase 
activity (%)
0 - + 2351 -
30 - - 1075 -54.3
30 - + 1185 -49.6
30 + _ 1437 -38.9
Each point represents the mean of duplicate observations.
TABLE 7 (a), (b)
THE EFFECT OF EDTA (2mM) ON THE TEMPERATORE-DEPENDENT LOSS OF 
ALA SYNTHASE ACTIVITY IN (a) SONICATED AND (b) INTACT CELLS
3.10.8 The Effect of Succinylacetone, EDTA and Pyridoxal Phosphate on 
the Temperature-Dependent Loss of ALA Synthase Activity
Intact bone marrow cells were preincubated in incubation 
medium both in the presence and absence of succinylacetone 
(2mM).
The results (Table 8) demonstrated that succinylacetone 
(2mM) alone could partially prevent the temperature-dependent 
loss of ALA synthase activity by decreasing the loss from 62% 
to 32%. In the presence of both succinylacetone (2mM) and PLP 
(5mM) the loss of activity was further reduced to 21%. Once 
again, the presence or absence of EDTA (2mM) had no effect on 
enzyme activity.
This protective effect of PLP and SA was investigated in a 
series of further experiments (Table 9). The results 
demonstrated that succinylacetone (2mM) and PLP (5mM) together 
prevented the temperature-dependent inactivation of ALA 
synthase. PL (5mM) alone could not protect against the loss of 
enzyme activity, but in the additional presence of 
succinylacetone (2mM) the loss was reduced from 58% to 12%.
3.10.9 Hie Effect of Pyridoxal Phosphate and Succinylacetone on the 
Temperature-Dependent Loss of ALA Synthase Activity
The addition of succinylacetone (2mM) to the incubation 
medium during preincubation of sonicated cells led to a very 
surprising loss of the protective effect of PLP (5mM) on ALA 
synthase activity (Table 10). This indicates that the 
combination of PLP and SA will protect the enzyme in intact 
cells but not in sonicated cells.
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Incubation Incubation medium (1ml) Average Change in
time PLP (5mM) Succinyl EDTA corrected ALA synthase
at 37^c acetone (5mM) dpm activity
(mins) (2ofl) (%)
0 — — - 13748 -
30 - - - 5206 -62.1
30 - + - 9282 -32.5
30 + - + 6025 -56.2
30 + + _ 10864 i to • o
Each point represents the mean of duplicate observations.
TABLE 8
THE EFFECT OF SUCCINYLACETONE, EDTA AND PLP ON THE 
TEMPERATURE-DEPENDENT LOSS OF AIA SYNTHASE ACTIVITY IN INTACT 
CET.Tfi
Incubation Culture medium (1ml) Average Change in ALA
time EDTA S.A. PLP PL corrected synthase
at 37°C (2noM) (2mM) (5mM) (5nM) dpm activity (%)
(mins)
0 — — — — 2351 —
30 - - - - 999 -57.5
30 + - - - 1135 -51.7
30 - + - - 1518 -35.4
30 - - - + 1267 -46.1
30 + - - + 1213 -48.4
30 - + - + 1813 -22.9
30 - - + - 1603 -31.8
30 + - + - 2219 -5.6
30 _ + + — 2075 -11.7
Each point represents the mean of duplicate observations 
S.A. = succinylacetone
TABLE 9
THE EFFECT OF EDTA, SUCCINYLACETONE, PLP AND PL ON THE 
TEMPERATURE-DEPENDENT LOSS OF ALA SYNTHASE ACTIVITY IN INTACT
CFT.T-q
(a) Incubation Incubation Average Change in ALA
time medium (1ml) corrected synthase activity
at 37°C + succinyl dpm (%)
(mins) acetone (2mM)
+ PLP (mM)
0 0 2268 -
30 0 840 -62.9
30 0.5 775 -65.8
30 1.0 1062 -53.2
30 2.0 1354 -40.3
30 5.0 1597 -29.6
Each point represents the mean of duplicate observations.
TABLE 10
THE EFFECT OF PLP AND SUCCINYLACETONE ON THE TEMPERATURE- 
DEPENDENT LOSS OF ALA SYNTHASE ACTIVITY IN SONICATED CELLS
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3.10.10 Summary of Results
A temperature-dependent loss of ALA synthase activity 
(approximately 45%) was consistently observed during 
preincubation of bone marrow cells in serum, serum:culture 
medium (50:50 v/v) or in incubation medium at 37°C for 30 min 
prior to assay of ALA synthase. Neither PLP nor PN (0-5mM) 
when added to intact bone marrow cells could protect against 
the loss of enzyme activity. However, when the cells were 
sonicated prior to preincubation to disrupt cellular membranes, 
PLP at 5mM concentration or greater provided complete 
protection against this loss. PN at the same concentration did 
not. It was therefore concluded that PLP cannot traverse 
either the cell or mitochondrial membrane and so is unable to 
protect ALA synthase. Cell membrane rupture by sonication 
allowed PLP to gain access to the enzyme and protect against 
the loss of enzyme activity. Under the same conditions PN 
(5mM) was ineffective, probably due to an inability of 
sonicated cells to metabolise PN to the biologically active 
form of PLP.
The effects of two inhibitors of haem synthesis on ALA 
synthase activity during preincubation were examined. EDTA 
(2mM) was found to have no effect on ALA synthase activity in 
both intact and sonicated cells while succinylacetone (2mM) was 
found to partially prevent the loss of activity in intact 
cells. Succinylacetone (2mM) and PLP (5mM) added together to 
intact cells almost totally abolished the loss of enzyme 
activity. It is postulated that succinylacetone facilitated 
the transport of PLP across the cell/mitochondrial membrane. 
Conversely, when succinylacetone (2mM) and PLP (5mM) were
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added together to sonicated cells, the ability of PLP to 
protect against the temperature dependent loss of ALA synthase 
activity was greatly reduced. EDTA did not interfere with the 
protective action of PLP in sonicated cells.
3.10.11 Discussion
The loss of ALA synthase activity in the absence of 
exogenous PLP apparently results from a temperature-dependent 
inactivation of the enzyme. The protection afforded by the 
cofactor, PLP, suggests that the irreversible inactivation at 
37°C may occur following removal of the cofactor from the 
enzyme. However, at 4°C the enzyme is stable following removal 
of the cofactor and may be reconstituted upon the addition of 
PLP. This contrasts with the behaviour of many other PLP- 
containing enzymes which become unstable even at 4°C after 
removal of PLP (Dzelzkalns et al, 1982). A possible 
explanation of the observed rapid inactivation of ALA synthase 
at 37°C is that this process may be a specific event which 
forms an important part of the intracellular regulation of ALA 
synthase. It has been suggested that ALA synthase may be 
subject to certain rigid controls such as the loss of the 
cofactor, PLP, influencing its sensitivity to proteolytic 
enzymes in the matrix (DeLoskey and Beattie, 1984; Beattie et 
al, 1984).
Previous reports (Aoki, 1978; Katunuma and Kominami, 1977; 
Srivastava et al, 1983; Nakakuki et al, 1980) had indicated 
that ALA synthase was sensitive to various proteases. 
Nevertheless, the lack of protection against enzyme
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inactivation at 37°C afforded by a wide spectrum of protease 
inhibitors suggests that the primary event in the loss of 
activity does not involve proteolysis (Beattie et a l , 1984). 
Furthermore, it has been suggested (Beattie et al, 1984) that 
initial "tagging" of the enzyme at 37°C prevents reassociation 
with PLP, thus preventing catalysis. Consequently, the enzyme 
may then become subject to proteolytic digestion. This type of 
two-step processing has been reported for many enzymes (Fucci 
et al, 1983) and it has been speculated that the inactivation 
of an enzyme may mark the protein for proteolytic digestion and 
thus may play a major role in the regulation of protein 
turnover.
It has been suggested that erythroid ALA synthase activity 
may be susceptible to a controlling protease located on the 
inner mitochondrial membrane of bone marrow cells (Aoki, 1978). 
An inverse relationship has been demonstrated between ALA 
synthase activity and the protease activity in erythroblasts. 
However, it has since been demonstrated that this protease was 
similar to, but not identical with, the group specific 
protease(s) described previously for PLP and PN-dependent 
enzymes (Katunuma and Kominami, 1977). In addition, both 
purified and active forms of ALA synthase have been shown to be 
sensitive to thiol proteases (Srivastava et al, 1983; Nakakuki 
et al, 1980). Thus the role of any erythroid-specific protease 
remains to be assessed.
The aim of the work described here was to find a possible 
means of preventing the temperature-dependent loss of erythroid 
ALA synthase activity. This was of considerable relevance to 
the work described in this thesis as much of the experimental
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work was to be carried out on fractionated bone marrow 
erythroblasts. The fractionation process requires that the 
myeloid cell population be removed via cell lysis by monoclonal 
antibody TG-1. This requires a 30 minute incubation at 37°C, 
prior to density gradient centrifugation (Chapter 2) and so 
presents a possible source of loss of ALA synthase activity.
The results suggest that the loss of enzyme activity 
during the 30 minute preincubation period could only be 
prevented in intact cells by the combined presence of PLP (5mM) 
and succinylacetone (2mM). The reason for the success of this 
combination is unclear, but it may be speculated that PLP and 
succinylacetone form a complex which is more readily 
transported across the cell membrane than PLP alone. 
Succinylacetone is structurally similar to ALA which exists as 
an ALA-PLP complex during the final stages of ALA formation 
(Section 3.6). Although succinylacetone lacks the amino group 
responsible for Schiff base formation between ALA and PLP it is 
possible that a third molecule may intervene e.g. glycine. 
On entering the cell succinylacetone must dissociate from this 
complex possibly via reaction with ALA dehydratase since the 
affinity of succinylacetone for ALA dehydratase is 
approximately 1000 times that of the natural substrate, ALA. 
PLP may then enter the mitochondria and interact freely with 
ALA synthase.
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SUCCINYLACETONE ALA
In sonicated cells succinylacetone appears to interfere 
with the ability of PLP to protect against the temperature- 
dependent loss of ALA synthase activity. This is possibly due 
to an inability of the succinylacetone-PLP complex to 
dissociate in the ruptured cell. It is interesting to note 
that both succinyl ace tone and PLP are present in the incubation 
medium used to measure ALA synthase activity and the presence 
of succinyl acetone in the incubation mixture has been shown not 
to affect erythroid ALA synthase activity (Fitzsimons et al,
1986). The reason why this does not present a problem during 
assay may be that succinylacetone is present in much lower 
concentrations (O.lmM).
This theory could be examined experimentally by assessing 
the effect of using ALA, known to form a complex with PLP, in 
place of succinylacetone and in conjunction with 5mM PLP. The 
effects of this combination on ALA synthase activity in intact 
and sonicated cells could then be observed.
The experiments described here were conducted over a 2 
year period. As the protective effect of succinylacetone and
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PLP (2mM and 5mM respectively) on ALA synthase activity in 
intact cells was not realised until the end of this period the 
fractionation experiments described in subsequent chapters were 
completed without PLP and succinylacetone.
In order to ensure the consistent loss of ALA synthase 
activity during myeloid cell lysis, a control sample of whole 
unfractionated bone marrow was incubated at 37°C alongside the 
TG-1 treated samples. Enzyme activity was then assayed and 
compared with that in an identical sample maintained at 4°C 
prior to assay. The loss was consistent at approximately 45% + 
14% (n = 6) in 30 mins.
3.11 APPLICATION OF THE ALA SYNTHASE ASSAY TO OTHER TISSUES
The assay described has been optimised for the measurement 
of ALA synthase activity in bone marrow. It was demonstrated 
for the first time here that this assay could successfully be 
employed in the measurement of ALA synthase activity in other 
tissues i.e. rat liver and brain. Working in collaboration 
with other workers in the University Department of Medicine, 
this method was used to measure ALA synthase activity in rat 
liver and brain.
Experimental
Eight fully grown Sprague Dawley rats were treated in the 
following manner, then sacrificed:-
4 controls:- untreated
4 test injected with phenobarbitone, a known
inducer of hepatic ALA synthase.
Both liver and brain were then assayed for ALA synthase
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activity. In addition, enzyme activity in crude tissue 
homogenate was compared with that in mitochondrial preparation.
The results are expressed as picomoles of ALA formed per gram 
of protein per hour for rat liver (Table 11(a)) and for rat 
brain (Table 11(b)).
Results
(i) AIA Synthase Activity in Rat Liver
ALA synthase activity was successfully measured in rat 
liver using this assay method (Table 11(a)). The activity 
detected in crude homogenate was broadly similar to that 
detected in mitochondrial preparations indicating that crude 
tissue homogenate was an adequate method of sample preparation. 
Phenobarbitone produced an increase in detectable enzyme 
activity of approximately 25%. Significantly, when the same 
tissue preparations were assayed for ALA synthase activity 
using the method of Freshney and Paul (1970) no increase in 
enzyme activity in response to phenobarbitone treatment could 
be detected (results not shown). This highlights the 
inadequacies of the method of Freshney and Paul (1970) as 
discussed in Section 3.9.4.
The results reported here are comparable with those 
reported by other workers (Brooker et al, 1982; Wolf son et al, 
1980; Strand et al, 1972).
(ii) ALA Synthase Activity in Rat Brain
ALA synthase activity was successfully measured in rat 
brain using this assay method (Table 11(b)). In this case the
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(a)
AIA SYNthASE ACTivitY (p moles ALA/g protein/hr) 
Homogenate Mitochondria
Control Phenobarbitone Control Phenobarbitone
386,000 463,330 303,670 . 420,590
278,160 487,450 318,510 422,740
(b)
AIA SYWBASE ACl'ivnY (p moles AEA/g protein/hr) 
Homogenate Mitochondria
Control Rienobarbitone Control Rienobarbitone
65,270 71,350 599,080 427,600
76,520 65,960 336,190 392,200
TABLES 11 (a),(b)
THE MEASUREMENT OF ALA SYNTHASE ACTIVITY IN (a) RAT LIVER AND
(b) RAT BRAIN: EFFECT OF PHENOBARBITONE
activity detected in mitochondrial preparations was several 
fold greater than that detected in crude tissue homogenates 
suggesting a requirement for a cleaner tissue preparation. 
Phenobarbitone treatment had no effect on brain ALA synthase 
activity.
The results reported are comparable with those reported by 
other workers (Paterniti et al, 1978).
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CHAPTER 4
THE ENZYME FERROCHELATASE
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4 THE ENZYME FERROCHELATASE
4.1 THE REACTION CATALYZED BY FERROCHELATASE
It was first concluded from the study of avian 
erythrocytes (Granick and Gilder, 1946; Granick, 1954), that 
the terminal step in haem biosynthesis, the chelation of iron 
by protoporphyrin, occurs enzymatically (Granick, 1954; 
Goldberg et al. 1956; Krueger et al. 1956). The enzyme 
activity of the cell extract was heat labile, temperature 
dependent and exhibited a pH optimum of 8.0. Since haem 
formation was maximal under nitrogen and reducing conditions it 
was concluded that haem was formed from Fe(II) and porphyrin. 
Subsequent studies on avian erythrocytes (Nishida and Labbe, 
1959; Labbe, 1959; Labbe and Hubbard, 1960; 1961) using 
classical methods of cell fractionation and protein 
purification yielded fractions with increased specific activity 
which were non-dialyzable and heat labile suggesting that the 
catalytic activity was dependent upon protein. The partially 
purified fractions also required the presence of a cofactor 
which could be satisfied by glutathione (GSH) or ascorbic acid 
(Goldberg, 1959; Lochhead and Goldberg, 1959). The activity 
was inhibited by mercurials leading to the conclusion that the 
observed catalysis was dependent on a sulphydryl group.
Numerous publications have since described the preparation 
and properties of ferrochelatase from a variety of sources 
(Porra and Jones, 1963; 1963; Yoneyama et al, 1965; Neuberger 
and Tait, 1964; Porra and Ross, 1965; Jones, 1968; Goldin and 
Little, 1969; Camadro and Labbe, 1982; Bloomer and Morton, 
1982; Dailey and Fleming, 1982; 1986).
The enzyme ferrochelatase (haem synthase; iron-
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protoporphyrin chelating enzyme; protohaem ferrolyase, EC 
4.99.1.1) catalyzes the final step in the haem biosynthetic 
pathway i.e. the insertion of iron (II) into protoporphyrin 
IX to form protohaem with the loss of two protons (Figure 12).
Protoporphyrin IX + Fe2+ » protohaem + 2H+.
Enzyme activity is maximal when ferrochelatase is surrounded by 
a lipid environment (Sawada et al, 1969; Simpson and Foulson, 
1977; Taketani and Tokunaga, 1981).
4.2 THE LOCATION AND MOLECULAR PROPERTIES OF FERROCHELATASE
Ferrochelatase is located 'in vivo1 as an intrinsic 
membrane protein which spans the inner mitochondrial membrane 
(Ferreira et al, 1988) with its active site present on the 
matrix side of the membrane (Harbin and Dailey, 1985). The 
enzyme is enriched in lysine (11%) and hydrophobic amino acid 
residues (48%) (Taketani and Tokunaga, 1981) and has a reported 
M.W. of 40,000 as determined by SDS-PAGE (Dailey and Fleming, 
1983; Hanson and Dailey, 1984). However, there is still 
disagreement regarding the m.w. of the native enzyme as values 
of 200,000 and 240,000 have also been reported (Taketani and 
Tokunaga, 1981; 1982). One explanation for this discrepancy is 
that the dialysis used in some preparations may lead to 
aggregation of the membrane protein. However, although the 
enzyme is now generally believed to be a monomer, the 
possibility of a multisubunit structure exists and resolution 
of this uncertainty must await determination of the 'in situ' 
structure of the membrane protein. For the present, most 
workers have accepted a M.W. of 40,000 for mammalian 
ferrochelatase.
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4.3 THE SYNTHESIS OF FERROCHELATASE
Like ALA synthase, ferrochelatase is synthesised in the 
cytoplasm and must be imported into the mitochondria to reach 
its functionally active site. Such proteins are usually 
synthesised as precursors on cytoplasmic ribosomes and contain 
N-terminal extensions which target the protein to the 
mitochondria. Insertion and translocation into the 
mitochondrial inner membrane requires an electrical membrane 
potential and, on entering the mitochondria, the proteins are 
processed by a proteinase which cleaves off the N-terminal 
extension. Both 'in vivo1 and 'in vitro' studies of mouse 
hepatic and erythroid enzyme (Karr and Dailey, 1988) have 
demonstrated that ferrochelatase is synthesised as a larger 
precursor of m.w. 43,000 and is then translocated and processed 
to a mature-sized protein of m.w. 40,000 in an energy-requiring 
step. Prior to this study there had been no report of the 
synthesis and membrane insertion of ferrochelatase. The low 
abundance of ferrochelatase in cells, its poor immunogenicity, 
and the presence of a blocked N-terminus had limited such work.
4.4 THE PROPERTIES OF THE PURIFIED ENZYME
Ferrochelatase has been purified from rat (Taketani and 
Tokunaga, 1981), beef (Dailey and Fleming, 1983; Taketani and 
Tokunaga, 1982) mouse (Dailey et al, 1986) and human liver 
(Mathews-Roth et al, 1987) and from chicken erythrocytes 
(Hanson and Dailey, 1984). Although the bovine enzyme is best 
characterised, the enzymes from all of these sources share many 
common characteristics but differ substantially from bacterial 
ferrochelatases (Dailey, 1982; 1977).
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Studies of kinetic parameters have indicated that 
protoporphyrin IX, the natural substrate, has the lowest 
measured Km and Vmax (Table 12, Review, Dailey, 1989). 
However, there are large quantitative variations in the data 
from various laboratories (Table 12). This may be explained by 
several factors:
1. A variety of different tissues and animal species have been
used as a source of the enzyme, therefore interspecies 
variations are expected.
2. Differences are likely to exist with regard to assay
techniques.
3. The purity of the porphyrins and the manner in which they have
been prepared may significantly affect enzyme activity.
4. The nature of the enzyme preparation, i.e. membrane-bound 
versus solubilised and purified, is also likely to have a 
significant effect on the enzyme activity.
The most reliable comparisons are either qualitative or 
quantitative but from a single laboratory.
Only dicarboxylic porphyrins of the IX isomer are 
substrates of ferrochelatase. Porphyrins with 2,4 
substitutions that are charged or larger than vinyl groups are 
competitive inhibitors of the enzyme with respect to the 
porphyrin substrate (Honeybourne et al, 1979; Dailey and Smith, 
1984).
The enzyme is strongly inhibited by metal ions such as 
Mn2+, Cd2+, Co2+, Zn2+, Pb2+, Hg2+ and Cu2+ (Dailey and
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Fleming, 1983; Fadigan and Dailey, 1987; Tokunaga and Sano, 
1972; Labbe and Hubbard, 1961) which are competitive with 
respect to ferrous iron. Assuming a M.W. of 40,000 per mole of 
enzyme, inactivation data show that one mole of N- 
methylprotoporphyrin binds and one mole of N-ethylmaleimide 
inactivates one mole of enzyme (Dailey and Fleming, 1986). 
Should then the enzyme exist as multiple subunits each subunit 
is able, at least 'in vitro', to catalyze the insertion of 
iron. Reported values for the Km of iron have also varied 
enormously (Table 12) again for the reasons previously 
described. Strong enzyme inhibitors such as mercury have a Ki 
similar to the Km for iron (Dailey, 1989).
4.5 THE RELATIONSHIP BETWEEN IRON METABOLISM AND FERROCHELATASE
The presence of adequate quantities of ferrous iron is an 
absolute requirement for optimal ferrochelatase activity. 
However, the details of the acquisition and utilisation of iron 
for haem synthesis remain unclear.
The iron compartments in man may be separated on the basis 
of anatomic distribution, chemical characteristics and function 
into six compartments (Table 13). The largest of the 
compartments is Hb iron, containing approximately 3g iron.
4.5.1 Storage Iron:
Iron in the storage compartment exists as either ferritin 
or hemosiderin.
Ferritin is a water soluble complex of ferric hydroxide 
and a protein, apoferritin. Apoferritin forms a shell within 
which ferric ions (up to 2,000), hydroxyl ions and oxygen are
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COMPARTMENT IRON CONTENT (mg) TOTAL BODY IRON (%)
Haemoglobin iron 2,500 67
Storage iron 1,000 27
(Ferritin hemosiderin)
Myoglobin iron 130 3.5
labile pool 80 2.2
Other tissue iron 8 0.2
Transport iron 3 0.08
NOTE:
These values represent estimates for an average person i.e. 
70kg, 177cm in height. They are derived from data in several 
sources.
TABLE 13
THE IRON COMPARTMENTS IN NORMAL HUMAN BEINGS ( Haematology 
Chapter 18, page 168, (1977) W.J. Williams, E. Beutler, A.J.
Erslev, R.W Rundles (eds).
dispersed in a lattice-like arrangement (Harrison et al, 1967; 
Brady et al, 1968; Hoy et al, 1974). This permits a semi­
crystalline structure to form. Ferritin is normally found in 
trace amounts in plasma and in most, if not all, cells of the 
body. Multiple molecular forms of ferritin or isoferritins are 
found in several tissues. The terms "anabolic ferritin" and 
"catabolic ferritin" have sometimes been attached to 
erythroblast and reticuloendothelial ferritin respectively. It 
has not however been shown that "anabolic ferritin" is directly 
used for haem synthesis (Cartwright and Deiss, 1975) or that 
"catabolic ferritin" is derived from Hb catabolism. The 
concentration of Fe^+ ions in or near the cell enhances 
apoferritin formation both ’in vitro’ (Drysdale and Shafritz, 
1975) and 'in vivo' (Bernier et al, 1970). Apoferritin 
exhibits enzymatic properties in the oxidation of Fe2+ to Fe^+, 
thus facilitating the uptake of iron by the cell and the 
incorporation of iron into ferritin (Bryce and Crichton, 1973).
H e m o s i d e r i n  is m a i n l y  found in c e l l s  of the 
reticuloendothelial system and, under pathological conditions, 
it may accumulate in large quantities in most tissues of the 
body. Hemosiderin may represent partially denatured, partially 
deproteinised insoluble ferritin aggregates (Sturgeon and 
Shoden, 1964).
The iron content of the storage compartment varies both in 
normal circumstances and in disease. Iron depletion occurs 
when iron loss exceeds iron absorption. The mobilisation of 
storage iron involves iron release from intracellular ferritin 
as Fe2+.
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4.5.2 The Labile Iron Pool
The labile iron pool is a concept derived from studies of 
iron kinetics (Greenberg and Wintrobe, 1946; Pollycove and 
Mortimer, 1961; Hosain et al, 1967). Iron leaves the plasma 
and enters the interstitial and intracellular fluid 
compartments. Here it may be bound to cell membranes or to 
intracellular proteins for a brief period prior to 
incorporation into haem or storage compounds. A widely 
distributed intracellular protein may be responsible for the 
short-term binding and release of iron and therefore may 
represent the labile iron pool. It has been postulated that an 
acetate-extractable ferroprotein (AEP) with a m.w. of 12,000 
represents such a protein. The Fe3+ binding kinetics of AEP 
exhibits an exponential curve with a T 1/ 2 o f 30 hr, similar to 
that proposed for iron in the labile pool (Boulard et al, 
1972).
4.5.3 Transport Iron
The transport compartment is the smallest of the iron 
compartments, yet kinetically it is the most active because the 
iron in it is normally "turned over" at least 10 times per 24 
hr. This compartment represents the intermediate pathway 
through which iron may be interchanged between compartments. 
Transport iron is bound to the specific protein transferrin, an 
elongated ^-globulin of m.w. 80,000. At each end of the 
molecule globular glycoprotein moieties can bind one trivalent 
iron atom. Iron binds to these two sites in a random manner. 
Yet, the two sites may not be identical as evidence suggests 
that one of the sites, when occupied by iron, has higher
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affinity for the erythroblast membrane than does the other site 
(Zapolski et al, 1974; Fletcher and Huehns, 1967; 1968). 
Normally, one third of the plasma transferrin iron binding 
sites are occupied. This is subject to large diurnal 
fluctuations and also varies under different physiological and 
pathological conditions.
Ferritin may also serve as a mechanism of iron transport. 
It enters plasma mainly as a result of Hb catabolism and is 
rapidly removed from plasma by the liver. The plasma 
concentration of ferritin is normally small (lOOng/ml). 
However, due to the rapid turnover of plasma ferritin, up to 
20mg of ferritin iron may be transported through the plasma 
daily (Siimes and Dallman, 1974).
(i) Iron Requirements
To provide sufficient iron for normal synthesis of Hb and 
other iron proteins, the body absorbs small amounts of iron 
through the intestinal mucosa to balance the small amount (lmg) 
excreted per day. The average daily dietary intake of iron 
is 10-20mg, thereby making dietary causes of iron deficiency 
uncommon in the Western World.
(ii) Transport of Iron
Iron within the body is virtually in a closed system in 
which it cycles from the plasma to the developing 
erythroblasts, then into the circulating blood for about 120 
days, and finally to the phagocytic reticulum cells. Here it 
is removed from the Hb and released back into the plasma to 
repeat the cycle. The transport of iron in the plasma is of
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central importance to this process.
Transferrin provides the means of moving iron through the 
plasma and interstitial fluids to the erythroblasts of the bone 
marrow, hepatocytes and other cells. Reticuloendothelial cells 
do not have transferrin receptors but acquire iron from the 
catabolism of Hb in the red cells that they destroy. The 
binding of transferrin and release of iron are active processes 
which can be abolished by enzyme inhibitors (Sly et al, 1975). 
Evidence supporting this concept comes from studies of 
reticulocytes; although Hb synthesis is nearly complete by this 
stage of erythrocyte maturation, the membrane of a reticulocyte 
can still bind 25,000 to 50,000 iron-laden transferrin 
molecules per minute (Van Bockxmeer and Morgan, 1979).
4.5.4 Iron in the Erythroblast
Molecules of transferrin iron appear to enter the 
erythroblast by a process of endocytosis, where the iron- 
transferrin complex is bound to a "carrier" molecule of m.w. 
20,000 (Jandl and Katz, 1963; Sly et al, 1975; Morgan and 
Appleton, 1969; Martinez-Medellin and Schulman, 1972; Sullivan 
et al, 1976). It is, however, uncertain as to whether 
transferrin itself ever penetrates the outer cell membrane 
(Barnes et al, 1972; Loh et al, 1977). It has been proposed 
that iron, as the iron-transferrin-carrier complex, is 
transported to the mitochondria where haem synthesis occurs. 
The fate of transferrin has not yet been resolved completely. 
Electron microscopy can visualise iron in mitochondria as 
amorphous aggregates, called ferruginous micelles. When haem 
synthesis is impaired, as in lead poisoning or in the
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sideroblastic anaemias, the mitochondria accumulate excessive 
amounts of these amorphous iron aggregates.
The importance of transferrin in the delivery of iron to 
the erythroblast is emphasised from the observation that when 
transferrin is congenitally absent, iron accumulates mainly in 
the liver. Little gets into the bone marrow and a severe 
hypochromic microcytic anaemia results (Drysdale and Shafritz, 
1975).
(i) Release of Iron From Transferrin
Iron is released from transferrin only at specific sites 
on receptor cells. The mechanism of iron release from 
transferrin is not known but may involve reduction of the iron 
or of the binding groups, chelation by an external ligand or 
displacement of bicarbonate. Egyed et al (1980) have suggested 
that intracellular haem proteins may play a role in this 
release process, while more recent work suggests that 
pyrophosphate may act as a ligand for iron release and 
subsequent delivery to mitochondria (Nilsen and Romslo, 1984; 
1984; 1985).
Maximum iron uptake occurs in early and intermediate 
erythroblasts and further maturation of the erythroid cells is 
associated with a decrease in the number of transferrin binding 
sites (Nunez et al, 1977; Van Bockxmeer and Morgan, 1979). The 
transferrin receptor has now been identified as a glycoprotein 
of m.w. 350,000 consisting of two unequal subunits (I^ibman and 
Aisen, 1977; Sullivan and Weintraub, 1978).
Although the process by which iron is mobilised for 
incorporation into haem remains unclear, this process must
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deliver iron in the divalent state to protoporphyrin.
Iron Reduction
Since ferrochelatase has an absolute requirement for 
ferrous iron, and because biological iron complexes such as 
transferrin and ferritin chelate ferric iron, a mechanism for 
ferric iron reduction must exist in the cell. It has been 
demonstrated that ferric chloride can be reduced to ferrous 
iron by mitochondria with NADH or succinate serving as 
reductants (Barnes and Jones, 1973; Barnes et al, 1972). 
However, ferritin or transferrin iron was not reduced. The 
ferrous iron generated in this fashion was used by 
ferrochelatase for haem biosynthesis when porphyrin was also 
supplied. The reduction was shown to be coupled to the 
electron transport chain at the level of NADH and succinate 
dehydrogenases.
More recently, Taketani et al (1985, 1986) have examined 
this problem by a different approach. They fractionated the 
bovine heart mitochondrial electron transport chain into 
complexes I, II and III and then assayed these complexes 
for ferrochelatase and iron reduction activity. Complex I 
contained both ferrochelatase activity and an NADH-dependent 
ferric-iron-reducing system which was strongly stimulated by 
FMN.
The ferric iron reduction system is currently then poorly 
understood. Data suggests that this system is sensitive to 
inhibition by lead at lower concentrations than ferrochelatase 
indicating that lead may not directly inhibit ferrochelatase
o l
but rather may reduce the availability of the Fe substrate.
4.6 THE REACTION MECHANISM FOR FERROCHELATASE
Although the precise nature of the reaction mechanism for 
ferrochelatase remains to be elucidated in detail, recent 
advances have been made. Three main areas have been 
specifically examined:
(i) Protein Amino Acid Resides Involved In Iron Binding
Reaction of a single sulphydryl residue per monomer of 
purified ferrochelatase results in the total loss of activity 
(Dailey, 1984). However, reversible inhibition by sodium 
arsenite as well as by Hg^+, strongly suggests that two vicinal 
sulphydryl groups are involved in catalysis. Ferrochelatase is 
protected against inactivation by N-ethylmalemide in the 
presence of ferrous iron, but not in the presence of porphyrin. 
This supports a model where vicinal sulphydryl residues are 
involved in ferrous iron binding by the enzyme (Dailey, 1984).
(ii) Protein Residues Associated with Porphyrin Binding
Since the second substrate of ferrochelatase is a 
dicarboxylate porphyrin there is a possible role for protein 
cationic residues in porphyrin binding (Dailey and Fleming, 
1986). Bovine ferrochelatase is rapidly inactivated by the 
arginyl reagents butanedione, cyclohexanedione and 
comphorquinone 10-sulphonate, but not by lysyl specific 
reagents. The enzyme is protected against inactivation by 
porphyrin but not by ferrous iron. The kinetics of the 
modified enzyme support the model for arginyl involvement in 
the binding of porphyrin but not of iron.
The current data support a model whereby iron binding 
occurs via vicinal sulphydryl groups prior to porphyrin binding
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which involves protein arginyl residues(s).
(iii) Enzyme Kinetic Studies
An enzymatic kinetic mechanism for bovine ferrochelatase 
has been proposed based upon substrate and inhibitor studies 
(Figure 13) (Dailey and Fleming, 1983). The reaction consists 
of two substrates, porphyrin and ferrous iron, and two 
products, protohaem and two protons. The enzyme is proposed to 
bind initially the divalent iron with the concomitant release 
of two protons. The binding of protoporphyrin then follows. 
Iron insertion into the porphyrin macrocycle occurs with the 
exchange of the two pyrrolic nitrogen protons to the enzyme, 
thereby, displacing the ferrous iron chelate. Ferro-protohaem 
is released, completing the cycle. Elimination of the second 
product, the two protons, occurs only upon initiation of a new 
catalytic cycle. Hence, ferrochelatase has a sequential Bi-Bi 
mechanism.
4.7 THE RELATIONSHIP WITH PROTOPORPHYRINOGEN OXIDASE
It has been suggested that 'in vivo1 protoporphyrinogen 
oxidase, the antipenultimate enzyme of the haem biosynthetic 
pathway, and ferrochelatase are arranged in a complex whereby 
the product of one enzyme i.e. protoporphyrin IX is directly 
channelled to the next without being diluted in the 
phospholipid matrix (Ferreira et al, 1988). The isolated 
enzymes have calculated Km's in the pM range; a concentration 
that would not normally be approached in the cell. In a 
multiprotein complex substrate channelling would eliminate the 
release of intermediates and obviate the need to justify
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FERROCHELATASE (adopted from Dailey and Fleming, 1983),
seemingly high experimentally determined Km's. Both enzymes 
are integral membrane proteins and the exact nature of the 
interaction between them is currently under investigation 
(Figure 14).
4.8 THE PHYSIOLOGICAL ROLE OF FERROCHELATASE
Since the chelation of iron into protoporphyrin also 
occurs nonenzymatical ly (Kassner and Walchak, 1973; Taketani 
and Tokunaga, 1984) the necessity for an enzyme has been 
questioned. The demonstration that humans and cattle with 
protoporphyria have defects in ferrochelatase activity (Becker 
et a l , 1976; Bloomer, 1980; 1980; Bloomer et al, 1976; 
Bonkowsky et al, 1975; Bottomley et al, 1975; Brenner and 
Bloomer, 1980; Brodie et al, 1977; de Goeij et al, 1975; Ruth 
et al, 1977) causing excessive accumulation and excretion of 
protoporphyrin indicates that the enzyme is necessary for haem 
formation to proceed normally under physiological conditions. 
It is, however, surprising that individuals demonstrating 
deficiency of ferrochelatase to 10-30% of normal activity do 
not usually develop anaemia (Turnbull et al, 1973).
4.9 THE IMPORTANCE OF FERROCHELATASE: ROLE IN HAEM SYNTHESIS AND 
ERYTHRDPOIESIS
The most striking molecular event during erythroid 
differentiation is the accumulation of Hb. Haem synthesis is 
central to this process, being inextricably linked to the 
control of erythroid maturation, to the promotion of globin 
synthesis and many other complex processes within the cell 
(Chapter 1, Section 1.13). Yet, strangely, in contrast to the
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POSSIBLE MODELS FOR THE INTERACTIONS OF THE TERMINAL 
TWO ENZYMES OF THE HAEM BIOSYNTHETIC PATHWAY (AS 
SUGGESTED BY FERREIRA ET AL [1988])
information available for hepatic cells, the control of haem 
synthesis in erythroid cells is not fully understood. Studies 
of erythroid haem synthesis have been carried out on various 
cell types using a variety of techniques and the results have 
inevitably contrasted sharply. Human erythroid haem synthesis 
has received relatively little attention but clearly demands 
further investigation.
It is the aim of the work in Chapter 5, 6, 8 and 9 to 
focus on the terminal stage of haem synthesis, in particular, 
the reaction catalysed by ferrochelatase, and its role in haem 
synthesis in the maturing erythroid cell.
There is evidence that ferrochelatase may exercise a 
limiting role for haem synthesis in erythroid cells:- 
Hb formation does not occur in FEL cells treated with DMSO 
until ferrochelatase activity increases. Other enzymatic 
activities of the haem pathway increase sequentially and 
considerably earlier than ferrochelatase (Sassa, 1976; 
Rutherford et a l , 1979) . In addition, the study of
differentiation of induced FEL cells has shown that total haem 
production is affected by protoporphyrin only after 48 hr, 
indicating that iron insertion into protoporphyrin is limiting 
for haem formation (Fadigan and Dailey, 1987).
Haemin, but not ALA, PBG or protoporphyrin, can increase Hb 
concentration in undifferentiated Friend cells (Granick and 
Sassa, 1978; Ross and Sautner, 1976; Dabney and Beaudet, 1977).
A mutant clone of FEL cells with normal induction responses of 
ALA synthase, ALA dehydratase and PBG deaminase, does not make
Hb after DMSO treatment (presumably due to an enzyme block 
after PBG deaminase), but does so after DMSO plus haemin 
addition (Sassa et al, 1978; Eisen et al, 1978).
4. Treatment of a wild type clone of FEL cells with haemin can 
increase not only the synthesis of Hb but also levels of ALA 
synthase, ALA dehydratase, PBG deaminase and ~^Fe incorporation 
into haem (Hoffman et al, 1980).
The increase in ALA synthase activity induced by haemin 
treatment of erythroid cells represents a striking contrast to 
haemin induced suppression of the hepatic enzyme. A similar 
finding of haemin-mediated induction of haem pathway enzymes, 
including that of ALA synthase, has been reported in human 
erythroleukaemia cells K562 (Hoffman et al, 1980). 
Furthermore, haemin, but not ALA, stimulates Hb formation in 
normal mouse bone marrow cultures (Porter et al, 1979).
However, in view of the fact that haemin induces 
differentiation of FEL cells, it is possible that this results 
in secondary stimulation of ALA synthase activity.
5. The ferrochelatase deficiency in erythropoietic protoporphyria 
(EPP) appears to be expressed in terms of protoporphyrin 
accumulation mainly in erythroid tissue, although 
ferrochelatase is presumably deficient in all tissues, 
suggesting that deficient ferrochelatase may become limiting in 
erythroid cells but not in non-erythroid tissues. This, 
however, does not cause anaemia.
On the other hand, Beaumont et al (1984) have suggested 
that there is a simultaneous induction of the enzymes of haem
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biosynthesis in DMSO-treated FEL cells. In this study, 
appearance of ferrochelatase activity did not significantly 
differ from that of the earlier enzymes of the pathway implying 
that late induction of ferrochelatase activity was not rate- 
limiting for haem formation.
Further evidence for a possible regulatory function of 
haem on ferrochelatase activity in erythroid cells has been 
presented from various studies and inhibition of ferrochelatase 
by haemin has been reported in different tissues:-
1. With Co^+ and deuteroporphyrin as substrates ferrochelatase 
activity of Rhodopseudomonas spheroides was effectively 
inhibited by haemin in a non-competitive manner with respect to 
both substrates (Jones and Jones, 1970). Furthermore, the 
inhibitory action of haemin on ferrochelatase purified from 
Spirillum intersonni and also R. spheroides has been reported 
(Dailey, 1977; 1982).
2. Inhibition of ferrochelatase activity by haemin has also been
demonstrated in rat liver (Roller and Romslo, 1977). In
addition, the study of purified bovine hepatic ferrochelatase
with Fe^+ and protoporphyrin as substrates demonstrated that
2+haemin was a non-competitive inhibitor with respect to Fe 
(Dailey and Fleming, 1983).
3. Two groups working with rat liver mitochondria have suggested 
that the local concentration of haem formed within the 
mitochondrial matrix space may be high enough to inhibit 
ferrochelatase activity and thereby partially control its own 
synthesis (Roller and Romslo, 1977; Jones and Jones, 1970).
135
The inhibition of ferrochelatase by haemin may be a 
possible site for regulation of the haem biosynthetic pathway. 
In erythroid cells, however, other enzymes of haem synthesis 
together with the acquisition of iron from transferrin have 
also been implicated in this control (Chapter 1, Section 
1.12).
It was intended that the use of cell separation 
techniques previously described (Chapter 2) coupled with the 
development of a highly sensitive radiochemical assay for 
ferrochelatase activity, would provide hitherto unavailable 
information regarding the relative activities of AIA synthase 
and ferrochelatase in maturing erythroid cells. These 
techniques would then facilitate the study of normal and 
abnormal human erythroid haem synthesis.
4.10 DISEASES ASSOCIATED WITH DECREASES IN FERROCHELATASE ACTIVITY
Reduction in ferrochelatase activity of the bone marrow of 
occasional patients with sideroblastic anaemia has previously 
been reported (Valentine, 1983), while it is also known that 
ferrochelatase is depressed in erythropoietic protoporphyria 
and lead intoxication (Schwartz et al, 1971).
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CHAPTER 5
DEVELOPMENT OF AN ASSAY TO DETERMINE FERROCHELATASE ACTIVITY
IN HOMAN BONE MARROW
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5 DEVELOPMENT OF AN ASSAY TO DETERMINE FERROCHELATASE ACTIVITY IN
HUMAN BONE MARROW
5.1 PRINCIPLE OF ENZYME ACTIVITY ASSAYS
The quantity of enzyme activity in a given tissue is 
normally defined as the amount of product formed from substrate 
per unit time under specified conditions (Mahler and Cordes, 
1969). Enzymes are assayed under test conditions in which the 
pH is optimum and the substrate concentration is above 
saturation level, such that the initial reaction rate is zero- 
order for substrate. For a catalyzed reaction, the rate is 
proportional to enzyme concentration alone when the reaction is 
zero-order for substrate and cofactors (Lehninger, 1972).
5.2 THE ASSAY OF FERROCHELATASE ACTIVITY
The measurement of ferrochelatase activity is fraught 
with difficulties. However, several methods are currently 
available, each varying in sensitivity and suitability for 
specific tissues.
5.2.1 Measurement of Porphyrin Disappearance by Spectrophotometric or 
Fluorometric Methods
Ferrochelatase activity may be assayed by measuring the 
consumption of porphyrin substrate, spectrophotometrically or 
fluorometrically (Labbe, 1959; Porra et al, 1967; Jones and 
Jones, 1969; Camadro and labbe, 1982). However, loss may occur 
by reactions other than ferrochelatase e.g. by photocatalyzed 
oxidation reactions. Moreover, sufficient substrate 
concentrations must be provided to maintain a linear rate of 
product formation throughout the incubation and ideally greater 
than 90% of the substrate should remain at the end of the
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incubation. The presence of such a large excess of porphyrin 
in the incubation mixture results in a lack of accuracy and 
sensitivity for these methods.
5.2.2 Measurement of Haem Formation by the Pyridine Haemochrome 
Procedure
Haem formation can also be measured by the pyridine 
haemochrome procedure (Porra and Jones, 1963; McKay et al, 
1969; Porra, 1976; Dailey et a l , 1986). Haem concentrations 
are calculated from the reduced minus oxidised spectrum of 
pyridine haemochromogens over a wavelength range of 500-600 nm. 
Ihe sensitivity of these methods is also low as the presence of 
endogenous haem may cause a high background against which any 
small increase would be difficult to detect. Greater 
sensitivity is achieved using mesoporphyrin as substrate 
(Porra, 1976) since alkaline pyridine mesohaemochromogen has an 
absorption peak distinct from that of background endogenous 
protohaemochromogen.
5.2.3 Measurement of Haem Formation by Radiochemical Methods
Radiochemical methods with 59Fe2+ ions as substrate 
(Krueger et al, 1956; Goldberg et a l , 1956; Goldberg, 1959; 
Bottomley, 1968; Bloomer and Morton, 1982; Dailey and Fleming, 
1986) potentially provide much higher sensitivity than other 
methods, but suffer from difficulty in separating labelled haem 
from free 59Fe2+ ions. In addition, the assays are tedious and 
great care must be taken to ascertain the purity and recovery 
of the radioactive haem product.
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5.2.4 The Need for a Sensitive Assay
Most of the above methods have been primarily used to 
study tissues which contain high levels of ferrochelatase 
activity e.g. liver. Many are not sensitive enough to 
measure the levels of activity that occur in some mammalian 
tissues. In the case of human bone marrow, although unit 
activity may be high, very limited cell numbers are available 
and endogenous haem is present in large enough quantities to 
make the detection of newly synthesised haem difficult. It was 
therefore necessary to develop a highly sensitive radiochemical 
method suitable for the measurement of bone marrow 
ferrochelatase activity which could overcome the problem of 
product isolation. The remainder of this chapter describes in 
stepwise fashion the experimental progression towards this 
goal.
5.3 A RADIOCHEMICAL ASSAY FOR FERROCHELATASE ACTIVITY
5.3.1 Choice of Incubation Medium
Tris buffer (50mM) was suitable incubation medium for the 
assay of ferrochelatase activity. This has been the chosen 
buffer of several workers (Dailey et al, 1986; Bloomer and 
Morton, 1982).
As enzyme activity is almost universally measured between 
pH 7.2 and 7.6, initial experiments were carried out at pH 7.4. 
Later work confirmed that this was the most suitable pH for 
enzyme measurement in human bone marrow (Section 5.8.4). The 
need for individual constituents in the enzyme reaction mixture 
has been examined (Section 5.8).
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Choice of Substrates
Ferrochelatase activity can be studied with compounds 
other than the natural substrates, iron and protoporphyrin IX.
Porphyrin
In addition to protoporphyrin IX, other 2-carboxylate 
porphyrins e.g. deutero and mesoporphyrin serve as good 
substrates for ferrochelatase and provide activity that is 
several times greater than protoporphyrin (Jones and Jones, 
1969? Johnson and Jones, 1964; Porra and Jones, 1963). 
However, protoporphyrin IX is the natural substrate for 
ferrochelatase and was chosen for use in the work described 
here for several reasons:-
Enzyme activity determined with one type of porphyrin or metal 
substrate may differ from that determined with another 
substrate (Tephly, 1978).
Solvent extraction, the usual technique for isolating haem, is 
unsuitable when mesoporphyrin or deuteroporphyrin is used as 
substrate because of low extraction efficiency (Dailey et al, 
1986).
Protoporphyrin IX is the natural substrate and it is not known 
whether in disease states enzyme activity differs for different 
substrates.
Radioactive Metal
Only the reduced form of iron i.e. ferrous iron (Fe^+) 
is incorporated into protoporphyrin IX by ferrochelatase. 
Ferric iron (Fe^+) cannot act as substrate (Porra and Jones,
2 "f* * o j.
1963). Co ions and Zn ions are more efficient enzyme 
substrates than Fe^+ ions (Johnson and Jones, 1964). However, 
for reason (1 ) stated above Fe^+ ions were chosen as 
substrate.
(a) Choice of ^Fe Product
Several preparations of ^Fe are commercially available, 
varying significantly both in suitability and cost. The choice 
of product is dependent on several factors - (1 ) those 
previously chosen by other workers in the assay of 
ferrochelatase activity; (2 ) the availability and (3 ) the 
cost.
Two types of -^Fe products were tested:
(1) ^9pe2+ as FeSC>4 :‘-n H2SO4 (New England Nuclear) (Bloomer
and Morton, 1982). This was supplied in a minimum quantity of 
lmCi at a cost of £200.
(2) 59Fe3+ as FeCl^ in 0.10M HC1 (Amersham International). This
was used under conditions which favoured the conversion of 
59Fe3+ ions to 59pe2+ ions (section 5.8.2) and was supplied in 
small quantities of lOOjuCi at a cost of £70.
Initial experiments were carried out using ^FeSc^. Thereafter 
^FeCl 3 was chosen in preference to ^FeSc^.
(b) The Storage of Radioactive Iron
Many problems exist with regard to the storage of 
radioactive iron.
Firstly, when large quantities of iron are stored over a 
period of weeks or months (as with ^ F e S 0 4 ) insoluble iron 
hydroxide may form (Li et al, 1988). To avoid this, iron
141
should be purchased regularly in small quantities. Safety 
precautions must also be taken. No more than lOOpCi of 59Fe is 
permitted to be held in the laboratory at any one time and 
should be shielded by a lead screen to block the high energy 
gamma rays of the ^9Fe isotope.
Secondly, as the half life (tV 2) of 59Fe is only 44.7 
days, regular purchasing is necessary to maintain the specific 
activity and hence the sensitivity of the assay.
For these reasons, ^9FeCl3 was a more suitable choice of 
substrate than ^9FeSO^.
5.4 ISOLATION OF THE HAEM PRODUCT
A critical feature of the assay of ferrochelatase activity 
is the ability to isolate and quantify haem, free from 
porphyrin substrate and non-haem radioactive metal. This 
presents a considerable problem in radiochemical assays. Other 
workers have used solvent extraction alone as a means of 
isolating haem (Bloomer et al, 1983; Camadro and Labbe, 1982). 
However, this was not ideal as work described here has now 
shown significant ’carry-over1 of free ^9Fe along with ^9Fe- 
labelled haem (Section 5.6.4).
The first step in the development of a method to measure 
ferrochelatase activity in human bone marrow, was to set up a 
procedure to isolate and collect the haem product.
5.4.1 Methods Currently Available for the Isolation of Porphyrins
As only small cell numbers can be obtained by human bone 
marrow aspiration, a very sensitive method of measurement, such
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as that offered by radiochemical assay, was required for this 
work. This had to be coupled to a sensitive and efficient 
method for the isolation of the labelled-haem product.
The use of RPHPLC for the isolation of haem was first 
demonstrated by Tangeras (1984) in the assay of rat liver 
ferrochelatase activity. Free porphyrin carboxylic acids can 
be separated by HPLC using either ion-exchange, normal-phase, 
reversed-phase or reversed-phase ion-pair chromatographic 
systems (Evans et al, 1975; Longas and Poh-Fitzpatrick, 1980; 
Englert et al, 1979; Bonnett et al, 1978). A reversed-phase 
ion-pair system was reported to be the most reproducible method 
for the analysis of tetrapyrroles. Tangeras (1984) used RPHPLC 
to isolate haem in the assay of ferrochelatase activity by a 
non-radiochemical method. In the work described here, a 
modification of this RPHPLC method was coupled with a 
radiochemical assay in an attempt to improve the sensitivity 
and accuracy of previous assays. The principles of HPLC have 
been outlined (Chapter 3, Section 3.8.4).
5.5 RPHPLC SEPARATION OF HAEM, PROTOPORPHYRIN AND IRON
5.5.1 Materials
The separation of haem, protoporphyrin and iron was 
achieved by RPHPLC using an HPLC pump (Waters, Model 510), a 
valve loop injector of 50|al capacity (Rheodyne, Model 7125) and 
a variable wavelength spectrophotometric detector (Waters, 
Model 484) set to 398nm (cell pathlength, 1cm) connected to a 
data module recording integrator (Waters, Model 740). The 
column used was a reversed-phase silica supported pre-packed
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Apex C18 column (15cm x 4.6I.D., particle size 5pM) (Crawford 
Scientific) and samples were collected from the column using a 
fraction collector (Gilson, Model 203). Activity was counted 
on a gamma counter (Packard Minaxi gamma, 5000 series, Model 
A5550).
Tetrabutylammonium hydrogen sulphate (TBAHS), the ion- 
pairing agent, haem and protoporphyrin IX were purchased from 
Sigma Chemical Co. and HPLC grade methanol obtained from 
Rathburn Chemicals. Samples were applied to the column in 
ammonium acetate (lM), pH 7.0 (BDH). (See section 5.7.2 for 
solubility of haem).
5.5.2 Methods
The mobile phase recommended by Tangeras (1984) i.e. 
MeOH:H20 (97:3), TBAHS (ImM), acetic acid (lOmM), produced 
good separation of haem (lOOpM) and protoporphyrin IX (lOOpM) 
when injected in 0.05ml of ammonium acetate (1M), pH 7.0 at a 
flow rate of 1ml min"l. However, these conditions did not 
separate haem and iron (O.lpCi, ^^FeSO^) which eluted 
simultaneously approximately two minutes after sample 
injection. Alterations to the flow rate did not improve 
separation and prevented satisfactory peak resolution. The 
water content of the mobile phase was therefore increased. At 
a MeOH: H 20 ratio 83: 17 satisfactory separation of haem, 
protoporphyrin and iron was achieved, but the chromatography 
deteriorated and both haem and protoporphyrin peaks were less 
well defined. This was corrected by increasing the 
concentration of the ion-pairing agent, TBAHS, from ImM to 2mM 
(Figure 15).
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Peak 1 = solvent front Peak 2 = ~^Fe ions
Peak 3 = haem/[^^Fe]-haem Peak 4 = protoporphyrin
Mobile phase (MeOHrf^O, 83:17; Acetic acid, 10mM) 
contained the ion-pairing agent, tetrabutylammonium 
hydrogen sulphate (TBAHS), at concentrations of (a) 1mM 
and (b) 2nM. See text for further details.
FIGURE 15
THE SEPARATION OF RADIOACTIVE IRON, HAEM AND
PROTOPORPHYRIN USING REVERSED-PHASE HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY
The mobile phase chosen for routine use in the assay of 
ferrochelatase activity comprised Me0H:H20 (83:17), TBAHS 
(2mM), acetic acid (lOmM). TBAHS and acetic acid were added to 
the water prior to the addition of methanol. The pH was 
adjusted with ammonium hydroxide (5M) to 6.5 at ambient 
temperature. The addition of methanol altered the final pH of 
the mobile phase to 7.0.
Under the described conditions, (flow rate 1.0ml min- ,^ 
wavelength 398nm) the retention times of Fe^+ ions, haem and 
protoporphyrin were 3.0, 5.5 and 9.5 minutes respectively, with 
haem eluting over a 2-3 min period (Figure 15).
Approximately 25,000 cpm were injected into the HPLC as 
radioactive ferrous sulphate (-^FeSO^). ^ F e  was detected in 1 
min fractions. Iron elution was complete at 4 minutes and 
subsequent fractions contained background counts of 
approximately 60cpm. ^ F e - l a b e l l e d  haem was successfully 
isolated at 5.5 minutes.
5.5.3 RPHPLC of Haem
A linear relationship was demonstrated between the peak 
area of haem as determined by RPHPLC and the injection volume 
(and hence haem content) (Figure 16).
5.5.4 Stability of Haem
The quality of haem chromatography was maintained 
following overnight storage at 4°C under nitrogen in dried form 
or in ammonium acetate (1M), pH 7.0. Storage at 4°C for longer 
periods resulted in peak splitting and shoulder formation due 
to the oxidation of haem and/or the formation of haem 
aggregates.
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FIGURE 16
THE RELATIONSHIP BETWEEN INJECTION VOLUME 
AND PEAK AREA OF HAEM AS DETERMINED BY 
RPHPLC.
Thus, a highly effective RPHPLC method was developed for 
the isolation of haem from free iron and protoporphyrin. The 
next stage was to try to develop a method for the removal of 
haem from the bone marrow sample prior to RPHPLC and to compare 
this RPHPLC method of product isolation with those used by 
other workers.
5.6 EXTRACTION CMF HAEM FROM THE INCUBATION MEDIUM
Porphyrin extraction from biological samples may be 
achieved with organic solvents such as ethylacetate: acetic 
acid (4 : 1 vol/vol) (Bloomer and Morton, 1982) or acidified 
methylethyl ketone (butan-2-one) (Dailey, 1986). Such 
extraction has frequently been assumed to effect 100% haem 
extraction (Bloomer et a l , 1983; Camadro and Labbe, 1982; 
Fadigan and Dailey, 1987) and is essential for the removal of 
cellular debris.
The effectiveness and consistency of haem extraction using 
organic solvent was assessed.
Experimental
A mixture of haem (50pM), protoporphyrin IX (lOOpM) and 
iron (lOOpM) as F e C ^  was prepared in tris buffer (50mM), pH 
7.4, to mimic ferrochelatase assay conditions. This was 
divided into 12 aliquots of 1.0ml; 6 were extracted with 3ml 
ethylacetate : acetic acid (4 ; 1 vol/vol) and 6 were extracted 
into 3ml acidified methylethyl ketone. The samples were 
evaporated to dryness at 37°C under N2 then reconstituted in 
lml ammonium acetate (1M) (Section 5.7.2). A portion of the 
reconstituted sample (0.05ml) was then taken for RPHPLC 
(Section 5.5).
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5.6.1 Porphyrin Extraction with Ethylacetate: Acetic Acid
1. Ethylacetate : acetic acid (4 : 1 vol/vol) (1.5ml) was added to 
incubation medium (1.0ml) containing haem, protoporphyrin and 
iron. The contents were mixed thoroughly (1 min) and the 
phases separated by centrifugation at 3,000 rpm (5 min).
2. The organic layer was removed.
3. A further 1.0ml of ethylacetate : acetic acid (4 : 1 vol/vol) 
was added per tube and Step 1 repeated.
4. The organic layer was removed and added to that removed in Step 
2.
5. Steps 3 and 4 were repeated.
5.6.2 Porphyrin Extraction with Acidified Methylethyl Ketone (Butan- 
2-one)
1. HC1 (0.5M, 0.5ml) was added to incubation medium (1.0ml)
containing haem, protoporphyrin and iron.
2. Methylethyl ketone (1.5ml) was added to each sample. The 
contents were mixed thoroughly (1 min) and the phases separated 
by centrifugation at 3,000 rpm (5 min).
3. The organic layer was removed.
4. A further 1.0ml of methylethyl ketone was added per sample and 
Step 2 repeated.
5. The organic layer was removed and added to that removed in Step
3.
6. Steps 4 and 5 were repeated.
The following method was used to calculate the percentage 
recovery of haem.
Haem (50juM), identical to that used in each experiment, 
was dissolved in ammonium acetate (1M). Aliquots of haem
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solution (0.05ml) were then assessed for haem peak area by 
RPHPLC (n = 6) and the mean peak area was taken to represent 
100% recovery. Linearity of peak area with volume injected had 
been established (Section 5.5.3). The peak area following 
extraction was related to the peak area prior to extraction and 
thereafter was corrected to 100% recovery.
(i) Acidification of the Organic Solvent
Acidity was of critical importance during the extraction 
of haem into methylethyl ketone. The reaction mixture was 
acidified with HC1 (0.5ml). At concentrations of _< 0.2M HC1, 
haem was not extracted. At concentrations > 0.2M HC1 the 
extraction efficiency varied between 73-86% and could not be 
improved by increasing the acidity to 5M HC1 (x = 78%, S.D. = 
4.6%, C.V. = 5.9%, n = 6).
HC1 Molarity (M) % Haem Extracted Peak Area of
Protoporphyrin
1 75 2 761 150
1 76 2 233 313
2 78 488 099
2 80 452 155
5 73 62 900
5 86 —
Protoporphyrin recovery varied significantly and was 
greatly reduced when extracted in the presence of 5M HC1. A 
reduction in protoporphyrin extraction allowed sample extracts 
to pass more easily through the sorbent extraction column 
(section 5.7) prior to RPHPLC. Nevertheless, since acid may 
damage the HPLC column, 1M HC1 was chosen for routine use. The 
presence of protoporphyrin and/or iron did not affect the 
extraction efficiency for haem.
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(ii) Effect of Acid on Haem
Other workers have avoided acidic conditions when 
extracting the metal porphyrin from biological samples, 
believing that this may release the metal from the porphyrin 
ring (Scobie et al, 1981). RPHPLC analysis of extracted haem 
showed that this did not occur under the described conditions 
since no protoporphyrin was detected following acid treatment 
of haem solutions.
5.6.3 Choice of Organic Solvent for the Extraction of Haem
Extraction of haem was equally efficient (x = 78%, n = 6) 
with ethylacetate : acetic acid (4 : 1, vol/vol) or acidified 
methylethyl ketone and was consistent (C.V. = 6%). Acidified 
methylethyl ketone was chosen for routine use since this was 
very volatile, with 3.0ml evaporating to dryness under N 2 at 
37°C in approximately 20 minutes in comparison to the 40 
minutes required to evaporate ethylacetate : acetic acid (4 : 
1, vol/vol).
5.6.4 Haem Extraction by Organic Solvent as a Means of Haem Isolation
Haem was extracted into acidified methylethyl ketone from 
a further 6 samples. Each sample (pH 7.4) also contained
O.lpCi of 59Fe (25,000 cpm) as FeCl3 in 0.1M HC1. This 
quantity of activity was approximately one tenth of that 
required in the assay of ferrochelatase but was chosen to avoid 
contamination of the HPLC equipment with large quantities of 
59Fe.
Results
Approximately 15% of the original ^9Fe ions were carried
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over into organic solvent and isolated by HPLC as a radioactive
C Q
^Fe peak distinct from that of haem.
Organic solvent extraction alone was not therefore 
adequate for isolating ^Fe-labelled haem as had been suggested 
by other workers (Bloomer et al, 1983; Camadro and Labbe, 
1982). RPHPLC represented a suitable further step for the 
complete isolation of ^Fe-labelled haem from free ^ F e  ions. 
However, in the assay of ferrochelatase activity a vast excess 
of ^ F e  ions would be present in the incubation mixture ( >
250,000 cpm, i.e. greater than a 10-fold increase in the 
quantity used here). Hence, an intermediate step between haem 
extraction by organic solvent and RPHPLC was required to 
significantly reduce the quantity of free 59pe ions. This 
reduction would enable successful isolation of ^ F e - l a b e l l e d  
haem from free Fe^+ ions without undue contamination of HPLC 
equipment with free ^Fe.
5.7 PARTIAL ISOLATION OF HAEM PRIOR TO RPHPLC
RPHPLC is highly sensitive to the presence of biological 
contaminants in organic extracts which may interfere with the 
effective separation of haem, protoporphyrin and iron. It was 
therefore necessary to remove these contaminants. In addition, 
the presence of excess free ^9pe ions, carried over during 
extraction of haem into organic solvent, would result in 
equipment contamination with high ^9pe background counts. It 
was thus necessary to reduce ^Fe cpm prior to HPLC.
Sorbent extraction using disposable solid phase columns 
containing packing material similar to that of the HPLC column
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is commonly used as sample preparation prior to RPHPLC. 
Sorbent extraction was examined as a possible means of 
achieving partial isolation of ^Fe-labelled haem prior to 
RPHPLC.
5.7.1 Sorbent Extraction
Sorbent extraction is a physical extraction process that 
involves a liquid and a solid phase. The solid phase has a 
greater attraction for the isolate than the solvent. The 
specific properties of a given bonded silica sorbent result 
from the functional group covalently bonded to the silica 
substrate and a variety of different bonded silicas are 
commercially available, offering a wide range of selective 
properties for extraction.
(i) Properties of Bonded Silicas
Bonded silicas are formed by the reaction of organosilanes 
with activated silica. The product is a sorbent with the 
functional group of the organosilane attached to the silica 
substrate through a silyl ether linkage. Another reaction 
called endcapping may be performed subsequently to inactivate 
remaining silanol groups on the silica and so minimise 
interactions with the silica substrate.
Bonded silicas equilibrate rapidly to new solvent 
conditions and allow many solvent changes to be performed 
rapidly. Methanol is an effective solvating agent because it 
can interact with both the silanols on the silica and the 
carbon atoms of the bonded functional group.
(ii) Choice of Sorbent Extraction Columns
Sorbent extraction interactions can be grouped into one of four
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classes:
(1) Non-polar
(2) Polar
(3) Ion-Exchange
(4) Covalent
For the isolation of haem a non-polar interaction is most 
suitable whereby interactions occur between the C-H bonds of 
the sorbent functional groups and those of the isolate. The 
most commonly used sorbent for non-polar interactions is 
octadecyl silane (C18), a non-selective sorbent. Various other 
hydrocarbon chain lengths are also commercially available
i.e. C2, C8. Two columns, Sep-pak and Bond Elut, were 
examined for use in the partial isolation of haem prior to 
RPHPLC:-
(1) 'Sep-pak' Disposable Sorbent Extraction Columns (Waters)
Packing Material: Hydrocarbon chain length C18.
'Sep-pak' columns are uncapped and retention is by both 
hydrophobic and ionic interactions
(2) 'Bond-Elut' Disposable Sorbent Extraction Columns
(Analytichem)
Packing Material: Hydrocarbon chain lengths C2, C8, C18. 
'Bond-Elut' columns are capped and retention is mainly by 
hydrophobic interaction.
Retention of isolates by non-polar interactions is 
facilitated by polar solvents. Elution of isolates from non­
polar sorbents is facilitated by solvents of sufficient non­
polar character to disrupt the non-polar substrate/sorbent
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5.7.2
(i)
(ii)
(iii)
interactions.
Several experiments were carried out to determine the most 
suitable solid phase column for the retention and subsequent 
elution of haem. The combined behaviour of haem, 
protoporphyrin and Fe ions was examined on such columns.
Partial Isolation of Haem by Sorbent Extraction
The Solubility of Haem
Haem dissolves relatively well either at extreme alkaline 
pH (i.e. > 11) or extreme acidic pH ( < 3) but not in neutral 
solvent. Haem must be dissolved initially in acid or alkali 
and the solution then pH'd to neutrality.
The method developed for the preparation of stock haem 
solution (prepared fresh daily) was as follows:- 
lOOpM Haem
lmg of haem was dissolved by the sequential addition of 
0.3ml of ammonium hydroxide (5M), 14.55ml of ammonium acetate 
(1M), pH 7.0 and the solution was brought to neutrality with
0.15ml of glacial acetic acid.
Activation of Sorbent Extraction Columns
Columns were activated with methanol (2ml), followed by 
ammonium acetate (1M), pH 7.0 (5ml).
Retention of Haem by Sorbent Extraction Columns
lml of haem (50juM) in ammonium acetate (1M), pH 7.0 was 
applied at a flow rate of approximately 1.0ml min  ^ to four of 
each of the following columns.
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Sorbent Extraction Columns
Sep-pak
Hydrocarbon Chain Length 
C18
Packing Volume 
lOOOmg
'Bond-Elut1 C2, C8, C18 300mg
The haem solution had an initial absorbance at 400nm of
0.101 while the A 4Q0nm t l^e eluate in each case was zero. 
The A ^ o n m  eluate after washing the columns with
ammonium acetate (1M), pH 7.0 was also zero.
The retention of haem was 100% on all columns and washing 
with ammonium acetate (1M), pH 7.0 did not elute any haem. All 
tested columns were therefore suitable for the retention of 
haem. The retention pattern of iron on the columns was later 
examined (Section XI).
(iv) Choice of Eluting Solvent
The eluting solvent had to satisfy two criteria.
(1) Haem had to be readily soluble in the chosen eluting solvent 
to achieve maximal elution in minimum volume.
(2) The eluting solvent had to be volatile so that haem could be 
concentrated by solvent evaporation prior to HPLC.
Five solvents were examined:
1. Methanol
2. Methanol: hydrochloric acid (5M) (99:1, pH 3.0)
3. Methanol: sodium hydroxide (1M) (99:1, pH 9.0)
4. Methanol: ammonium acetate (1M) (90:10, pH 6.64)
5. Methanol: ammonium hydroxide (5M) (99:1, pH 10.5)
Each eluting solvent was applied (3 x 1ml) to four columns 
of each type and the eluate collected. Excepting methanol,
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haem eluted well and was visible as a dark brown, colour. 
A400nm rea<lings showed that most haem eluted in the first ml. 
The A400nm ^or ^aem was similar for each eluting solvent but 
was greater than in the original ammonium acetate (1M) solvent. 
Haem recovery was not determined at this stage.
Methanol: ammonium acetate (1M) was chosen as the eluting 
solvent for haem in subsequent experiments because:-
1. Ammonium acetate (1M) was the solvent in which haem was applied 
to the sorbent extraction column.
2. Ammonium and acetate ions were present in the HPLC mobile 
phase.
Since C2, C8 and C18 columns retained haem equally well, 
the use of the more expensive C18 columns was discontinued.
A further three solvents comprising of methanol: ammonium 
acetate (1M), were examined for their ability to effect haem 
elution from C2 and C8 'Bond-Elut' columns.
MeOH : ammonium acetate (1M) (v/v) pH 
70 : 30 
80 : 20 
90 : 10
1.0ml haem (50pm) in ammonium acetate (1M), pH 7.0, 
A^ 400nm 0-184), was applied to each column type. The
columns were washed with ammonium acetate (1M) and haem eluted 
in 2.0ml of each eluting solvent (Table 14). The experiment 
was carried out in triplicate. The results showed that:-
The recovery of haem was higher (15 - 40%) from C2 than from 
C8 columns.
6.30
6.46
6.64
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C2 'Bond-Elut'
A400rnn
MeOH:AA 70:30 80:20 9Q;1Q
Column 0 ^  Ja)_ Cb)_ Jai (b)
Elution (1) 0.159 0.140 0.409 0.483 0.736 0.801
(1ml)
Elution (2) 0.588 0.591 0.359 0.324 0.053 0.011
(1ml)
'Iatal A400nm °-747 °-731 0.768 0.807 0.789 0.812
C8 'Bond-Elut
A ^ n m
MeOH:AA 70:30 80:20 90:10
Column ja)^  jb)^  {a)_ fa)_ (a)^  (b)
Elution (1) 0.399 0.420 0.571 0.425 0.625 0.650
(1ml)
Elution (2) 0.141 0.123 0.063 0.289 0.046 0.033
(1ml)
Total A400ran °-540 0-543 0.634 0.714 0.671 0.683
NOTE:
A.A. = Ammonium Acetate (1M);
(a) and (b) are duplicate columns.
TABLE 14
THE ELUTION OF HAEM FROM SORBENT EXTRACTION COLUMNS (C2 AND 
C8) USING VARIOUS COMBINATIONS OF METHANOL:AMMONIUM ACETATE 
(1M) AS ELUTING SOLVENT
2. With both C2 and C8 columns MeOH: ammonium acetate (1M) (90:10)
was more efficient at eluting haem than both 80:20 and 70:30 
combinations.
3. Recovery was slightly improved using MeOH:ammonium acetate (1M)
(95:5)) as the eluting solvent (results not shown).
Methanol : ammonium acetate (1M) (95:5), pH 6.9 was chosen 
as eluting solvent for routine use.
(v) Choice of Sorbent Extraction Column
Columns with packing material of short hydrocarbon chain 
length i.e. C2 or C8 may have an advantage over columns with 
longer hydrocarbon chain packing as impurities may more readily 
elute at the ammonium acetate wash. In theory, haem may also 
elute more efficiently because it will bind less strongly to 
hydrocarbons of shorter chain length. This has been 
demonstrated experimentally in the previous experiment as haem 
eluted more readily and with greater percentage recovery from 
C2 columns than from C8 columns. All subsequent experiments 
were carried out using C2 'Bond-Elut1 columns.
(vi) Optimum Packing Volume
The packing volume of C2 'Bond-Elut' columns (lOOmg or 
300mg) made no material difference to the retention or elution 
of haem and haem recoveries were consistent to within 5%. C2 
'Bond-Elut' columns with lOOmg of packing material were chosen 
for routine use.
(vii) Optimum Elution Volume
The aim was to elute haem from the C2 'Bond-Elut' column 
in the smallest volume that would permit maximum haem recovery.
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Using methanol : ammonium acetate (1M) (95:5), pH 6.9, the 
optimum elution volume was three volumes of 1ml. The eluted
sample was evaporated to dryness under N 2 at 37°C in 40
minutes.
(viii) Consistency of Haem Recovery
Earlier work (Section 5.7.2 (vi) ) suggested that haem 
recovery was highly consistent. To verify this 6 identical 
samples of haem were applied to 6 activated C2 'Bond-Elut' 
columns. The A^qq^  of the original haem solution (3.0ml) was
0.101 and the average A^q q ^  of the eluted haem solution 
(3.0ml) was 0.446 (S.D. = 0.020, C.V. = 4.5%, n = 6). This
confirmed earlier results that the optical density was higher
in the eluting solvent than in ammonium acetate (1M) and again 
demonstrated recoveries consistent to within 5%.
(ix) Viability of C2 'Bond-Elut' Columns for Re-Use
The C2 'Bond-Elut' columns were examined for repeated use 
by applying five haem samples consecutively to one column. 
The column was reactivated between samples with methanol (2ml) 
followed by ammonium acetate (1M) (5ml). The average A^qq^  of 
the eluted haem solution was 0.422 (S.D. = 0.006, C.V. = 2.7%, 
n = 5) indicating that the lOOmg C2 'Bond-Elut' columns could 
be re-used up to 5 times without affecting haem recovery.
(x) Percentage Recovery of Haem From C2 'Bond Elut Columns
The retention of haem on C2 'Bond-Elut' columns in 
ammonium acetate (1M), pH 7.0, was 100% (Section 5.6.2). The 
A400nm haem is dependent on the nature of the solvent. 
Elution in MeOH : ammonium acetate (1M), pH 6.9 (95:5) resulted
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in higher absorbance readings than for haem in the original 
solution of ammonium acetate (1M). To calculate the percentage 
recovery of haem from the column a reference graph was 
constructed relating the A^qq^  of known concentrations of haem 
in ammonium acetate (1M), pH 7.0, to the A 400nm in MeOH : 
ammonium acetate (1M), pH 6.9, (95:5) (Figure 17). This was 
carried out in triplicate [due to difficulty experienced in 
dissolving dried haem directly in MeOH: ammonium acetate (1M), 
(95:5)] over the concentration range 0.6jum - 600pm. A straight 
line reference graph was obtained over the range 0.6pm - 450pm. 
At concentrations exceeding this, linearity was not maintained 
presumably due to the propensity of porphyrins to aggregate 
and change absorbance maxima in the 400nm region with 
increasing concentration (Gallacher and Elliot, 1973). The 
Beer-Lambert relationship between absorbance and concentration 
could, however, be applied over the linear portion of the 
graph -
A = Eel
A = absorbance units E = molar extinction coefficient 
c = concentration 1 = pathlength
Since E and 1 are both constant, the absorbance, A is 
proportional to the concentration c. Using the reference 
graph, it was established that the recovery of haem from the C2 
'Bond-Elut' column, using MeOH: ammonium acetate (1M), pH 6.9 
(95:5) as the eluting solvent, consistently fell within the 
range 95-100%.
(xi) Partial Separation of Haem and ^ F e  by Sorbent Extraction
Further experiments were designed to investigate whether
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FIGURE 17
REFERENCE GRAPH FOR DETERMINATION OF 
HAEM RECOVERY DURING SORBENT EXTRACTION 
USING C2 'BOND ELUT' COLUMNS.
59Fe and haem could be successfully separated on C2 columns 
following organic solvent extraction such as to make the use of 
RPHPLC unnecessary.
^ F e  (2.5jjCi) was applied to five activated C2 'Bond Elut1 
columns in 3.0ml neutral tris buffer (50mM). Both eluate and 
columns were then counted on a gamma counter for 1 minute each.
average cpm
Activity applied to columns 484,293
Activity retained by columns 50,361 (+ 13 871)
Activity in eluate 433,931 (+ 12 886)
(+ 1 S.D.)
11.6% of the ^ F e  was retained by the columns. Since it 
was intended that a similar amount of radioactive iron should 
be used in the assay of ferrochelatase activity, C2 columns 
were suitable for the removal of up to 90% of the free 59Fe2+ 
ions. ^9Fe retention did not alter in the presence of haem 
(lOOyuM) and/or protoporphyrin (lOOpM).
The retention of 59Fe i0ns was not reduced either by 
saturating the C2 column with cold FeSO^ prior to the addition 
of ^9Fe or by repeated washing of the column with water or tris 
buffer, pH 7.0. Tris buffers in the lower pH range (pH 4.0) 
removed up to 50% of the retained ^ F e  but also allowed haem to 
elute from the column.
Although it was not possible to isolate haem using sorbent 
extraction alone, this stage was useful for the partial 
isolation of haem prior to RPHPLC. This significantly reduced 
the ^9Fe Cpm injected into the HPLC and facilitated ^ F e -
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labelled haem isolation by RPHPDC. In a typical assay 500000 
59
Fe cpm could be reduced to 7500 cpm using organic solvent 
extraction followed by sorbent extraction prior to RPHPLC.
5.7.3 Summary of Sample Preparation Prior to RPHPLC
Sample preparation prior to RPHPLC may be summarised by 
the following steps:
Haem was extracted from the incubation medium with 
acidified organic solvent.
1. HC1 (1.0M, 0.5ml) was added to incubation medium (1.0ml)
containing haem, protoporphyrin and iron.
2. Methylethyl ketone (1.5ml) was then added to each sample and 
haem extraction effected as described in Section 5.6.2. As 
non-specific contamination of organic solvent with 15% of 
original ^ F e  Cpm j_s kn0wn to occur (Section 5.6.4), further 
sample preparation to reduce this contamination is required 
prior to RPHPLC.
3. The samples were evaporated to dryness under N 2 at 37°C and 
reconstituted in 2.0ml of ammonium acetate (IM), pH 7.0 by the 
sequential addition of 0.2ml ammonia (5M), 1.7ml ammonium 
acetate (IM) and 0.1ml glacial acetic acid.
The samples were then prepared for RPHPLC by sorbent 
extraction.
4. C2 'Bond-Elut1 columns were activated by 2.0ml of methanol,
followed by 5.0ml of ammonium acetate (IM), pH 7.0.
5. Samples were applied to the columns in 2.0ml of ammonium
acetate (IM), pH 7.0 at a rate of 1ml min”-^.
6. The columns were washed with 2.0ml of ammonium acetate (IM), pH 
7.0.
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7. Haem was eluted in 3 volumes (3 x 1.0ml) of the eluting 
solvent, methanol : ammonium acetate (IM) (95:5), pH 6.9 at a 
flow rate of 1ml min- -^.
8. Each sample was evaporated to dryness under N 2 at 37°C in a 
sample concentrator.
9. The samples were reconstituted in 0.2ml of the eluting solvent 
and an aliquot taken for RPHPLC (0.05ml).
Losses of haem were most likely to occur at haem 
extraction into organic solvent (Section 5.6.3). Losses were 
minimal at the stage of sorbent extraction.
With conditions now established for haem isolation the 
optimum conditions for the enzyme reaction were determined.
5.8 DETERMINATION OF OPTIMUM ASSAY CONDITIONS
5.8.1 The optimum assay conditions for ferrochelatase activity
were determined in normal whole human bone marrow.
Cells
(a) Cell Number
1 x 10? cells were used per assay. This was approximately 
equivalent to the number of cells available following bone 
marrow fractionation.
(b) Cell Preparation
The cells were prepared for initial work by ultrasonic 
disintegration in incubation medium (0.85ml per 2 x 10^ cells) 
as previously described for the ALA synthase assay (Chapter 3, 
Section 3.8.8). 0.4ml of cell suspension were taken for assay.
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(i) Incubation Medium
The reaction took place in tris buffer, final pH 7.4 in a 
volume of 1.0ml.
(a) Reaction Under N2
The reaction took place under N2 at 37°C in the dark.
(b) Presence of ascorbic acid as reducing agent 
Ascorbic acid was present at a concentration of 4.25mM.
(iii) Means of assessing haem recovery
The endogenous haem peak in identical marrow samples, as 
determined by RPHPIC, was used as a means of assessing relative 
recoveries. All cpm were then corrected to the peak area of the 
sample with the highest recovery.
5.8.2 Optimum Iron Concentration
(i) The Radioactive : Nonradioactive Iron Ratio (Specific
Activity)
The most suitable radioactive iron substrate was ferric 
chloride (^FeCl^) in hydrochloric acid (0.1M) (Amersham 
International) purchased in batches of lOOpCi in a volume of 
1.0ml. The iron content per batch of ^ F e C ^  could be 
calculated, and, on average -
lpCi ~  lnmole —  lOpl.
Other workers have used large amounts of radioactive iron 
(e.g. lOpCi) in the assay of ferrochelatase activity (Bloomer 
and Morton, 1982). However, this was undesirable and perhaps 
unnecessary. The aim, therefore, was to determine the minimum 
amount of radioactivity per assay which could provide adequate
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sensitivity.
The radioactive iron would primarily be in the form of 
ferric ions (^ 9Fe3+) and so would be unable to act as substrate 
for ferrochelatase. To correct this, non-radioactive ferrous 
ions (Fe3+) were added in excess such that mass action favoured 
the conversion of 59Fe3+ ions to 59Fe2+ ions> The presence of 
the reducing agent, ascorbic acid (in which the non-radioactive 
iron was dissolved), maintained the radioactive iron as ^9Fe3+ 
ions.
Experimental
Ascorbic acid was prepared fresh on the day of assay by 
dissolving ascorbic acid (0.25g) in distilled deionised water 
(10ml). The addition of 0.03ml of this solution to the final 
reaction mixture (0.97ml) gave a final ascorbic acid 
concentration of 4.25mM. Ferrous chloride (FeC^) was included 
in the ascorbic acid solution at various concentrations to 
produce final assay concentrations in the range (10 - 500pM). 
Radioactive iron (2pCi) was added to each assay. The enzyme 
reaction was initiated by the addition of 0.05ml of 
protoporphyrin (final concentration lOOpM). The reaction was 
terminated at 1 hour and the haem extracted then isolated by 
RPHPLC.
Results
The results were expressed as the mean of duplicate 
samples.
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[Iron] pM ~^Fe:Fe Corrected average cpm in haem
500 1 : 250 86
100 1 : 50 385
50 1 : 25 983
20 1 : 10 2311
10 1 : 5 5918
The results indicated that at iron concentrations of 20
and lOpM 59a ^Fe:Fe ratio of 1:10 or 1:5 provides suitable
sensitivity enabling ^ F e - h a e m  t 0  k e  easily detected 
(background counts up to 100 cpm). Various concentrations of 
iron (specific activity 0.2) were examined in the range 0-40pM 
to determine the saturating concentration of iron for 
ferrochelatase. Corrected cpm in haem were then plotted as a 
function of iron concentration.
The results from three experiments, each using duplicate 
samples, indicated that a plateau in enzyme activity was 
attained at an iron concentration of between 5 and lOpM. 
Thereafter, the addition of iron to a concentration of 40pM may 
cause slight enzyme inhibition (Figures 18 and 19). This was 
consistently observed and it may be speculated that iron has a 
regulatory role in ferrochelatase function. However, any firm 
conclusions must await more detailed experimentation.
A concentration of lOpM iron (specific activity 0.2) was 
chosen for routine use i.e. in 1.0ml of incubation medium 
8nmoles of non-radioactive iron and 2nmoles of radioactive iron 
were present, the equivalent of 2pCi of ^FeCl^ per assay.
5.8.3 Time Course for Ferrochelatase Activity
The rate of haem formation was investigated for comparison
164
UP
TA
KE
 
O
F5
9F
e 
IN
TO
 
H
A
E
M
 
CP
M 
(x
10
3) 
/1
07
C
E
LL
S
7.5-
5.0'
2 .5-
2015105
Iron concentration (yM)
NO TE :
Each point represents the mean of two 
observations.
Assay conditions are described in the text.
FIGURE 18
UPTAKE OF59Fe INTO HAEM AS A FUNCTION
OF IRON CONCENTRATION.
UP
TA
KE
 
O
F
59
Fe 
IN
TO
 
HA
EM
 
CP
M 
(x
10
3) 
/1
07
CE
LL
S
7.5-
5.0-
2.5-
4020 30
Iron concentration (uM)
NOTE :
Each point represents the mean of two 
observations.
Assay conditions are described in the text.
FIGURE 19
UPTAKE OF59Fe INTO HAEM AS A FUNCTION
OF IRON CONCENTRATION.
with previous reports (Krueger et al, 1956; Nishida and Labbe, 
1959; Porra and Jones, 1963; 1963; Porra et al, 1967). A plot 
of haem formation as a function of reaction time is shown over 
a period of three hours (Figure 20). The concentrations of 
iron (specific activity 0.2) and protoporphyrin were lOjuM and 
lOOpM respectively.
The reaction maintained linearity for 30 minutes after 
which a plateau was reached, presumably due to a shortage of 
substrate or enzyme instability. The results were verified 
using a second bone marrow sample.
To ensure linearity of haem formation an incubation time 
of 20 minutes was chosen for routine use.
5.8.4 The Effect of pH on Ferrochelatase Activity
Haem formation during a 20 minute incubation was plotted 
as a function of pH over the pH range 6.0 - 8.7 (Figure 21). 
The results clearly demonstrated optimum bone marrow 
ferrochelatase activity at pH 7.3 in agreement with that 
reported by Bottomley (1968).
The pH optimum of 7.3 for human bone marrow ferrochelatase 
activity differs from that determined in other tissues. For 
example, a pH optimum for ferrochelatase activity of 7.9-8.0 
has been reported in avian erythrocyte (Schwartz et al, 1959) 
and rat liver (Labbe and Hubbard, 1960; Li et al, 1988; 
Taketani and Tokunaga, 1981) while a value of 8.2 has been 
recorded for the reticulocyte enzyme in peripheral blood 
(Langelaan et al, 1970). However, it would seem logical that 
enzyme activity is optimal at physiological pH when using the
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UPTAKE OF59Fe INTO HAEM AS A FUNCTION
OF pH.
natural substrates for the enzyme. Discrepancies may possibly 
be explained by the use of different substrates such as Zn^+ 
and mesoporphyrin (Li et al, 1988; Taketani and Tokunaga, 
1981).
A shoulder was observed on the pH curve between pH 7.6 and 
7.8. This has also been observed for mesohaem formation by pig 
liver extract at pH 9.0 (Porra and Jones, 1963) and for 
protohaem formation in extracts from chicken erythrocytes also 
at pH 9.0 (Sawada et a l , 1969). Dailey and Lascelles (1974) 
have suggested that this biphasic pH optima curve is an 
artifact due to the known propensity of aqueous porphyrins to 
aggregate (Gallacher and Elliot, 1973).
5.8.5 Optimum Protoporphyrin Concentration
The concentration of protoporphyrin in the reaction 
mixture was examined over the range 0-100pM. Haem formation 
was plotted as a function of protoporphyrin concentration 
(Figure 22). A plateau in ferrochelatase activity was attained 
at a protoporphyrin concentration of approximately 40pM.
To ensure o ptimum ferrochelatase activity the 
protoporphyrin concentration for routine use was lOOpM.
5.8.6 Choice of Reducing Agent
A reducing agent is essential for the assay of 
ferrochelatase activity -
(1) to maintain the iron substrate as Fe^+ as opposed to Fe^+;
(2) to maintain the active sulphydryl groups of the ferrochelatase 
molecule in the reduced form.
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UPTAKE OF59Fe INTO HAEM AS A FUNCTION
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Several different reducing agents have been chosen for
this purpose e.g. dithiothreitol (DTT), cysteine, 2-
mercaptoethanol, glutathione (GSH) or ascorbic acid (Dailey and
Fleming, 1986; Krueger et a l , 1956; Goldberg et al, 1956;
Bloomer and Morton, 1982). Some reducing agents may facilitate
non-enzymatic haem formation thought to occur via the formation
of an iron-sulphur complex (Tokunaga and Sano, 1972). Based on
these observations, Kassner and Walchak, (1972), demonstrated
that thiol reductant DTT, cysteine or 2-mercaptoethanol act to 
3+reduce Fe ions and form a catalytically active iron-thiol 
complex. GSH, however, is ineffective at promoting non- 
enzymatic haem formation and this may be attributed to the 
formation of a stable iron-thiol complex which is an inactive 
species for haem formation.
DTT and ascorbic acid are most commonly used and were 
examined for use in the assay of ferrochelatase in bone marrow 
cells.
(i) DTT (Cleland's Reagent)
DTT was an unsatisfactory reducing agent in the assay of 
bone marrow ferrochelatase activity. It interfered with haem 
extraction into methylethyl ketone and so reduced haem 
recovery. Similar findings have been reported (Bloomer and 
Morton, 1982) and its use was therefore discontinued.
(ii) Ascorbic Acid
Ascorbic acid (Bloomer and Morton, 1982) was an effective 
reducing agent which facilitated the ferrochelatase enzyme 
reaction. A suitable concentration was determined for routine 
use.
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(iii) Optimum Ascorbic Acid Concentration
The concentration of ascorbic acid (reagent grade, BDH) 
was examined over the concentration range 4.25-42.50mM, similar 
to that used in the measurement of rat liver ferrochelatase 
(Bloomer and Morton, 1982). Haem formation was plotted as a 
function of ascorbic acid concentration (Figure 23).
The results demonstrate a steady decline in ferrochelatase 
activity with increasing ascorbic acid concentration at a fixed 
pH of 7.4. The aerobic degradation of haems in the presence of 
thiols or ascorbic acid has been reported (Porra et al, 1967) 
but has not been observed under anaerobic conditions similar to 
those used in this assay.
The experiment was repeated over the concentration range 
0-4.25mM and optimum ferrochelatase activity was observed at an 
ascorbic acid concentration of 4.25mM (Figure 24). In all 
subsequent experiments ascorbic acid was maintained at this 
concentration.
The removal of ascorbic acid from the incubation medium 
resulted in a 50% reduction in enzyme activity. Significant 
enzyme activity remained indicating that mass action favours 
the conversion of 5 9 pe3+ ^ons to 59pe2+ ions even in the 
absence of a reducing agent. This activity was shown not to be 
due to non-enzymatic haem formation (Section 5.11).
5.8.7 The Need for Anaerobiosis
Anaerobic conditions have generally been utilised for 
enzyme assays of ferrochelatase. The reaction has been 
reported to be inhibited by oxygen (Labbe and Hubbard, 1960;
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Porra and Jones, 1963) and so is normally carried out under N2. 
This provides optimum conditions for maintaining the iron 
substrate as Fe^+ and ensures that active sulphydryl groups do 
not undergo oxidation. It has, however, been reported (Dailey 
et al, 1986) that the measurement of ferrochelatase activity in 
PEL cells does not require anaerobic conditions.
In the measurement of human bone marrow ferrochelatase 
activity it was consistently found that anaerobiosis was 
indeed necessary as up to 50% of the enzyme activity was lost 
in the presence of 0 2* All assays of bone marrow 
ferrochelatase activity were carried out under N2.
5.8.8 Linearity of Ferrochelatase Activity with Cell Number
Various cell numbers ranging from 1 x 10^ - 35 x 10^ were 
assayed for ferrochelatase activity. Haem formation was 
plotted as a function of cell number (Figure 25) and the 
reaction was found to be linear to a cell number of 30 x 10^. 
Similar results were also obtained from a second experiment.
Other workers have also demonstrated a linear relationship 
between cell number and ferrochelatase activity in human bone 
marrow (Bottomley, 1968) and in cultured skin fibroblasts 
(Bonkowsky et al, 1975). However, linearity of enzyme activity 
with cell number has not been demonstrated for ferrochelatase 
in the liver (Porra et al, 1963).
5.9 RECOVERY OF HAEM FROM HOMAN BONE MARRCW: INTERFERENCE FROM 
ENDOGENOUS Hb
Endogenous haem is present in substantial amounts in bone 
marrow in the form of haemoglobin (Hb). It has been shown that
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following the incubation stage of the ferrochelatase assay a 
minimum concentration of 0.3M HC1 (0.5ml) is required to 
terminate the enzyme reaction, precipitate protein and to 
facilitate haem extraction (Section 5.6). However, the 
presence of HC1 at this concentration also led to Hb 
dissociation thereby releasing large quantities of free haem. 
This endogenous haem resulted in poor chromatographic isolation 
of haem. This gross excess of endogenous haem liberated from 
Hb made it impossible to add cold carrier haem at reaction 
termination to assess haem recovery. Mitochondrial 
preparations are free of Hb and the assay of enzyme activity 
using carrier haem and mitochondrial preparations is discussed 
in Section 5.9.8. Several other steps were examined in the 
hope of overcoming endogenous haem release and so allow for the 
addition of cold carrier haem as internal standard to each 
enzyme assay.
5.9.1 Use of an External Standard
The inclusion of an external standard in the reaction 
mixture was considered. Such a compound had to satisfy two 
criteria i.e. to have:-
(1 ) an extraction efficiency into acidified methylethyl ketone 
which was identical to that of haem;
(2) the potential to chromatograph by RPHPLC independently 
from haem and iron producing a recognisable peak which could be 
accurately quantified.
No such compound could be identified.
5.9.2 The Consistency of Haem Extraction
(1) Haem (0.1ml, lOOpM) in ammonium acetate (IM), pH 7.0 was
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extracted from incubation medium (1 .0ml) into acidified 
methylethyl ketone. The percentage recovery was assessed by 
relating the peak area of haem as determined by RPHPLC 
following extraction with the peak area of haem prior to 
extraction.
The average recovery was 75% + 7.6% (x + I.S.D., n = 10) 
with a coefficient of variation (C.V.) of 9.7%.
(2) Cell pellets from 0.25ml of blood were sonicated in incubation 
medium. The samples were extracted to investigate whether 
endogenous haem liberated from Hb behaved in a manner similar 
to carrier haem.
Actual recoveries could not be determined as haem could 
not be accurately quantified, but variations in recovery were
observed and the C.V. found to be 8 .8 % (n = 10).
(3) Haem was extracted from samples of both blood and bone marrow 
samples suspended in incubation medium. A linear relationship 
was demonstrated between haem extraction and cell number 
(Figure 26).
The results from (1), (2) and (3) above indicated that the 
recovery of haem was relatively consistent at 75% with a
variation of less than 1 0%.
Ideally, for a sensitive assay, the precision should fall 
within 5% variation. Several possibilities, i.e. protein 
precipitation by various means, were explored in an attempt to 
enable haem recovery to be assessed more accurately by avoiding 
the release of endogenous haem from Hb. All of these methods 
were unsuccessful.
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EXTRACTED AND THE PEAK AREA OF HAEM 
AS DETERMINED BY RPHPLC.
5.9.3 Comparison of TCA and HC1 for Use at Reaction Termination
A comparison was made between 0.5ml of trichloroacetic 
acid (TCA, 10% w/v) and 0.5ml of HC1 (1.0M) for use at reaction 
termination.
Both HC1 (1M) and TCA (10% w/v) could precipitate protein, 
however no haem was extracted into methylethyl ketone in the 
presence of TCA (10% w/v). Although TCA did not cause Hb 
dissociation it did precipitate free haem and so was useless 
for the purposes of this assay.
5.9.4 Haem Extraction in the Absence of Organic Solvent
In an attempt to prevent Hb dissociation the enzyme 
reaction was terminated by placing the samples in ice following 
incubation. This resulted in protein precipitation in the 
absence of acid. The supernatents were then applied to the C2 
'Bond-Elut' columns, omitting the process of haem extraction 
into acidified organic solvent. However, this was not found to 
be feasible as haem recovery was extremely low. This was 
possibly due to precipitation of haem along with protein and/or 
reduced haem retention on the Bond-Elut column.
The next approach was to attempt to remove Hb from the 
bone marrow. This would enable the addition of a known 
quantity of exogenous cold carrier haem to allow haem recovery 
to be calculated.
Hb required to be removed quickly and efficiently, without 
removing, or inactivating, ferrochelatase. Several methods 
were assessed for their ability to extract endogenous Hb 
without causing haem dissociation.
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5.9.5 Salt Precipitation of Protein
Salt precipitation of protein was examined as a possible 
means for the removal of endogenous Hb for use prior to 
addition of internal standard.
(i) Principles of Salt Precipitation
Proteins precipitate at low and high salt concentrations. 
Precipitation at high concentrations is useful; the proteins do 
not denature and different proteins precipitate at different 
concentrations. The agent most frequently used is ammonium 
sulphate (NH^SO^.
(ii) Experimental
(NH^^SO^ (reagent grade, May and Baker) was added at 
saturating concentration to several samples containing 
sonicated red cells from 0.25ml of blood in incubation medium 
(3ml). The samples were thoroughly mixed (1 min) then spun at 
lOOOg for 5 minutes. The supernatant was removed and the 
procedure repeated (x 2) to ensure maximal protein removal.
(iii) Results
Following salt fractionation, the samples remained red in 
colour and turned brown upon the addition of 0.5ml of HC1 
(1.0M) indicating the release of free haem. Extraction and 
RPHPLC analysis demonstrated that substantial quantities of Hb 
remained following salt fractionation. This method of Hb 
removal was therefore inefficient.
5.9.6 Ion-Exchange Removal of Protein
Ion-exchange was examined as a possible means for the 
removal of endogenous Hb.
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(i) Principles of Ion-Exchange
Proteins bind to ion exchangers via electrostatic 
interactions. Protein binding depends on (1) the type of ion 
exchanger; (2) the overall charge of the protein (hence the pH 
of the solution); (3) the ionic strength of the solution. 
The solution contains ions of opposite charge to the ion- 
exchanger which compete with the protein for the ion-exchanger. 
A protein that binds at low ionic strength will be displaced at 
high ionic strength because of increased competition.
Conventional ion exchange chromatography takes place in a 
column. This is impractical for the removal of Hb during the 
assay of ferrochelatase activity as limited time is available 
and the enzyme must be maintained at 4°C throughout.
(ii) Experimental
Sephadex beads (Pharmacia, G-75) were added to samples 
containing Hb then removed by centrifugation (lOOOg, 5min). 
Two types of ion exchangers were tested -
CM-sephadex = carboxymethyl C^COO”
DEAE-sephadex = diethylaminoethyl Q ^ H ^ N ^ H  (C2H5 ) 2
The beads (5g) were swollen in 20ml of tris buffer (50mM) 
at various pH's. (Note: isoelectric point of Hb is 6.8).
pH of Tris Buffer (50mM) 
CM-sephadex 5.5, 6.0, 6.5
DEAE-sephadex 8.0, 8.5, 9.0
lml of beads was added to duplicate samples, one of which 
contained a known quantity of free haem (0.1ml of haem (lOOpM
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in ammonium acetate 1M) ). The samples were mixed and the 
beads removed. This step was repeated twice more.
(iii) Results
All Hb could be removed from the samples using CM-sephadex 
beads at pH 5.5, 6.0 and 6.5 but no free haem could be detected 
by RPHPLC in the samples to which free haem had been added. 
DEAE-sephadex beads failed to achieve complete Hb removal.
Hence, this method of endogenous Hb removal was not viable 
due to the additional loss of free haem.
5.9.7 Separation of Haem and Hb by Density Centrifugation
Density centrifugation was examined as a possible means 
for removal of endogenous Hb to facilitate the use of exogenous 
haem as internal standard.
(i) Principles of Density Centrifugation
Lymphocyte separation medium (L.S.M.) (Pharmacia) is an 
aqueous solution of ficoll (Pharmacia Fine Chemicals) and 
sodium metrizoate commonly used for the separation of blood 
components according to density. The density (1.077 +
O.OOlg/ml) may be altered by the addition of a salt solution.
(ii) Experimental
(1) L.S.M. (4.0ml) preparations of various densities were added to
1 0ml capacity glass centrifuge tubes:
% L.S.M % NH^Cl (0.15M)
100
95
90
85
80
75
70
0
5
10
15
20
25
30
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(2) Sonicated blood in incubation medium (2ml), haem (5pM) in 
incubation medium (2ml) or haem (5pM) plus sonicated blood in 
incubation medium (2ml) were applied to duplicate tubes at each 
density.
(3) The tubes were then spun at 400g (1500rpm) for 30 minutes in a 
refrigerated centrifuge.
(iii) Results
In each case, with the exception of 100% L.S.M., 
separation of haem and Hb occurred. Haem was recovered by 
diluting the L.S.M. followed by centrifugation. Haem was 
resuspended in 2ml of ammonium acetate (1M), pH7, then passed 
through an activated C2 'Bond-Elut1 column prior to isolation 
by RPHPLC.
In each case, all Hb was removed. However, the recovery 
of haem in those tubes to which free haem had been added was 
poor and very variable, reaching a maximum of 32% with L.S.M : 
NH 4C1 (0.15M) (80:20) (x = 21%, S.D. = 7.5, C.V. = 30, n = 
5).
Density centrifugation was therefore abandoned as a means 
of separating carrier haem and Hb because the recovery of haem 
was unacceptably low and inconsistent.
5.9.8 Mitochondrial Preparation of Bone Marrow
Mitochondrial preparations would provide a Hb-free deposit 
for the measurement of enzyme activity to which cold carrier 
haem could be added to assess recovery. The use of 
mitochondrial preparations has often been favoured in enzyme 
assays and may provide higher activity than a crude tissue
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preparation.
A method for preparing Hb-free mitochondria was developed. 
The aim was to determine the ultracentrifuge setting required 
to separate Hb from cell debris. A concentrated red cell 
pellet of peripheral blood (0.25ml) was used in each case.
Experimental
Six cell pellets were sonicated (3 x 5* at 15 microns) in 1ml 
of culture medium in a 6ml capacity centrifuge tube to release 
Hb.
The tubes were filled with culture medium then spun in a 
refrigerated ultracentrifuge (Beckman, model L2-65B, rotor head 
40.3) at 20,000rpm for 10 minutes.
The culture medium was removed.
Two pellets were resuspended in 1ml of ferrochelatase 
incubation medium then extracted into acidified methylethyl 
ketone and treated as for a ferrochelatase assay through to the 
RPHPLC stage.
Of the remaining four pellets, all were resuspended in culture 
medium; two were centrifuged once more at 2 0 , 0 0 0 rpm (10 
minutes) and two were centrifuged twice more at 20,000 rpm (10 
minutes).
These pellets were then treated as described in step (4).
No free haem was added to any of the samples such that any 
free haem detected by RPHPLC would indicate its release from Hb 
upon treatment with 0.5ml of 1.0M HC1 (1M).
(ii) Results
No. of Spins on Ultracentrifuqe Area of Haem on HPLC
231,101
247,529
39,887
34,056
Complete removal of Hb was achieved by three spins at
20,000 rpm (10 minutes). Under these circumstances it would be 
possible to add a known quantity of exogenous haem to each 
sample to assess haem recovery.
(iv) Linearity of Ferrochelatase Activity in Mitochondrial
Preparations with Cell Number
Bone marrow mitochondrial preparations were made at cell 
numbers ranging from 5 x 10^ - 30 x 10^ and assayed for enzyme 
activity. Haem formation was plotted as a function of cell 
number (Figure 27) and the reaction was found to be linear to a 
cell number of 25 x 10^. Similar results were also obtained 
from a second experiment.
The results were similar to those for whole untreated bone 
marrow (Section 5.8.8) where linearity of enzyme activity was 
maintained to a cell number of 30 x 10^. However enzyme 
activity was significantly less in mitochondrial preparations. 
This observation was further investigated.
(v) Loss of Ferrochelatase Activity During Mitochondrial
Preparation
Bone marrow from the same individual was divided into four
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cell pellets of 20 x 10^ cells. Two pellets were placed on ice 
whilst mitochondrial preparations were made from the remaining 
two. The four samples were sonicated (3 x 5* at 15 microns) in 
incubation medium then assayed for ferrochelatase activity.
Sonicated Sample cpm in Haem
Mitochondrial prep. 418 *
335 *
Whole bone marrow 5,573
5,538
(* Corrected to 100% recovery)
Whole bone marrow had an activity more than 10 times that 
of a mitochondrial preparation. Thus, this method for removing 
Hb from bone marrow samples resulted in a very substantial loss 
of ferrochelatase activity.
Freeze-thawing was examined as a possible means of 
reducing the loss of enzyme activity evident in mitochondrial 
preparations. Bone marrow from a second individual which had 
been stored at -80°C for several weeks was prepared in the same 
manner. The samples were however freeze-thawed (x 3) in 
incubation medium : glycerol (80:20 vol/vol, 0.85ml) prior to 
assay as an alternative to sonication.
Freeze-thawed Sample in Presence cpm in Haem
of Glycerol
Mitochondrial prep. 345 *
401 *
Whole bone marrow 1,665
1,580
1,972
1,594
(* Corrected to 100% recovery)
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These results showed that for samples prepared by freeze- 
thawing in the presence of glycerol, the activity in whole bone 
marrow was 4-5 times that of mitochondria.
The preparation of mitochondria for assay resulted in such 
a dramatic loss of ferrochelatase activity that this was no 
longer regarded as a feasible means of removing endogenous 
haem. Centrifugation of samples at 40,000 rpm instead of
20,000 rpm did not reduce the loss of activity.
In whole bone marrow the activity detected in the second 
marrow sample was significantly less (69%) than that of the 
first sample. This discrepancy was too large to be explained 
by the expected natural variation in enzyme activity between 
normal individuals. It therefore seemed likely that this could 
be attributed to differences in either:-
(1 ) the method of sample preparation -
i.e. sonication in the absence of glycerol versus freeze- 
thawing in the presence of glycerol.
(2) the instability of the enzyme during storage at -80°C - 
the first bone marrow sample was assayed fresh while the second 
sample had been stored for several weeks at -80°C.
These possibilities were examined experimentally. Section
5.10 describes the investigation to find the most suitable 
sample preparation method prior to enzyme assay. Section 5.14 
addresses the question of enzyme stability in an attempt to 
find the most suitable means of bone marrow storage prior to 
assay.
(vi) Rejection of Mitochondrial Preparation as a Useful Sample 
Preparation Method
No alternative remained but to assay bone marrow and 
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erythroblast activity directly without making a mitochondrial 
preparation. As a means of removing mature erythrocytes from 
aspirated bone marrow cells, the samples were centrifuged at 
3000 rpm for 5 min. The "buffy coat" (i.e. nucleated cells) 
was then carefully removed leaving most mature erythrocytes in 
the cell pellet.
5.9.9 Chosen Method for Assessing Haem Recovery
Under circumstances whereby large quantities of endogenous 
haem were present, individual sample recoveries could not be 
exactly determined. Following these extensive investigations 
the decision was taken to accept the final percentage recovery 
as 75% (+ 7.6%) (as determined in Section 5.9.2 (i)).
5.10 SAMPLE PREPARATION
Since the method of sample preparation was originally 
optimised for the measurement of ALA synthase activity in bone 
marrow and may not represent the optimum procedure for 
measurement of ferrochelatase activity, other methods of sample 
preparation were examined i.e.
(1) sonication
(2) freeze-thawing
Note: manual homogenisation was not possible as the cell 
pellets were very small.
5.10.1 Comparison of Freeze-thawing and Sonication
Several samples (2 x 10^) cells were prepared for assay 
either by freeze-thawing or by sonication in the presence or
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absence of glycerol (20% v/v). The samples were assayed for 
ferrochelatase activity. The sample with the largest haem peak 
area as determined by HPLC was taken to represent 100% 
recovery. All other sample recoveries were corrected to this 
value.
(i) Experimental
Freshly prepared cell pellets were suspended in culture 
medium (1.0ml) in an ultracentrifuge tube (6ml capacity):
(a) Freeze-thawing
The tubes were packed in dry ice/methanol for 5 minutes, 
then placed in hot water ( 70°C) for 5 minutes. This process 
was carried out in triplicate.
(b) Sonication
to 15 microns in air dampened to 12 microns in culture medium 
(3 pulses of 5 seconds).
The tubes were filled with culture medium and a 
mitochondrial preparation made to remove endogenous Hb. The 
samples were assayed in duplicate for ferrochelatase activity 
and a known quantity of haem was added at reaction termination 
as internal standard.
Sonication was carried out using a V q" titanium probe set
(ii) Results
Preparation of Sample Corrected cpm in Haem
Sonication in culture medium 415
335
Sonication in culture medium/20% glycerol 834
1,007
Freeze-thawed in culture medium 960
1,119
Freeze-thawed in culture medium/20% glycerol 1,550
1,602
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The results demonstrated that:
(1) Freeze-thawed samples had ferrochelatase activities 2-3 times 
greater than sonicated samples.
(iii) Inclusion of Glycerol During Sample Preparation
(2) The presence of 20% glycerol (v/v) during sonication resulted 
in ferrochelatase activities similar to freeze-thawed samples.
(3) The presence of 20% glycerol during freeze-thawing resulted in 
ferrochelatase activities 50% greater than those in the absence 
of glycerol.
5.10.2 Optimum Procedure for Sample Preparation
Freeze-thawing of bone marrow samples in the presence of 
20% glycerol provided maximum ferrochelatase activity (Section 
5.10.1). To optimise this procedure it was necessary to 
establish the most suitable number of times to freeze-thaw the 
sample.
(i) Experimental
n
Several fresh bone marrow samples (10 cells) were freeze- 
thawed in incubation medium in the presence of 2 0 % glycerol 
various numbers of times, ranging from 1 to 6. The cells were 
then assayed for enzyme activity.
(ii) Results
Haem formation was plotted as a function of freeze-thaw 
episodes (Figure 28). The optimum number of times to freeze- 
thaw was three.
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5.11 NON-ENZYMATIC HAEM FORMATION
Haem formation has been demonstrated in the absence of 
ferrochelatase (Granick and Mauzerall, 1958; Kassner and 
Walchak, 1973; Heikel, Lockwood and Rimington, 1958; Tokunaga 
and Sano, 1972).
Although non-enzymatic haem formation has characteristics 
which parallei those reported for enzymatic haem formation, 
non-enzymatic and enzymatic haem formation differ in several 
respects:
(1) The optimum pH of haem formation normally differs for the non- 
enzymatic and enzymatic reaction.
(2) Ferrochelatase is activated by GSH and ascorbate (Taketani and 
Tokunaga, 1981; Yoneyema et al, 1965) but the non-enzymatic 
reaction is not observed under such conditions. The formation 
of an active iron-thiol complex such as that formed with DTT, 
cysteine or 2-mercaptoethanol seems to be more essential for 
non-enzymatic synthesis (Taketani and Tokunaga, 1982; Kassner 
and Walchak, 1973).
(3) Non-ionic detergents decrease non-enzymatic haem formation but 
ferrochelatase can react with completely solubilised porphyrins 
in the presence of non-ionic detergents.
(4) The enzyme itself catalyzes the formation of haem in 
mitochondria since heat and trypsin treatment completely 
destroy activity (Taketani and Tokunaga, 1981; Yoneyema et al, 
1962).
(i) Experimental
The reaction of iron with protoporphyrin IX was studied in 
aqueous solution in the absence of cellular material.
184
(ii) Results
Non-enzymatic haem formation did not occur supporting the 
view that non-enzymatic and enzymatic syntheses are 
independent. This lack of non-enzymatic haem formation may 
partly be due to the presence of ascorbate as reducing agent 
and the absence of exogenous fatty acids.
Routinely, control tubes were included alongside each set 
of enzyme assays. These contained all the requirements for 
enzyme assay with the exception of cells.
5.12 THE USE OF NON-IONIC DETERGENTS
A non-ionic detergent such as tween-20 or triton X-100 is 
frequently included in the incubation medium for ferrochelatase 
activity. It is believed that the presence of a detergent may:
(1 ) prevent porphyrin aggregation;
(2 ) inhibit the non-enzymatic formation of haem;
(3) release the enzyme from the mitochondrial membrane.
For example, Bloomer and Morton (1982) incubated a liver 
tissue preparation with tween-20 for 20-30 minutes on ice 
before commencing the enzyme reaction. This resulted in a more 
homogeneous suspension and increased the activity in the 
sample.
In the assay of ferrochelatase activity in bone marrow it
was decided following experimentation to exclude detergent from
the reaction mixture because -
(1) Triton X-100 (reagent grade, BDH) used over the concentration 
range 0 .0 1 %-2 % markedly reduced haem recovery at sorbent 
extraction.
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(2) Under the established conditions non-enzymatic haem formation
did not occur thereby making inhibition unnecessary.
(3) Freeze-thawing in the presence of glycerol (20% v/v) was a
suitable means of providing homogeneous suspension with 
ferrochelatase available for enzyme assay.
High concentrations of detergent may have inhibited 
ferrochelatase activity. in the presence of non-ionic 
detergents, the porphyrin nucleus is surrounded by the micelle 
and at high concentrations is unable to come into contact with 
the iron (Phillips, 1967).
5.13 THE USE OF FATTY ACIDS
It has been reported that lipids activate mitochondrial 
ferrochelatase (Sawada et al, 1969; Simpson and Poulson, 1977). 
This was clearly demonstrated for ferrochelatase purified from 
rat liver mitochondria. Fatty acids markedly increased enzyme 
activity while phospholipids were less effective (Taketani and 
Tokunaga, 1981). It has been shown that the addition of fatty 
acids but not neutral lipids and phospholipids causes non- 
enzymatic haem formation (Taketani and Tokunaga, 1982). It is 
generally believed that fatty acids interact with the porphyrin 
and aid haem formation via increasing electrostatic effects.
Experimental
Bone marrow samples were incubated with varying 
concentrations of palmitic acid (hexadecanoic acid, Sigma) in 
the range 0-5mM (Figure 29) to examine the effect of fatty 
acids on ferrochelatase activity. Palmitic acid was chosen 
because a ten-fold stimulation of rat liver ferrochelatase
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FIGURE 29
UPTAKE OF59Fe INTO HAEM AS A FUNCTION
OF PALMITIC ACID CONCENTRATION.
activity had been demonstrated with 2mM palmitic acid (Taketani 
and Tokunaga, 1981). Fatty acids of shorter chain length were 
less effective.
The results obtained with bone marrow, however, indicated 
that palmitic acid (0-5mM) did not increase ferrochelatase 
activity beyond that of the control. It would seem likely that 
the bone marrow preparation contained sufficient endogenous 
quantities of fatty acids to sustain enzyme activity at the 
optimum level. It is noteworthy that most workers who have 
observed an increase in enzyme activity with fatty acids have 
studied partially purified enzyme preparations which may lack 
fatty acids required for optimal ferrochelatase activity.
Therefore, no fatty acids were added during the 
measurement of ferrochelatase in bone marrow.
5.14 STABILITY OF FERROCHELATASE
5.14.1 Examination of Storage Methods for Human Bone Marrow
The stability of ferrochelatase was examined. Pellets of 
normal human bone marrow (2 x 10^ cells) were stored under 
different conditions, then assayed for ferrochelatase activity.
(1) Two cell pellets of fresh bone marrow were assayed directly.
(2) Two cell pellets were stored for 3 days at -80°C.
(3) Two cell pellets were stored for 3 days at -20°C.
(4) Two cell pellets were stored overnight in 1.0ml of culture
medium at 4°C.
Duplicate samples were assayed from each pellet.
Results
The results are expressed in Table 15.
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cpm in haem average cpm
(1) Fresh bone marrow 13,720 13,873
13,796
14,000
13,976
(2) Bone marrow stored 6,047 7,369
at -80°C 7,842
7,763
7,822
(3) Bone marrow stored 6,677 6,272
at ”20°C 6,622
6,096
5,692
(4) Bone marrow stored 13,978 13,961
at 4°C (overnight) 13,851
14,005
14,011
TABLE 15
EFFECTS OF STORAGE METHOD ON FERROCHELATASE ACTIVITY
These results demonstrate that bone marrow stored frozen 
at either -20°C or -80°C loses up to 50% ferrochelatase 
activity, while overnight storage at 4°C leads to no such loss. 
This was verified using bone marrow from a further five 
individuals.
In the light of these results, all bone marrow samples 
whether whole or fractionated (Chapter 2) were stored overnight 
at 4°C, then assayed for ferrochelatase activity the following 
day.
5.14.2 The Effect of Temperature on Ferrochelatase Activity
Enzyme stability during the period of incubation at 37°C 
required to achieve white cell lysis was examined.
7
Two samples of whole unfractionated bone marrow (2 x 10 
cells) were obtained from several patients. One sample was 
incubated at 37°C for 30 minutes prior to enzyme assay 
(equivalent to the incubation period with the monoclonal 
antibody TG-1) (Chapter 2, Section 2.5). No loss of activity 
was detected in this sample relative to the sample maintained 
at 4°C.
Ferrochelatase was not therefore prone to the loss of 
activity which was observed for ALA synthase under the same 
conditions (Chapter 3, Section 3.10).
5.15 SUMMARY OF ASSAY METHOD FOR THE MEASUREMENT OF FERROCHELATASE 
ACTIVITY IN HUMAN BONE MARROW
5.15.1 Materials
The following chemicals were purchased from Sigma Chemical 
Company - tris HC1 (reagent grade); tris base (reagent grade);
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ammonium acetate (reagent grade); tetrabutylammonium hydrogen 
sulphate (TBAHS) (reagent grade).
Ferrous chloride (FeC^) (reagent grade); ascorbic acid 
(reagent grade); trichloroacetic acid (TCA) (reagent grade) and 
ammonium hydroxide (reagent grade) were purchased from BDH.
Protoporphyrin IX was purchased from Porphyrin Products 
Inc., U.S.A., ^FeClg from Amersham International in 0.1M HC1, 
lOOpCi ml--*-; glacial acetic acid (reagent grade) from May and 
Baker and methanol (HPLC grade) was purchased from Rathburn 
Chemicals.
5.15.2 Methods
Assays were carried out in glass tubes (methylethyl ketone 
damaged plastic) which were then discarded to avoid 
contamination problems since iron adheres very strongly to 
glassware.
Ascorbic Acid
0.25g ascorbic acid in incubation medium (10.0ml)
(1) Sample Preparation
Cells were either assayed fresh for ferrochelatase activity or 
after storage overnight at 4°C in culture medium (Appendix I).
Incubation medium (0.85ml of tris buffer (50mM), pH 8.3 / 
glycerol, 80:20 vol/vol) was added to cell pellets. The 
samples were then freeze-thawed (x 3) via alternate submersion 
in dry ice/methanol and hot water (70°C).
Two aliquots of 0.4ml were taken from each tube for assay. 
Linearity has been demonstrated for 1-30 x 10^ bone marrow 
cells per assay.
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(2) Assay Mixture
0.02ml ^FeClg (~2pCi,'-~2nmoles)
0.03ml FeCl2 8nmoles) in ascorbic acid
Radioactive and non-radioactive iron were thoroughly mixed.
The following were then added:
0.50ml incubation medium
0.40ml sample in incubation medium.
The reaction was initiated by the addition of 0.05ml 
protoporphyrin (lOOnmoles) in incubation medium.
(3) Enzyme Incubation
The tubes were sealed under thoroughly mixed, then
incubated at 37°C in the dark for 20 minutes.
(4) Reaction Termination
The reaction was terminated by the addition of 0.5ml HC1 (1M).
(5) Blank
(a) As for samples, but reaction terminated at 0 time 
or
(b) As for samples, but no cells added.
(6) Methylethyl Ketone Extraction of Haem
(a) Methylethyl ketone (1.5ml) was added to each sample.
(b) The samples were mixed, then centrifuged at 3,000rpm for 5
minutes to allow phase separation.
(c) The organic phase was removed.
(d) Extraction was repeated twice more, using 1.0ml of methylethyl
ketone each time.
(e) The organic phases were pooled for each sample, then evaporated
to dryness under N 2 at 37°C.
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(7) Sample Reconstitution
Samples were reconstituted in ammonium acetate (1M), pH 7.0, 
(2.0ml) by the sequential addition of 0.3ml ammonium hydroxide 
(5M), 1.7ml ammonium acetate (1M), pH 7.0 and 0.15ml glacial 
acetic acid.
(8 ) Partial Isolation of Haem by Sorbent Extraction
(a) Activation of C2 'Bond-Elut' Columns
Columns were activated by methanol (2.0ml) followed by ammonium 
acetate (1M), pH 7.0 (5.0ml).
(b) Application of Samples
Reconstituted samples were applied to activated columns at a 
flow rate of 1.0ml min--*-. Columns were washed with ammonium 
acetate (1M), pH 7.0, (2.0ml). Haem was then eluted in 3 
volumes (1.0ml) of methanol: ammonium acetate (1M) (95:5) at pH 
6.9.
(c) Sample Concentration
Samples were evaporated to dryness under N2 at 37°C. At this 
stage samples could be stored overnight at 4°C under
(9) Sample Reconstitution
Samples were reconstituted in 0.2ml methanol: ammonium acetate 
(1M), (95:5), pH 6.9. 0.05ml was then taken for RPHPLC.
(10) RPHPLC Separation of Haem, Iron and Protoporphyrin
(a) Mobile Phase
Methanol: water (83:17)
Acetic acid (10mm)
TBAHS (2mM)
pH* 6.5 (actual pH 7.0)
Flow rate: 1.0ml min ^
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(b) Detector
Measuring wavelength = 398nm 
AUFS = 0.1
(c) Column
Apex octadecyl 15cm x 4.6 I.D., particle size 5pM.
(d) Fraction Collector
Fractions were collected at 0.5 min intervals at 3.5 - 9.5 
minutes following sample injection.
(11) Calculation of Results 
Results are expressed as:
pmoles haem formed/1 0 ^ cells/ 2 0 minutes = corr.e.9^ j....cPm ,-Hl-ft.aerQ
cpm/pmole 59pe substrate
(12) Recoveries
Recoveries were calculated on an extraction efficiency of 75% 
(+ 7.6%). No suitable method was found for the incorporation of 
an internal standard.
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CHAPTER 6
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6 ALA SYNTHASE AND FERROCHELATASE ACTIVITIES DURING NORMOBLASTIC
EKYTHROPOIESIS
6.1 AIMS OF THE STUDY
The aim of the work described in this chapter was to 
provide a measure of ALA synthase and ferrochelatase activities 
in whole bone marrow and isolated human erythroblasts. The 
effect of differentiation on enzyme activity during 
normoblastic erythropoiesis was examined. Specifically, it was 
intended to resolve the conflict as to whether ALA synthase and 
ferrochelatase appear simultaneously (Beaumont et al, 1984) or 
sequentially (Sassa, 1976) during normal erythroid 
differentiation. It was hoped also to determine if either ALA 
synthase (Levere and Granick, 1965) or ferrochelatase (Sassa, 
1976) might be rate limiting for erythroid haem biosynthesis.
The multiple roles for erythroblast haem beyond its 
specific complexing with globin have been discussed in Chapter
1. A clear understanding of the ability of erythroid cells to 
synthesise haem during their development is then an essential 
prerequisite to gaining an insight into the manner in which 
intracellular free haem may be involved in the regulation of 
globin synthesis, iron metabolism, haem metabolism and 
differentiation.
6.2 EXPERIMENTAL
6.2.1 Patients Studied
Bone marrow was obtained from 15 patients, all of whom 
showed normoblastic erythroid hyperplasia in the marrow. 
Erythroid hyperplasia was required to provide adequate 
erythroid cell numbers for fractionation. All patients were
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shown to have normal haematinic levels folate and
ferritin-ferritin as a measure of iron status). In all cases 
transferrin saturation was >30% ensuring adequate iron 
availability to the erythroblasts. For complete patient 
details see Appendix 2.
One patient with erythroid hyperplasia taking high dose 
steroids (prednisolone 60mg/day) was also examined. The 
results from this patient are presented separately.
6.2.2 Enzyme Measurements
ALA synthase and ferrochelatase activities were first 
measured as described (Chapters 3 and 5 respectively) in whole 
unfractionated bone marrow to allow comparison with previous 
assays which have only measured enzyme activity in whole marrow 
(Bottomley et a l , 1968; 1973; Aoki et al, 1974; Konopka and 
Hoffbrand, 1979; Manabe et al, 1982; Tanaka and Ohta, 1972; 
Stavem et a l , 1985). ALA synthase and ferrochelatase 
activities were then measured in each of the four percoll 
fractions obtained from bone marrow (Chapter 2). Fractions 1 
to 4 contained purified age-matched erythroblasts. The 
differentiation status of the erythroblasts in each fraction 
has been described (Chapter 2, Table 1). The least dense 
erythroblasts were recovered in fraction 1. Light microscopy 
and differential erythroblast counting showed that most pro and 
early erythroblasts (E^ cells) were found in this fraction. 
Fraction 2 contained predominantly intermediate erythroblasts 
(E2 cells) with less cells. Fraction 3 contained E2 cells 
with some late erythroblasts (E3 cells). Fraction 4 (i.e. the
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most dense fraction) contained predominantly cells with less 
e 2 cells. Measurement of enzyme activity in the fractions 
therefore provided a measure of haem synthesis during 
erythropoietic development.
Fractionated samples from 10 marrows were stored in 
duplicate at -80°C during the developmental period of the 
ferrochelatase assay. All samples were assayed for ALA 
synthase activity. As it was shown that, unlike ALA synthase, 
ferrochelatase was unstable at -80°C (Chapter 5, Section 5.14) 
these samples were unsuitable for ferrochelatase measurement. 
Ferrochelatase activity was measured in the fresh non-frozen 
erythroblast fractions obtained from the other 5 marrow 
samples.
6.3 RESULTS
The results for whole bone marrow haem enzyme activity are 
expressed as enzyme activity per 1 x 1 0  ^ erythroblasts per 
hour. The results for fractionated samples are similarly 
expressed per 1 x 1 0^ erythroblasts per hour and are related to 
fraction number (and hence differentiation status).
6.3.1 ALA Synthase Activity in Whole Human Bone Marrow
ALA synthase activity was measured in whole unfractionated 
bone marrow (10 x 1 0  ^cells) from each patient to establish a 
normal range of enzyme activity (Table 16). This served only 
as a crude indicator of erythroblast enzyme activity as the 
contribution made by the white cell populations in the bone 
marrow and the effects of erythroblast differentiation status 
on enzyme activity were not considered (Chapter 2, Section
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ALA SYNTHASE ACTIVITY 
(p moles ALA/10^  erythroblasts/hour)
WHOLE BONE MARROW 608 + 334
FERROCHELATASE ACTIVITY 
(p moles haem/10^ erythroblasts/hour)
WHOLE BONE MARROW 164 + 50
The results are expressed as x + 1 S.D. where n = 15 (ALA 
synthase activity) and n = 4 (ferrochelatase activity).
TABLE 16
THE NORMAL RANGES OF ALA SYNTHASE AND FERROCHELATASE 
ACTIVITIES IN WHOLE UNFRACTIONATED HUMAN BONE MARROW
2.2). However, since other workers have measured ALA synthase 
activity in whole bone marrow, this enabled direct comparisons 
of enzyme activity to be made. The ALA synthase activity 
detected in whole bone marrow (608 + 334 pmoles ALA/10^ 
erythroblasts/hour, x + 1 S.D., n = 15) was similar to that 
reported by Fitzsimons et al (1986).
Furthermore, measurement of ALA synthase activity in whole 
unfractionated bone marrow (10 x 1 0 )^ following preincubation 
for 30 minutes at 37°C permitted assessment of the effect of 
incubation on enzyme activity. ALA synthase was prone to a 
temperature-dependent inactivation at 37°C due to the 
dissociation of the enzyme cofactor, PLP (Chapter 3, Section 
3.10). This loss of activity during incubation at 37°C (30 
minutes) was routinely measured. The loss of enzyme activity 
was found to be consistent at 45% + 14%.
6.3.2 Ferrochelatase Activity in Whole Human Bone Marrow
Ferrochelatase activity was also measured in whole 
unfractionated tone marrow (20 x 1 0^ cells) from four samples 
to establish a normal range of enzyme activity (Table 16). The 
activity detected (164 + 50 pmoles haan/1 0  ^erythroblasts/hour, 
x + 1 S.D., n = 4) was similar to that reported by Bottomley 
(1968) (112-300 pmoles haem/1 0  ^ nucleated red cells/hour) and 
slightly higher than that reported by Tanaka and Ohta (1972) 
(80.6 + 18.6 pmoles haem/1 0 6 erythroblasts/hour) in normal 
human bone marrow. Bone marrow ferrochelatase activities in 
much higher ranges have also been reported (Stavem et al, 1985)
i.e. 4800-9420 and 16500-17100 pmoles/1 0 6 erythroid cells/hour
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respectively. These seemingly high results were obtained using 
two different assay methods and may be explained by a lack of 
assay specificity. The first method measured the decline in 
fluorescence in the HCl-acid phase while the second attempted 
to isolate radiolabelled haem by organic solvent extraction 
alone. The latter method is now known to be ineffective 
(Chapter 5, Section 5.6.4). It is therefore unlikely that 
either method was a reliable measure of ferrochelatase 
activity.
Routine measurement of ferrochelatase activity in normal 
human bone marrow following preincubation for 30 minutes at 
37°C indicated that ferrochelatase did not show the 
temperature-dependent inactivation (Chapter 5, Section 5.14.2) 
as found with ALA synthase (Chapter 3, Section 3.10).
6.3.3 ALA Synthase Activity During Normoblastic Erythropoiesis
ALA synthase activity was maximal in the erythroblasts of 
percoll fractions 1 and 2 and was approximately four times that 
found in the late erythroblasts of percoll fraction 4 (Figure 
30) (p < 0.001). Enzyme activity was high in pro and early 
erythroblasts (percoll fraction 1 ) and remained high as the 
cells differentiated towards intermediate erythroblasts 
(percoll fraction 2). Further differentiation towards the 
intermediate and late erythroblasts of percoll fractions 3 and 
4 was associated with a marked decline in enzyme activity. 
This indicates that induction of ALA synthase activity occurs 
early during normoblastic erythroid differentiation and 
confirms the preliminary findings of Fitzsimons et al (1986).
Bone marrow reticulocytes were present in significant
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quantities in percoll fraction 4 and outnumbered cells by a 
ratio of > 10:1. Low levels of ALA synthase activity in this 
fraction relative to the activity found in reticulocyte free 
fractions 1 and 2, indicate that the enzyme activity present in 
reticulocytes may be several hundred fold lower than that of 
cells (Fitzsimons et al, 1986). The magnitude of this 
difference highlights the dangers involved in extrapolating 
results obtained from the study of haem synthesis in 
reticulocytes to that in erythroblasts.
Morphological examination clearly demonstrated that 
considerable ALA synthase activity was present in the cells of 
fraction 1 before the appearance of significant quantities of 
cytoplasmic Hb.
6.3.4 Ferrochelatase Activity During Normoblastic Erythropoiesis
The ferrochelatase activity observed in the different 
fractions in 4 patients with normoblastic erythroid hyperplasia 
is shown in Figure 31. In one patient insufficient erythroid 
cells were recovered in percoll fraction 1 to permit 
measurement of ferrochelatase activity. The reproducibility of 
the assay was impressive in every instance with enzyme activity 
of duplicate samples within 7.5% variation.
The recorded enzyme activity from the 4 patients showed 
considerable individual variation. The pattern of enzyme 
development in 3 of the patients showed a peak in enzyme 
activity in fractions (2 or 3) containing erythroid cells more 
mature than those found in fraction 1. In the fourth sample no 
enzyme activity was measured in fraction 1 because of the low
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number of erythroblasts obtained from the percoll gradient. It 
was not therefore possible to determine which fraction 
contained peak ferrochelatase activity in this sample.
As it is difficult to draw conclusions from only 4 samples 
it was thought more worthwhile to examine enzyme activity in 
the individual patients in relation to their ALA synthase 
activity.
6.3.5 The Relationship Between ALA Synthase and Ferrochelatase 
Activities During Normoblastic Erythropoiesis
The relationship between ALA synthase and ferrochelatase 
enzyme activities was examined during normoblastic 
erythropoiesis in the four individuals described in the 
previous section.
To permit comparison, consideration was given to two 
points. Firstly, the time scales of the enzyme incubations 
were considered. The ALA synthase assay incubation time was 
one hour whereas a 20 minute incubation period was used for 
ferrochelatase. However, as the ferrochelatase reaction 
demonstrated linearity over 20 minutes (Chapter 5, Section
5.8.3) it was possible to extrapolate the recorded enzyme 
activity to one hour. Secondly, it was estimated that the 
activity of ALA synthase would need to be approximately eight 
fold that of ferrochelatase as eight molecules of ALA are 
required to form each molecule of haem (Chapter 1, Section
1.3).
With these factors considered it was possible to 
demonstrate a close temporal relationship between ALA synthase 
and f e r r o c h e l a t a s e  activities during normoblastic
199
erythropoiesis (Figures 32-35). In 3 of the marrows examined, 
peak ferrochelatase activity was seen to develop later than 
peak ALA synthase activity (Figures 32-34). The results from 
the fourth individual (Figure 35) do not permit such a 
comparison as peak ferrochelatase activity cannot be judged. 
It is, however, clear that peak activity in this patient occurs 
either in the erythroblasts of fraction 2 or would have been 
found in the early cells of fraction 1 had sufficient cells 
been obtained at fractionation. It is, however, unlikely that 
peak activity would have been found in fraction 1 because no 
dpm were recovered from the few cells that were present in this 
fraction, thereby suggesting that their enzyme activity was low 
and that peak activity is indeed present in Fraction 2.
These results suggest that the development of ALA synthase 
and ferrochelatase activities during visually recognisable 
normoblastic erythropoiesis may be a sequential rather than a 
synchronous process (Sassa, 1976). In 3 of the 4 patients ALA 
synthase activity in fraction 1 and/or 2 is considerably higher 
than ferrochelatase activity in the same fractions. 
Nevertheless, the quantitative relationship between the two 
enzymes in most cases indicates an activity of ferrochelatase 
relative to ALA synthase which is several times greater than 
would in theory be required to cope with the estimated ALA 
production. It is not, therefore, possible to establish 
whether the delay in achieving peak ferrochelatase activity 
relative to ALA synthase is sufficient to support the argument 
that delayed development of ferrochelatase activity is limiting 
for haem biosynthesis during erythroid differentiation.
The fifth patient (Figure 36) had been on high dose
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steroid treatment at the time of study. This patient therefore 
must be examined separately due to the possible effect of 
steroid hormones on erythroblast haem enzyme activity (Urabe et 
al, 1979; Granick and Kappas, 1967; Levere and Gidari, 1974). 
In this case the development of enzyme activity during 
erythropoiesis was similar to that of the first four patients 
but appeared at first to be synchronous rather than sequential. 
The results are, however, more easily interpretated when enzyme 
activities are examined separately. ALA synthase activity is 
high in Fraction 1 and increases by only 15% in Fraction 2 and 
3, before declining sharply in Fraction 4. Thus, in this 
patient, ALA synthase activity is initially high (Fraction 1) 
and does not change appreciably during early to intermediate 
erythroid development (Fractions 2 and 3). This implies that 
ALA synthase has attained peak activity early during erythroid 
development. Ferrochelatase activity, on the other hand, is 
relatively low in Fraction 1 at 15% of ALA synthase activity. 
However, activity increases by as much as 100% in Fractions 2 
and 3, before declining sharply in Fraction 4. This implies 
that ferrochelatase activity does not peak until the 
intermediate stages of erythroid development and hence lags 
behind the peak in ALA synthase activity.
These findings are consistent with the results obtained 
for two of the four patients previously discussed (Figures 33 
and 34). In terms of the fold increase in enzyme activity, 
ferrochelatase activity almost doubled during the intermediate 
stages of erythroid development (Fractions 2 and 3) in both 
patients, at,a synthase activity in the same patients is 
highest in the more immature cells (Fraction 1) and decreases
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during further development. This again indicates that peak AIA 
synthase activity precedes peak ferrochelatase activity and 
hence that the development of enzyme activity is a sequential 
process.
The results obtained from this work enabled a normal range 
of ALA synthase and ferrochelatase activities to be established 
for fractions 1 to 4 (Table 17). This represented the normal 
pattern of ALA synthase and ferrochelatase activity during 
normoblastic erythropoiesis. All further measurements of 
enzyme activity in abnormal or pathological states were then 
related to these values.
6.3.6 Summary
ALA synthase and ferrochelatase enzyme activities were 
measured in highly purified age-matched human erythroblasts 
using improved and newly developed sensitive, specific enzyme 
assays. The results suggest that during normoblastic 
erythropoiesis, sequential development of enzyme activity may 
occur. The results for ALA synthase activity confirmed 
previous findings (Fitzsimons et al, 1986) while the results 
for ferrochelatase activity demonstrated for the first time the 
pattern of enzyme activity during normoblastic erythropoiesis. 
Enzyme activity for the two enzymes demonstrated a similar 
pattern of development in three of four cases, although a delay 
in peak activity for ferrochelatase relative to peak ALA 
synthase activity was evident in three cases. Despite this, 
quantitative analysis of enzyme activity was unable either to 
establish or refute the suggestion that ferrochelatase is 
limiting for haem formation (Sassa, 1976) •
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AIA SYNTHASE ACTIVITY 
(p moles/10^ erythroblasts/hour)
PERCOLL FRACTION (x + 1 S.D., n = 15)
FRACTION 1 418 + 249
FRACTION 2 406 + 156
FRACTION 3 261+123
FRACTION 4 1 2 0 + 9 9
FERROCHELATASE ACTIVITY 
Cp moles/1 0” erythroblasts/hour)
PERCOLL FRACTION (x + 1 S.D., n = 4)
FRACTION 1 9 2 + 6 8
FRACTION 2 1 4 9 + 9 2
FRACTION 3 123 + 48
FRACTION 4 39 + 33
TABLE 17
THE NORMAL RANGES OF ALA SYNTHASE AND FERROCHELATASE 
ACTIVITIES DURING NORMOBLASTIC ERYTHROPOIESIS
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7 ALA SYNTHASE ACTIVITY DURING IRON AND HAEM DEFICIENT
ERYTHROPOIESIS
7.1 AIMS OF THE STUDY
The aim of the work described in this chapter was to 
closely examine ALA synthase activity during iron and haem 
deficient erythropoiesis. It is well established that hepatic 
ALA synthase is induced in response to haem deficiency and 
repressed by excess haem via negative feedback inhibition. 
However, erythroid ALA synthase has been less well studied and 
the effects of haem deficiency on the haem enzymes in erythroid 
cells are currently poorly understood.
7.2 EXPERIMENTAL
7.2.1 Patients Studied
Bone marrow was obtained from 10 patients with iron 
deficient polycythaemia (IDP) (and consequent haem deficiency). 
More clinical details are presented in Appendix 2. 
Polycythaemic patients were chosen as the increased cellularity 
in such marrow is sufficient to provide adequate erythroblast 
numbers for fractionation. In each case, iron deficiency was 
established by serum ferritin concentrations less than lOpg/ml 
and MCV values less than 75fl (normal range 80 - 100 fl). No 
stainable iron was demonstrated in these marrows using 
conventional light microscopy techniques.
7.2.2 Enzyme Measurement
ALA synthase activity was measured in each of the four 
percoll fractions obtained from TG-1 treated bone marrow 
(Chapter 2). Fractions 1 to 4 contained purified age-matched
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erythroblasts predominantly of pro, early, intermediate and 
late erythroblast status respectively. Differential counting 
of E p  E2 and E3 cells in the different fractions confirmed 
erythroblast maturity per fraction equivalent to that seen with 
normal marrow (Chapter 2, Table 1).
7.3 RESULTS
7.3.1 AIA Synthase Activity During Iron Deficient Erythropoiesis
The results expressed in Figure 37 and Table 18 indicate 
that ALA synthase activity in those immature erythroblasts of 
fractions 1 and 2 and in the more mature erythroblasts of 
fractions 3 and 4 was not increased by haem deficiency as might 
be expected for the "hepatic" enzyme. On the contrary, a 
significant reduction in ALA synthase activity was demonstrated 
during haem deficient erythropoiesis relative to normoblastic 
erythropoiesis (Chapter 6 , Figure 30). The reduction in enzyme 
activity was particularly marked in fractions 1 and 2 
(p < 0.001) but was also significant in fractions 3 and 4 
(p < 0.0 1 ).
The results suggest that ALA synthase activity in 
erythroblasts, in contrast to hepatocytes, may be reduced in 
response to haem deficiency. This further indicates that the 
regulation of erythroid ALA synthase may be different from 
hepatic ALA synthase.
7.3.2 Discussion
Iron deficiency results in the inadequate production of 
haem to form Hb. There is also secondary inhibition of globin
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ALA SYNTHASE ACTIVITY 
(p moles/1 0^ erythroblasts/hour)
PERCOLL NORMOBLASTIC IRON DEFICIENT p <
FRACTION ERYTHROPOIESIS ERYTHROPOIESIS
(x + 1 S.D., (x + 1 S.D.,
n = 15) n = 10)
FRACTION 1 418 + 249 134 + 90 0.000
FRACTION 2 406 + 156 127 + 83 0.001
FRACTION 3 261 + 123 116 + 99 0.010
FRACTION 4 120 + 9 9  49 + 61 0.010
TABLE 18
ALA SYNTHASE ACTIVITY IN FRACTIONATED BONE MARROW FROM 
PATIENTS WITH NORMOBLASTIC AND IRON DEFICIENT ERYTHROPOIESIS
synthesis (Freedman et al, 1974; 1976) and a marked
accumulation of protoporphyrin in erythrocytes (Pagliardi et 
a l , 1959; Heilmeyer and Clotten, 1962). There have been 
conflicting reports concerning alterations of other porphyrins 
and porphyrin precursors. No clear pattern has yet emerged 
with regard to the effect of iron deficiency on the enzymes of 
haem biosynthesis.
Several groups have demonstrated that ALA dehydratase 
activity in human erythrocytes does not differ in iron 
deficient patients from normal controls (Lichtman et al, 1963; 
Battistini et al, 1971), while others have reported increased 
ALA dehydratase activity in iron deficient patients 
(Chalevelakis et al, 1977; Campbell et al, 1978). Conversely, 
reduced ALA dehydratase has been shown in the whole blood, 
liver and bone marrow of iron deficient rats (Sharma et al, 
1973). When erythrocytes from patients with iron deficiency 
were incubated with ALA they produced more PBG and less 
porphyrins than controls, suggesting reduced activity of PBG 
d e a m i n a s e  (Prato et al, 1968). In such studies, 
reticulocytosis may influence the recorded activities of the 
haem enzymes as both ALA dehydratase and PBG deaminase activity 
in peripheral blood may be increased by elevated reticulocyte 
counts (Anderson et al, 1977).
It has been shown that ALA synthase activity is not 
significantly different in bone marrow in iron deficient 
patients than in normal subjects (Aoki et al, 1974).
It has been c l a i m e d  that the a c c u m u l a t i o n  of 
protoporphyrin in iron deficiency anaemia is less than one 
would expect if the pathway prior to ferrochelatase continued
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to operate at its normal rate (Moore and Goldberg, 1974). This 
would suggest that in addition to the block at the level of 
iron and protoporphyrin utilisation, there is a general slowing 
of the pathway prior to this. It has also been suggested that 
protoporphyrin may inhibit ferrochelatase activity in normal 
human bone marrow (Bottomley, 1968).
A reduction in ALA synthase activity during iron deficient 
erythropoiesis has been demonstrated for the first time in the 
work described in this chapter. Moreover, this work has 
identified that this reduction is most marked in the more 
immature erythroid cells, normally most active with regard to 
ALA synthase activity. This is in apparent contrast to the 
inducing effect of haem deficiency on ALA synthase activity in 
hepatic tissue. This finding provides support for there hieing 
different methods of regulation for the haem biosynthetic 
pathway in hepatic and erythroid tissue and may in part be 
explained by the recent confirmation of distinct housekeeping 
(Sutherland et a l , 1988) and erythroid-specific (Cox et al, 
1990) genes for ALA synthase. ALA synthase is well established 
as the rate controlling enzyme of haem biosynthesis in hepatic 
tissue, but its role in erythroid tissue has not been defined. 
It is clear from this work that the regulation of erythroid ALA 
synthase is different from that of hepatic ALA synthase.
The reduction in erythroid ALA synthase activity in iron 
deficient patients may be explained in several ways:
(1) Erythroid ALA synthase may be inhibited by the
accumulation of protoporphyrin. There is, however, currently 
no experimental evidence to support this.
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(2) Adequate free haem concentrations may be required for
optimal erythroid ALA synthase activity. Haem may therefore 
affect erythroid ALA synthase in an opposite manner to that of 
the housekeeping enzyme i.e. it may induce erythroid ALA 
synthase activity. This is most likely to occur post- 
transcriptional ly i.e. at translational or translocational 
levels or through a direct effect on enzyme activity (Chapter 
3, Section 3,5).
(3) Zinc protoporphyrin has been reported to accumulate in 
iron deficiency (Lamola and Yamane, 1974). As ferrochelatase 
is required to catalyze the formation of zinc protoporphyrin 
this suggests that enzyme activity is not compromised and that 
ferrous iron supply limits haem formation (Bottomley, 1977). 
It is possible that zinc protoporphyrin may exert an inhibitory 
role, not unlike haem in hepatic tissue, at the level of 
erythroid ALA synthase (Vreman and Stevenson, 1987). This 
observation requires clarification.
(4) A low iron diet plus a single dose of desferroxamine 
results in reduced cytochrome P4 5 0 ' but no increase in ALA 
synthase activity in rat hepatic tissue (White et al, 1978). 
This suggests that adequate iron may be required for normal ALA 
synthase activity.
This theory is supported by the recent suggestion of a 
possible role for iron in the regulation of erythroid ALA 
synthase mRNA translation (Chapter 3, Section 3.5.2) (Casey et 
al, 1988).
It is therefore difficult to determine whether the reduced 
erythroid ALA synthase activity observed during iron deficient
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erythropoiesis is a direct consequence of iron deficiency or of 
the resultant haem deficiency. In an attempt to resolve this 
uncertainty a patient with adequate iron stores, yet likely to 
hav e  e r y t h r o i d  haem d e f i c i e n c y  as a feature of 
hepatoerythropoietic porphyria (HEP), was examined.
7.4 BIOCHEMICAL INVESTIGATION OF HEPATOERYTHROPOIETIC PORPHYRIA - 
HOMOZYGOUS PORPHYRIA CUTANEA TARDA
A unique opportunity arose to examine the effect of haem 
deficiency on both erythroid and "hepatic" ALA synthase 
activities in a patient with hepatoerythropoietic porphyria 
(HEP). This provided further insight into the tissue-specific 
regulation of ALA synthase.
HEP is a rare type of porphyria believed to represent 
homozygous familial porphyria cutanea tarda (PCT). It is 
generally accepted that HEP is characterised by decreased 
uroporphyrinogen (URO) decarboxylase activity (Fujita et al, 
1987). However, only 15 cases have been reported in the world 
literature to date (Smith, 1986) and this has created 
difficulty with regard to achieving full clinical and 
biochemical characterisation of this disease. Two very similar 
cases, originally diagnosed and intensively investigated over 
several years (Gunther, 1967; Pinol Aquade et al, 1975) may be 
considered as "typical" HEP.
HEP is present from infancy and excess porphyrins 
(primarily uroporphyrin III) are found in urine, faeces and 
erythrocytes. This distinguishes HEP from the acute 
porphyrias, which present at puberty and have a normal 
erythrocyte porphyrin content. Although HEP is clinically
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similar to congenital erythropoietic porphyria (CEP), it 
differs biochemically in that the enzyme deficiency in CEP is 
uroporphyrinogen III cosynthetase. Markedly depressed liver 
and erythrocyte URO decarboxylase activity has been 
demonstrated in nine of the fifteen previously reported cases 
of HEP. Biochemically, HEP has many similarities with familial 
PCT, including porphyrin excretion patterns in urine and 
faeces, the presence of isocoproporphyrin and isomer III being 
predominant over isomer I porphyrin. The activity of URO 
decarboxylase is depressed in cases of PCI (Chapter 1, Section 
1.7.6) and is even further reduced in HEP.
7.5 EXPERIMENTAL
The study included porphyrin measurements in urine, faeces 
and erythrocytes; ferrokinetic studies; and haem biosynthetic 
enzyme activity measurements in bone marrow and liver of a 37 
year old male patient with suspected HEP.
Until recently ferrokinetic studies have been confined to 
measurement of plasma iron turnover (PIT), calculated from the
CQ
clearance of [ Fe]-transferrin from plasma and the serum iron 
concentration. In addition, red cell iron utilisation was 
usually measured after 14 days. These methods did not provide 
any indication of the rate or characteristics of erythropoiesis 
(Cavil 1 and Ricketts, 1980) but could demonstrate changes in 
the total plasma iron flow. Modern computer-assisted 
analytical methods applied to ferrokinetic data allow the 
distinction of erythroid from non-erythroid iron turnover and 
thus provide more accurate information regarding erythropoiesis 
(Cavill and Ricketts, 1980). Furthermore, the degree of
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ineffective erythropoiesis can be assessed accurately and a 
precise value for red cell lifespan obtained.
This study was carried out in collaboration with the 
Porphyrin Research Laboratories, Department of Medicine and 
Therapeutics, Western Infirmary, Glasgow and the Department of 
Haematology, University Hospital, Cardiff.
Clinical Features
The patient was a 37 year old male. The major clinical 
features exhibited by the patient were: (a) lifelong severe
photosensitivity; (b) hypertrichosis; (c) scleroderma-like 
changes; (d) anaemia (Hb = 10.9g/dl). Splenomegaly 8cm. (See 
photographic plate 7). No family members were available for 
study.
7.6 RESULTS
7.6.1 Porphyrin Measurements
Porphyrin analysis (Moore, 1983) (Table 19) showed 
excessive amounts of porphyrins in urine, faeces and blood. 
There were, in particular, significant quantities of 
uroporphyrin in blood and faeces. Total porphyrins in urine 
were increased 1 2 0 -fold relative to the normal range; 
coproporphyrin excretion in faeces was increased 160-fold, 
while protoporphyrin levels in whole blood were increased 5- 
fold. HPLC analysis (Seubert and Seubert, 1978) revealed 
excessive amounts of uroporphyrinogen, together with hepta (7- 
COOH); hexa (6 -COOH); penta (5-COOH) intermediates and 
coproporphyrinogen in urine. This excretion pattern would
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suggest a defect in the decarboxylation catalyzed by URO 
decarboxylase. Coproporphyrinogen was prominent in faeces, 
w h i l e  ery t h r o c y t e s  were found to contain excess 
protoporphyrinogen, uroporphyrinogen, coproporphyrinogen and 7- 
COOH, 6-C00H and 5-C00H intermediates. Liver and bone marrow 
both contained excess uroporphyrin.
Thus, the general porphyrin profile was consistent with 
that observed in HEP. This conclusion was further 
substantiated by porphyrin isomer examination which indicated 
the predominance of uroporphyrin isomer III. In CEP isomer I 
would be expected.
7.6.2 Haem Biosynthetic Enzyme Activity Measurements
Hepatic URO decarboxylase activity was undetectable. 
Significantly, ALA synthase (5280nmoles ALA/h/g protein) was 
elevated 25-fold in liver (normal range = 116-240nmoles ALA/h/g 
protein) but was markedly reduced in fractionated bone marrow 
erythroblasts. This was particularly evident in the more 
immature cells of fractions 1 and 2 which normally contain 
highest ALA synthase activity. In these cells ALA synthase 
activity was reduced to approximately one sixth of normal 
(Figure 38).
7.6.3 Ferrokinetics
Ferrokinetic studies demonstrated highly ineffective 
erythropoiesis ( > 75% ineffective). Red cell life span was 
not significantly reduced at 77 days which is towards the 
lower limit of normal for this ferrokinetic method. It was 
then clear that ineffective erythropoiesis (intramedullary
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FIGURE 38
ALA SYNTHASE ACTIVITY IN FRACTIONATED ERYTHROBLASTS FROM 
A PATIENT WITH HEPATOERYTHROPOIETIC PORPHYRIA
lysis of developing erythroblasts) rather than haemolysis 
(reduced red cell lifespan) was the cause of the anaemia. As 
haem has been shown to play a major role in the regulation of 
normal erythropoiesis (Chapter 1, Section 1.13) it is likely 
that erythroblast haem deficiency in HEP is the cause of the 
highly ineffective erythropoiesis.
7.6.4 Conclusions
This study has identified severely depressed URO 
decarboxylase activity which would explain the observed 
porphyrin excretion profile and the clinical and biochemical 
characteristics associated with HEP. PCT and HEP are 
characterised by reduced URO decarboxylase activity. In cases 
of PCT enzyme activity is reduced to approximately 50% of 
normal, while enzyme depression in HEP is more severe due to 
the homozygous nature of the defect. The anaemia has been 
shown to result from ineffective erythropoiesis as 
demonstrated by ferrokinetic studies.
Perhaps most significantly this study has shown that in 
response to reduced haem synthesis, ALA synthase activity 
increased in hepatic tissue and decreased in erythroblasts. 
This suggests that the regulation of haem synthesis in 
erythroblasts is different to that recognised to operate in 
hepatic tissue and supports the earlier finding of reduced ALA 
synthase activity during iron deficient erythropoiesis (Section 
7.3.1). This observation would support the view that haem 
deficiency rather than iron deficiency causes reduced erythroid 
ALA synthase activity. However, a possible contributory role
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for iron in the attenuation of erythroid ALA synthase activity 
cannot be discounted on the basis of this observation. This 
latter view is supported by the suggestion of a role for iron 
in the regulation of erythroid ALA synthase mRNA translation 
(Chapter 3, Section 3.5.2) (Casey et al, 1988). In addition, 
the possible existence of an erythroid-specific inhibitor for 
ALA synthase activity cannot be overlooked, although there is 
currently no experimental evidence to support this theory.
7.6.5 Summary
ALA synthase activity was measured in highly purified age- 
matched human erythroblasts from 10 patients with iron 
deficient polycythaemia.
It was demonstrated for the first time that during iron 
deficient erythropoiesis ALA synthase activity is seriously 
impaired. This was particularly evident in the more immature 
erythroid cells, normally most active with regard to ALA 
synthase activity. In order to determine whether the reduction 
in erythroid ALA synthase activity was a direct consequence of 
the iron deficiency or of the resultant haem deficiency a 
patient with erythroid haem deficiency hepatoerythropoietic 
■ porphyria (HEP) but adequate iron stores was examined. This 
patient demonstrated a similar pattern of reduced ALA synthase 
activity suggesting that the reduction in ALA synthase activity 
was most likely to be a consequence of the haem deficiency. A 
secondary role for iron in the regulation of ALA synthase 
activity cannot however be eliminated on the basis of these 
results.
The regulation of erythroid ALA synthase activity would 
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therefore appear to be different from that recognised to 
operate in hepatic tissue whereby ALA synthase activity is 
induced in response to haem deficiency. This may be explained 
by the existence of tissue-specific isoenzymes for ALA synthase 
in erythroid and hepatic tissue which are encoded for by 
separate genes on the X chromosome and chromosome 3 
respectively (Cox et al, 1990; Sutherland et al, 1988).
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CHAPTER 8
ALA SYNTHASE AND FERROCHELATASE ACTIVITIES 
DURING SIDEROBLASTIC ERYTHROPOIESIS
8 ALA SYNTHASE AND FERROCHELATASE ACTIVITIES DURING SIDEROBLASTIC
ERYTHROPOIESIS
8.1 AIMS OF THE STUDY
It was the aim of the work described in this chapter to 
examine ALA synthase and ferrochelatase activities during 
sideroblastic erythropoiesis (Chapter 1, Section 1.15.2).
Erythroid ALA synthase has been reported to be reduced in 
most types of sideroblastic anaemia (S.A.) (Cartwright and 
Deiss, 1975; Aoki et al, 1974; Bottomley, 1982) and it is 
generally believed that this is the primary defect which 
results in sideroblast formation. However, controversy 
surrounds this issue. Several reports have implicated abnormal 
intracellular iron metabolism (May et al, 1982; Wickramasinghe 
and Hughes, 1978) and abnormalities of other haem enzymes, 
particularly ferrochelatase (Ali and Sweeney, 1974; Ali and 
Brain, 1974; Labbe and Nielsen, 1976) as possible sites of the 
primary defect. A clear answer has not been forthcoming due to 
the hitherto inability to closely examine haem enzyme activity 
during erythropoietic development.
There is a broad spectrum of clinical settings in which 
the ring sideroblast abnormality occurs. SA may present as a 
congenital anaemia, usually X-linked (CSA); as an irreversible 
acquired erythroid defect (Primary Acquired Sideroblastic 
Anaemia, PASA) which may either be stable or may evolve 
relatively rapidly into acute leukaemia; and as a reversible 
phenomenon (Secondary Sideroblastic Anaemia, SSA) secondary to 
alcohol intoxication, copper deficiency, occasional haemolytic 
processes and the administration of certain drugs such as 
isoniazid or chloramphenicol (Bottomley, 1982). These varied
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associations have provided no clue for the etiologic or 
pathogenic mechanisms of the erythropoietic defect (s).
2 EXPERIMENTAL
2.1 Patients Studied
Bone marrow was obtained at the time of routine bone 
marrow examination from 11 patients with several types of SA. 
Three patients had congenital SA (CSA); seven patients had 
primary acquired SA (PASA); and one patient had secondary SA 
(SSA). Further patient details are presented in Appendix 2.
2.2 Enzyme Measurements
ALA synthase activity was measured in the four percoll 
fractions obtained from fractionated bone marrow (Chapter 2). 
Ferrochelatase activity was measured in six patients (1 CSA, 5 
PASA). Fractions 1 to 4 contained purified age-matched 
erythroblasts predominantly of pro, early, intermediate and 
late erythroblast status respectively.
3 RESULTS
3.1 ALA Synthase Activity During Sideroblastic Erythropoiesis
The results expressed in figure 39 represent ALA synthase 
activity during CSA and PASA. In each case ALA synthase 
activity was markedly decreased throughout erythropoiesis 
relative to that observed during normoblastic erythropoiesis 
(Chapter 6 , Figure 30). The reduction in enzyme activity was 
particularly marked in fractions 1, 2 and 4 (p < 0.001), but 
was also significant in fraction 3 (p < 0.001) (Table 20). It
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ALA SYNTHASE ACTIVITY IN FRACTIONATED HUMAN 
ERYTHROBLASTS : SIDEROBLASTIC ERYTHROPOIESIS
ALA SYNTHASE ACTIVITY 
(p moles/1 erythroblasts/hour)
PERCOLL NORMOBLASTIC
FRACTION ERYTHROPOIESIS
(x + 1 S.D. , 
n = 15)
FRACTION 1 418 + 249
FRACTION 2 406 + 156
FRACTION 3 261 + 123
FRACTION 4 120 + 99
SIDEROBLASTIC P <
ERYTHROPOIESIS
(x + 1 S.D.,
n = 1 0 )
71 + 54 0 . 0 0 0
53 + 30 0.001
115 + 55 0 . 0 1 0
35 + 29 0.001
TABLE 20
ALA SYNTHASE ACTIVITY IN FRACTIONATED BONE MARROW FROM 
PATIENTS WITH NORMOBLASTIC AND SIDEROBLASTIC ERYTHROPOIESIS
is therefore clear that ALA synthase activity is reduced 
throughout erythropoiesis in CSA and PASA.
In the case of SSA, however, ALA synthase activity in 
Fractions 1 to 4, i.e. throughout erythropoiesis, was not 
significantly reduced and remained within the normal range 
(Figure 40). Although enzyme activity in percoll Fraction 2 
was perhaps a little low, abundant activity was evident in 
Fraction 1.
One transfusion-dependent CSA patient (male, aged 4 years) 
was studied over a period of 1 year with regard to Hb levels 
and ALA synthase activity. The patient originally presented 
with a severe non pyridoxine responsive anaemia, Hb of 4.6g/dl 
and the marrow showed evidence of dyserythropoiesis with 24% 
ring sideroblasts. ALA synthase activity was markedly reduced 
in all 4 percoll fractions (Figure 41). Family studies were 
not available as the patient lived in England. During the 
period of regular transfusion Hb was maintained between 8 and 9 
g/dl. However, one year later the patient underwent 
spontaneous remission. Hb returned to normal/or possibly 
raised levels (14-15 g/dl), as did ALA synthase activity in all 
four percoll fractions (Fraction 41). This remission was 
associated with a switch to HbF production. This represents 
the first documented case of a patient with CSA making a full 
spontaneous recovery.
8.3.2 Ferrochelatase Activity During Sideroblastic Erythropoiesis
Fractionated sideroblastic bone marrow samples from six 
patients (1 CSA, 5 PASA) were assayed for ferrochelatase
activity.
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FIGURE 41
ALA SYNTHASE ACTIVITY IN FRACTIONATED HUMAN ERYTHROBLASTS 
FROM A PATIENT WITH CONGENITAL SIDEROBLASTIC ANAEMIA 
(BEFORE AND AFTER SPONTANEOUS REMISSION) .
Enzyme activity in all patients was difficult to detect in 
fractions 1 to 4 despite the use of a highly sensitive 
radiochemical assay. in four cases enzyme activity was 
completely undetectable whereas in the remaining two cases 
enzyme activity could just be detected. This indicated that 
ferrochelatase activity was impaired throughout erythropoiesis 
in a similar fashion to ALA synthase activity.
8.3.3 Discussion
SA is characterised by defective haemoglobinisation of red 
cells, ineffective erythropoiesis and an abnormal accumulation 
of iron in the maturing erythroblasts distributed in the form 
of a perinuclear ring (Chapter 1, Section 1.15.2). 
Erythroblasts from individuals with either the inherited or 
acquired types of SA have an inability to utilise iron and 
synthesise haem, although iron uptake and iron transfer to 
mitochondria remain normal (Bottomley and Moore, 1986).
Several theories have been forwarded to explain the 
reduction in haem synthesis. It has been argued that virtually 
all cases of SA show impaired ALA synthase activity and that 
this is the primary defect which leads to reduced haem 
synthesis (Cartwright and Deiss, 1975; Aoki et al, 1974). 
Other workers believe the primary defect to be an abnormality 
of mitochondrial iron metabolism (May et al, 1982) possibly 
associated with impaired mitochondrial function (Wickramasinghe 
and Hughes, 1978). However, in cases of pyridoxine-responsive 
CSA only ALA synthase is thought to be impaired. CSA usually 
follows X-linked inheritance (Lee et al, 1968; Bottomley, 1982; 
McKusick, 1986) and the erythroid ALA synthase gene has
218
recently been located on the X chromosome (Cox et a l , 1990) 
supporting the theory of a possible defect at the level of the 
erythroid ALA synthase gene. Moreover, the response of 
patients with CSA to pyridoxine is strong evidence in favour of 
decreased ALA synthase activity contributing to the anaemia. 
It has been argued that pyridoxine may improve haem synthesis 
and lessen the anaemia by preventing the temperature-dependent 
inactivation of ALA synthase by a controlling protease present 
in erythroid cells (Aoki, 1978; Aoki et al, 1979). In 
experimental models of pyridoxine deprivation or antagonism, 
mitochondrial iron-loading, reduced AIA synthase activity and 
hypochromic-microcytic anaemia are prominent findings 
(Bottomley, 1980). Most of the drugs (and in particular 
isoniazid) which induce SA in man and animals are thought to 
impair haem biosynthesis by diminishing the availability of PLP 
for ALA production (Haden, 1967; McCurdy and Donohoe, 1966; 
Roberts and Hoffbrand, 1966; Harris and MacGibbon, 1965; Tanaka 
and Bottomley, 1974). In acquired SA pyridoxine responsiveness 
is infrequently observed.
Reduced ALA synthase activity was found in the CSA and 
PASA patients included in this study. The low enzyme activity 
was mainly evident during early erythroid development (i.e. 
percoll Fractions 1 and 2). Mitochondrial iron deposits are, 
on the other hand, normally more evident in the later siderotic 
erythroblasts (Bottomley, 1982). In vitro studies of 
erythroid cell iron metabolism have not disclosed any 
abnormalities of iron uptake or transfer to mitochondria and 
merely reflsct reduced incorporation of iron into haem
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(Bottomley and Moore, 1986). The patient with SSA demonstrated 
normal levels of ALA synthase. This latter observation 
identified normal ALA synthase activity in ring sideroblastic 
erythroid cells and so casts doubt on the theory that reduced 
ALA synthase is the primary cause of ring sideroblast 
formation.
Conversely, increased bone marrow ALA synthase activity 
has been found in the acute reversible SA of alcoholics (Fraser 
and Schacter, 1980). Scrutiny of the clinical state of the 
alcoholic patient has led to the conclusion that chronic 
malnutrition and folate deficiency with megaloblastic marrow 
maturation are prerequisites for the occurrence of 
sideroblastic changes (Pierce and McGuffin, 1976). Comparison 
of enzyme activity in the presence and absence of pyridoxal 
phosphate (PLP) revealed that PLP metabolism in alcoholics may 
not be important in the inhibition of haem biosynthesis at the 
level of ALA synthase, but that rather an enzymatic block 
should be sought at a more distal site in the haem pathway. 
The biochemical pathogenesis of this disorder therefore remains 
unclear. A block at ferrochelatase is supported by increased 
red cell protoporphyrin and coproporphyrin levels in alcoholic 
patients with marrow ring sideroblasts (Ali and Sweeney, 1974; 
Moore, 1974). The observations that 'in vitro1 inhibition of 
globin synthesis by ethanol may be corrected by the addition of 
haem, but not by ALA (Ali and Brain, 1974) also suggests a 
blockade distal to ALA synthase. A proposed association of PLP 
as a cofactor requirement for ferrochelatase as well as ALA 
synthase (Labbe and Nielsen, 1976) provides a novel solution by 
which the postulated PLP deficiency noted in some studies could
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also explain the observations that support a distal block in 
haem synthesis.
Moore and co-workers have described diminished activity of 
erythrocyte ALA dehydratase following alcohol ingestion 
(Krasner et al, 1974; Moore et al, 1971) and suggest that this 
change may be mediated through a relative increase in reduced 
glutathione concentration. However, since the enzyme is 
dependent on zinc, an alternative mechanism may involve a 
concomitant zinc deficiency through excessive renal excretion 
in alcoholism (Sullivan, 1974). Impaired metabolism of 
pyridoxine has also been demonstrated in alcoholic patients. 
Blood concentrations of PLP are frequently diminished in 
alcoholics (Hines, 1975; Hines and Cowan, 1970; Lumeng and Li, 
1974; Pierce and McGuffin, 1976) but do not correlate 
consistently with morphological evidence of SA.
Reduced ferrochelatase activity during sideroblastic 
erythropoiesis in the patients examined in this study supports 
the theory of a distal blockade at ferrochelatase and/or iron 
metabolism. It is then possible that reduced ferrochelatase 
activity may cause haem deficiency which in turn leads to 
reduced ALA synthase activity. The results reported in Chapter 
7 suggest that reduced ALA synthase activity may occur 
secondary to haem deficiency. This argument is further 
developed in Chapter 9 in which the case for and the results of 
a therapeutic trial of haem therapy in sideroblastic anaemia 
are described.
The spontaneous remission seen in a patient with 
transfusion-dependent CSA does, however, cast doubt over
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reduced haem synthesis being the primary defect in SA. Prior 
to remission, ALA synthase was markedly reduced throughout 
erythroid development and HhA was predominantly produced (i.e. 
globin chain production was of type cx and £ ). Following 
remission, 95% HbF was produced (i.e. jB globin chain production 
was replaced by ft globin chain production) and ALA synthase 
levels were returned to normal. Hence, this patient has 
apparently overcome CSA by switching from j5 globin chain to 
ft globin chain production. This suggests that in this case of 
CSA the primary defect may lie at globin synthesis rather than 
at haem synthesis. Haem deficiency may, therefore, have been 
secondary>resulting in reduced ALA synthase activity. This 
remission may indicate a therapeutic role for agents which 
favour HbF production (i.e. increase ft globin chain 
production) in CSA e.g. hydroxyurea or 5-AZA cytidinej as have 
been used to promote HbF production in sickle cell anaemia.
8.3.4 Summary
ALA synthase and ferrochelatase activities were measured 
in highly purified age-matched human erythroblasts from 
patients with CSA, PASA and SSA.
One patient with SSA had ALA synthase activity within the 
normal range. In the remaining patients (CSA/PASA) ALA 
synthase and ferrochelatase activities were reduced throughout 
gj-ythropoiesis, particularly in the more immature erythroid 
cells. These results indicate that reduced ALA synthase 
activity is not present in all typos of S.A. and is therefore 
unlikely to be the primary defect responsible for ring 
sideroblast formation. The marked reduction in ferrochelatase
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activity in the six patients examined suggests a possible role 
for ferrochelatase deficiency and/or abnormal iron metabolism 
in the pathogenesis of this disease. As previously 
demonstrated (Chapter 7) haem deficiency may produce secondary 
inhibition of ALA synthase. Hiis indicates a possible role for 
haem therapy in the treatment of patients with SA. This may 
not only replace the haem deficiency but may also stimulate the 
impaired ALA synthase activity.
However, the spontaneous remission observed in a patient 
with transfusion-dependent CSA suggests that the primary defect 
in this case of CSA may lie at globin rather than haem 
synthesis. This patient was apparently able to correct for the 
defect in CSA by switching from P globin chain to 5 globin 
chain production.
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CHAPTER 9
TREATMENT OF SIDEROBLASTIC ANAEMIA WITH HAEM ARGINATE 
EFFECT ON HAEM SYNTHESIS
9 TREATMENT ON SIDEROBLASTIC ANAEMIA W ITH  HAEM ARGINATE: EFFECT
ON HAEM SYNTHESIS
9.1 AIMS OF TOE STUDY
It was the aim of this study to examine the effects of
haem therapy on haem synthesis and Hb concentration in
individuals with various types of SA.
Most cases of SA are refractory to treatment. Haem 
arginate is a new stable form of haem which has been used with 
some success in the treatment of porphyria (Herrick et al, 
1987; Mustajoki et al, 1986). It has been reported to be of 
potential therapeutic benefit in the treatment of various 
haematological disorders (Ruutu et al, 1987). The use of haem 
arginate in the treatment of SA is studied in detail with 
regard to ALA synthase and ferrochelatase activities and Hb 
concentration in the work described here.
9.1.1 Haem in the Treatment of Haematological Disorders
Haem was first used to treat porphyria nearly 20 years ago 
(Bonkowsky et al, 1971). Extensive investigations of porphyrin 
metabolism have shown that the administration of exogenous haem 
in the form of haemin or haematin results in the repression of 
the overproduction of porphyrin precursors in acute 
intermittent porphyria (AIP) and corrects the haem deficiency.
Abnormalities of enzymes in the haem biosynthetic pathway, 
such as ALA synthase and ferrochelatase, have also been found 
in SA and myelodysplastic syndromes (MDS) (Chapter 8). The 
rationale for haem treatment in MDS can be described as 
follows. A characteristic feature of SA is defective Hb 
synthesis morphologically evident as hypochromia despite
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abundant iron in the erythroblasts. Disturbances have been 
demonstrated in both haem and globin synthesis (White et al, 
1971). In the study of White and Ali (1973) exogenous haem 
normalised globin synthesis and so it was concluded that haem 
deficiency was the basic disturbance in Hb production. This 
finding has, however, been disputed (Peters et al, 1983). 
Abnormalities in the enzymes of haem synthesis have been 
demonstrated in patients with MDS (Pasanen et al, 1981).
The beneficial effects of exogenous haem on 'in vivo1 and 
'in vitro' haematopoiesis are well established. Haemin 
increases the number of erythroid burst forming units (BFU-E) 
in the rat bone marrow 'in vivo' and enhances the cell cycling 
of BFU-E (Monette et a l , 1984), augments colony formation by 
rat BFU-E 'in vitro' (Monette and Holden, 1982) and also 
induces maturation of leukaemic cell lines 'in vitro' 
(Rutherford et al, 1979), (further details in Chapter 1, 
Section 1.13).
The work so far described (Chapter 7) has confirmed the 
proposal that the regulation of the haem biosynthetic pathway 
is different in hepatic and erythroid cells. It has been 
demonstrated that in contrast to liver, haem deficiency in 
erythroid cells results in decreased ALA synthase activity. It 
has been suggested that the converse could be true (Granick and 
Sassa, 1978; Elder, 1981) i.e. that the administration of 
exogenous haem would result not only in the correction of the 
haem deficiency but also in increased activity of those enzymes 
of haem synthesis which are repressed. Therefore, if the 
primary abnormality in SA is reduced haem synthesis it would 
seem reasonable to attempt to correct this deficiency with
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exogenous haem and assess the effects of treatment on enzyme 
activity and haematopoiesis.
The role of haem therapy in the treatment of 
haematological disorders is unclear as it is not yet known to 
what extent exogenous haem is able to enter bone marrow cells. 
Furthermore, it is not clear if haem deficiency in SA is a 
primary abnormality or is related to abnormal intracellular 
iron metabolism or whether both reduced haem biosynthetic 
enzyme activity and iron abnormalities are secondary events in 
the pathogenesis.
(i) Haematin
Haematin (haemin hydroxide), is an effective form of 
treatment for acute porphyric attacks. It can, however, cause 
side-effects such as phlebitis at the site of infusion (Dhar et 
al, 1975). Moreover, a transitory renal failure with 
relatively large doses has been reported (Dhar et al, 1978). 
Treatment may also cause disturbances in haemostasis and even 
haemorrhagic complications (Glueck et al, 1983; Morris et al, 
1981; Petersen and Pierach, 1984). In solution, haem has a 
well known tendency both to aggregate (Shack and Clark, 1947) 
and to degrade (Jones, 1986; Goetsch and Bissell, 1986). It 
has been shown that the coagulation defects seen after haematin 
treatment are mainly caused by degradation and metabolisation 
products that bind to the coagulation proteins and reversibly 
inhibit their function (Jones, 1986).
(ii) Haem Arginate (Normosang)
Haem arginate was developed to find a well-tolerated and 
more stable haem compound (Tenhunen et al, 1987).
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Theoretically, a stable haem compound with a low tendency to 
degrade may have fewer side effects.
Haem arginate is a salt of haem and the physiological, 
basic amino acid arginine. The active ingredient is haemin 
which is utilised effectively through the same pathways as 
physiological haem (Tokola, 1987).
9.2 EXPERIMENTAL
9.2.1 Patients Studied
Six male patients took part in the study (age range 23-83 
years); one had CSA, the remainder had PASA. Of the five 
patients with PASA, three were stable and non transfusion 
dependent, one was newly diagnosed and one was transfusion 
dependent - see Appendix 2.
9.2.2 Haem Arginate Infusion
Haem arginate (3mg/kg) was given as an intravenous 
infusion over 30 minutes on days 1-5 and thereafter twice 
weekly for a further five weeks (i.e. total treatment period 
was 6 weeks).
9.2.3 Enzyme Measurements
ALA synthase and ferrochelatase activities were measured 
in whole and fractionated human bone marrow prior to treatment 
(Day 0) and during treatment (Day 5, Week 6 ).
9.3 RESULTS
9.3.1 Haemoglobin Levels
Hb levels remained unchanged throughout treatment in all
patients.
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9.3.2 Bone Marrow Morphology
Bone marrow morphology did not change during treatment. 
The percentage ring sideroblasts did not alter.
9.3.3 Haem Enzyme Activity in Whole Unfractionated Bone Marrow
No results were obtained for Patient 4 on day 5 due to 
inadequate cell numbers in the marrow sample taken on that day.
(i) ALA Synthase Activity
Prior to haem arginate treatment, the mean recorded ALA 
synthase activity in whole unfractionated bone marrow was 242 + 
142 (+ 1 S.D.) (Table 21). Enzyme activity rose to a level of 
393 + 141 (+ 1 S.D.) by day 5 of treatment. However, this rise 
in activity was not sustained and by week six had returned to a 
value of 215 + 144 (+ 1 S.D.). With regard to the individual 
patients, four of the five (1 CSA, 3 PASA) showed significant 
increases in enzyme activity on day 5 of treatment, two of 
which were restored into the normal range (Table 21). The 
increase in enzyme activity was not sustained to week 6 of 
treatment in any of the four patients (Table 21).
(ii) Ferrochelatase Activity
Prior to haem arginate treatment, ferrochelatase activity 
was undetectable in four of the six patients and well below the 
normal range in the remaining two patients (Table 22). At day 
5 , three of five patients showed a marked improvement with 
enzyme activity returning to near normal levels. The observed 
increase in enzyme activity was sustained to week 6 in only one 
patient. In the remaining two patients ferrochelatase activity 
did not improve during haem arginate treatment.
228
(p 
mo
le
s 
A
L
A
/
1
0 
er
yt
hr
ob
la
st
s/
ho
ur
)
CN T—
T— T_ T--
+  l +  l +
CN ro in
T--
CN ro CN
<o
TH
E 
EF
FE
CT
 
OF 
HA
EM
 
AR
GI
NA
TE
 
TR
EA
TM
EN
T 
ON 
AL
A 
SY
NT
HA
SE
 
AC
TI
VI
TY
 
IN 
WH
OL
E 
BO
NE
 
MA
RR
OW
 
FR
OM
 
PA
TI
EN
TS
 
WI
TH
 
SI
DE
RO
BL
AS
TI
C 
AN
AE
MI
A

These results suggest a possible positive effect of haem 
arginate on haem enzyme activity in certain patients with SA. 
However, no firm conclusion may be drawn from this study of 
unfractionated marrow due to the difficulty in assessing the 
relative contribution of the erythroid cells to the total 
marrow activity (Chapter 2). Fractionation of the bone marrow 
samples was carried out to gain insight into the effects of 
haem therapy on erythroid haem synthesis during the various 
stages of erythroid differentiation.
9.3.4 Haem Enzyme Activity in Fractionated Bone Marrow
Prior to treatment, all patients (1 CSA, 5 PASA) 
demonstrated reduced erythroblast ALA synthase activity (as 
described in Chapter 8) in each of the four percoll fractions 
(Figure 42). Enzyme activity remained low throughout 
erythropoietic development and failed to display the 
characteristic peak of ALA synthase activity in fractions 1 and 
2 as demonstrated during normoblastic erythropoiesis (Chapter 
6 , Figure 30). All reductions in enzyme activity were 
statistically significant (Mann Whitney U test, p < 0.001).
Ferrochelatase activity was also significantly reduced in 
all four percoll fractions such that four of the six patients 
had no detectable enzyme activity. The remaining two patients 
had low levels of ferrochelatase activity in each fraction 
which were significantly reduced (p < 0.0 0 1) relative to those 
found during normoblastic erythropoiesis (Chapter 6 , Figure 
31).
Results for five patients indicate an increase in ALA 
synthase activity following five days of treatment with haem
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FIGURE 42
ALA SYNTHASE ACTIVITY IN FRACTIONATED 
ERYTHROBLASTS FROM THE SIDEROBLASTIC PATIENTS 
(PRIOR TO TREATMENT WITH HAEM ARGINATB
arginate (Table 23, Figure 43). This was particularly 
significant (p < 0.01, p < 0.05) in the more immature cells of 
fractions 1 and 2 i.e. those cells normally most active with 
regard to ALA synthase activity. In these fractions, all 
patients showed increased ALA synthase activity on Day 5. This 
increase in activity was partially sustained until week six of 
treatment (Figure 44) with three of five patients maintaining 
ALA synthase activity in fractions 1 and 2 markedly above that 
of Day 0 values. Enzyme activity in the remaining two patients 
returned to Day 0 values.
Due to the small patient numbers in the study, the results 
were also examined on an individual basis. Two of the six 
patients demonstrated a dramatic response to haem arginate 
treatment with regard to haem enzyme activity. Patient One 
with PASA (Figure 45) and Patient Two with CSA (Figure 46) 
displayed a sharp rise in ALA synthase activity on day five 
achieving values within the normal range for percoll Fractions 
1 and 2. Normal ALA synthase levels were sustained until week 
six in Patient 1 but fell back outwith the normal range in 
Patient 2 (but still remained significantly higher than those 
recorded on Day 0).
Ferrochelatase activity, however, was very low in all the 
patients. By day 5 Patients 1 and 2 again demonstrated levels 
of activity in the normal range (Tables 24 and 25). This 
increase in enzyme activity was not, however, sustained until 
week 6 (Tables 24 and 25).
9.4 DISCUSSION
Markedly reduced ALA synthase and ferrochelatase
230
ALA SYNTHASE ACTIVITY 
(pnoles/1 O^erythroblasts/hour)
DAY OP TREATMENT DAY 0 DAY 5 WEEK 6
WITH HAEM ARGINATE ----- -----
FRACTION 1 70+31 175 + 127 166 + 135
FRACTION 2 68+40 218+191 160+116
ENACTION 3 133 + 61 154 + 112 105 + 59
FRACTION 4 39 + 17 53 + 53 47 + 41
NOTE:
Each point represents the mean of six duplicate observations 
(x + 1 S.D.)
TABLE 23
THE EFFECTS OF HAEM ARGINATE TREATMENT ON ALA SYNTHASE 
ACTIVITY DURING SIDEROBLASTIC ERYTHROPOIESIS
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FIGURE 43
EFFECT OF HAEM ARGINATE ON ERYTHROBLAST 
ALA SYNTHASE ACTIVITY : DAY 5 OF TREATMENT
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FIGURE 44
EFFECT OF HAEM ARGNATE ON ERYTHROBLAST 
ALA SYNTHASE ACTIVITY : WEEK 6 OF TREATMENT
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FIGURE 45
PATIENT 1:1°ACQUIRED SIDEROBLASTIC ANAEMIA
EFFECT OF HAEM ARGINATE THERAPY ON ALA SYNTHASE ACTIVITY
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FIGURE 46
PATIENT 2 : CONGENITAL SIDEROBLASTIC ANAEMIA :
EFFECT OF HAEM ARGINATE THERAPY ON ALA SYNTHASE ACTIVITY
FERROCHELATASE ACTIVITY
(pmoles/10 6 erythroblast s/hr)
haem  arginate Fraction Number
TREATMENT 1 2 3 4
DAYO N.D. N.D. N.D. N.D.
DAY 5 9 36 123 6
WEEK 6 N.D. 18 21 N.D.
NOTE:
Each point represents the mean of two observations. 
N.D. = not detectable
TABLE 24
PATIENT 1 :1°ACQUIRED SIDEROBLASTIC ANAEMIA:
EFFECT OF HAEM ARGINATE THERAPY ON FERROCHELATASE ACTIVITY
FERROCHELATASE ACTIVITY
(pmoles/10 6 erythroblast s/hr)
h aem  arginate Fraction Number
TREATMENT 1 2  3 4
DAYO N.D. N.D. N.D. N.D.
DAY 5 45 72 36 18
WEEK 6 N.D. N.D. N.D. N.D.
NOTE:
Each point represents the mean of two observations. 
N.D. -  not detectable
TABLE 25
PATIENT 2: CONGENITAL SIDEROBLASTIC ANAEMIA:
EFFECT OF HAEM ARGINATE THERAPY ON FERROCHELATASE ACTIVITY
activities were demonstrated throughout erythropoiesis in six 
patients with CSA and PASA (in agreement with the results 
previously discussed in Chapter 8 ). Following haem arginate 
treatment, the six patients demonstrated no change in Hb 
levels. Therefore, haem did not correct the inefficient 
erythropoiesis that characterised all the cases of SA. 
However, despite the absence of a direct therapeutic benefit, 
two of the six patients demonstrated significant changes in 
haem enzyme activities, in response to haem therapy, both ALA 
synthase and ferrochelatase activities in the early percoll 
fractions returned to values within the normal range at day 5.
This study provides evidence that during systemic haem 
arginate therapy haem is able to enter developing erythroblasts 
and influence haem biosynthetic activity and thereby suggests a 
potential therapeutic role for haem arginate in the treatment 
of patients with abnormalities of erythroid biosynthesis.
Two patients demonstrated increased haem enzyme activity 
in response to treatment, one PASA the other CSA. A further 
four patients with PASA failed to respond to treatment. Such 
findings highlight the possible heterogeneous nature of the 
defect responsible for the pathogenesis of PASA. The 
normalisation of ALA synthase with haem arginate treatment in 
CSA without morphological or clinical improvement casts doubt 
over the belief that reduced ALA synthase is the primary defect 
in CSA. This theory has been supported by several workers 
(Cartwright and Deiss, 1975; Aoki et al, 1974) and has been 
reinforced by the recent localisation of the erythroid ALA 
synthase gene to the X chromosome (Cox et al, 1990) (CSA 
usually has an X—linked inheritance pattern, Bottomley, 1982).
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However, the demonstration here of marked improvement in ALA 
synthase activity in response to haem arginate treatment 
without clinical improvement suggests that impaired ALA 
synthase activity is not the primary defect in this case of 
CSA. This is consistent with evidence that, in this patient, 
CSA is unlikely to be X-linked. The patient's mother could not 
be shown to be a carrier for CSA and five brothers were 
unaffected. The patient was, however, pyridoxine responsive 
suggesting a possible abnormality of the enzyme cofactor, PLP. 
ALA synthase is unstable in the absence of PLP, but in the 
presence of haem the resultant increase in enzyme activity may 
perhaps be sufficient to mask the effects of reduced enzyme 
stability. Ferrochelatase activity in this CSA patient also 
responded well to treatment, returning into the normal range on 
day five. This implies that ferrochelatase deficiency does not 
represent the primary defect in this case of CSA which may 
instead lie in a defect at an intermediate enzyme in the 
pathway or at an abnormality of intracellular iron metabolism. 
Hence, the nature of the defect in CSA remains uncertain. The 
same argument could apply to the patient with PASA whose haem 
enzymes responded well to haem therapy.
The non-sustained effect of haem therapy on haem enzyme 
activity (Patient 2) may indicate induction of haem oxygenase 
activity in response to the presence of exogenous haem. This 
observation may warrant follow up with a therapeutic trial of 
combined haem arginate and tin protoporphyrin, a potent 
inhibitor of haem oxygenase (Drummond and Kappas, 1981), as a 
means of sustaining the enzyme response. Tin protoporphyrin
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has recently been reported to have therapeutic value in the 
mangement of hyperbilirubinaemia in newborn infants (Kappas et 
al, 1988).
Haem arginate may therefore be of therapeutic benefit in 
future studies. The possibility remains whereby further 
patients with SA may be treated with haem arginate, perhaps in 
conjunction with tin-protoporphyrin. However, the failure of 
two patients to show any clinical improvement despite 
normalisation of haem enzyme activity may dampen enthusiasm for 
this study. Nevertheless, patients with other haematological 
abnormalities may be potential candidates for haem arginate 
therapy.
As a direct consequence of this work a further study has 
been funded (Nuffield Foundation) to examine the effects of 
haem arginate treatment on haem synthesis in patients with 
anaemia of chronic disease such as rheumatoid arthritis. The 
anaemia is characterised by iron deficient red cell indices 
with the paradoxical association of reduced serum iron despite 
normal/increased reticuloendothelial iron stores (Cartwright, 
1966). Macrophages have been widely considered as responsible 
for this reticuloendothelial iron block (Van Snick et al, 
1974). However, ferrokinetic studies have established that the 
hypoferraemia does not restrict marrow iron supply (Dinant and 
De Maat, 1978; Cavill and Bentley, 1982). Hypochromic 
microcytic red cells provide absolute evidence of Hb 
deficiency. Limited studies have identified abnormalities of 
haem biosynthesis. Erythrocyte protoporphyrin levels are 
raised and unexplained (Lee, 1983) and coproporphyrinogen 
oxidase activity is markedly reduced (Campbell et al, 1978).
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It has been postulated that a failure of ALA synthase and haem 
synthesis to increase in response to anaemia leads to marrow 
unresponsiveness (Campbell et al, 1978).
Finally, a finding of major significance from this work is 
the demonstration that erythroid ALA synthase has the ability 
to respond to haem argiante therapy in a manner which is 
opposite to that of "hepatic" ALA synthase i.e. the erythroid 
enzyme may be induced in response to exogenous haem. This is 
consistent with the earlier findings (Chapter 7) whereby 
erythroid ALA synthase was reduced in response to haem 
deficiency and thus represents very strong evidence in favour 
of the theory that the isoenzymes of ALA synthase in "hepatic" 
and erythroid tissue operate under strict and specific control 
mechanisms. Haem synthesis appears to be regulated by the size 
of the free haem pool in both tissues. However, in the case of 
the erythroid enzyme the effects of haem are linked to the 
differentiation status of the cells. Haem is thought to 
inhibit reticulocyte ALA synthase (Bruns and London, 1965; 
Ibrahim et al, 1978) but stimulate activity in immature 
erythroblasts (Granick and Sassa, 1978; Elder, 1981; Abraham 
and Levere, 1990). Other workers, however, have concluded from 
studies using FEL cells that the induction of erythroid ALA 
synthase gene transcription is developmentally regulated and 
largely unaffected by intracellular haem balance (Young and 
Dierks, 1990).
Due to the complicated nature of the erythropoietic 
process and the multiplicity of factors which are involved in 
its regulation (Chapter 1), it is unlikely that the regulation 
of erythroid haem synthesis will be fully understood for some
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time yet. Further work is required to examine the contribution 
of other factors to the regulatory mechanisms which operate. 
The role of other haem enzymes and intracellular iron 
metabolism in regulating erythroid haem synthesis have yet to 
be established.
9.4.1 Sunnary
Six patients with SA (1 CSA, 5 PASA) were given haem 
arginate infusions (3mg/kg) over a 6 week period in an effort 
to correct the haem deficiency, stimulate erythroid haem 
synthesis and restore more effective erythropoiesis to the 
sideroblastic clone. At day 5, two of six patients (1 CSA, 1 
PASA) demonstrated significant rises in ALA synthase and 
ferrochelatase activities in fractionated bone marrow with 
levels rising into the normal range. Despite the dramatic 
increase in enzyme activity none of the patients showed any 
change in Hb levels. The remaining four patients (PASA) showed 
no enzyme response to treatment.
These results question the nature of the primary defect in 
CSA. The primary defect in X-linked CSA is generally believed 
to lie at ALA synthase, a view reinforced by the recent 
localisation of the erythroid ALA synthase gene to the X 
chromosome. However, the dramatic response of ALA synthase to 
haem therapy in the patient described here was not associated 
with clinical benefit. Moreover, the similar response of 
ferrochelatase to haem therapy in this patient suggests that 
the primary defect is unlikely to lie at ferrochelatase.
The heterogeneous nature of PASA is highlighted by the
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fact that only one of five patients responded to haem therapy 
(in a similar manner to the patient with CSA) while the others 
did not.
The increase in enzyme activity in the two patients was 
only partially sustained at week six and so suggested haem 
oxygenase induction. This further suggests a role for combined 
therapy of haem arginate with tin-protoporphyrin, a potent 
inhibitor of haem oxygenase.
Although a direct therapeutic benefit of haem arginate 
therapy in the treatment of SA was not apparent, the response 
of the haem enzymes in two of six patients indicates that haem 
arginate does enter erythroblasts and is able to influence 
enzyme activity. This may indicate a potential role for haem 
arginate in the treatment of other haematological disorders in 
the future.
Finally, this work has demonstrated that the isoenzymes of 
ALA synthase in hepatic and erythroid tissue operate under 
distinct control mechanisms. In response to exogenous haem, 
erythroid ALA synthase may be induced while conversely hepatic 
ALA synthase is inhibited under the same conditions. The 
increase of erythroid ALA synthase in response to exogenous 
haem is compatible with the earlier observation (Chapter 7) 
that erythroid ALA synthase activity is reduced by haem 
deficiency.
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CHAPTER 10 
CONCLUSIONS
CONCLUSIONS
This thesis has presented evidence supporting different 
regulatory mechanisms for haem biosynthesis in erythroid and 
hepatic tissue. This is consistent with the recent 
identification of tissue-specific isoenzymes for ALA synthase 
which are encoded for by separate genes (Sutherland et al, 
1988; Cox et al, 1990).
ALA synthase is rate-1 imiting for hepatic haem 
biosynthesis and is under negative feedback control by haem. 
In erythroid tissue, however, ALA synthase activity appears to 
be decreased in response to haem deficiency. The reduced ALA 
synthase activity that characterises SA may be increased by 
haem infusion. This work has further shown that although 
exogenous haem increases ALA synthase and ferrochelatase 
activity in certain patients with SA, this improvement did not 
lead to increased Hb concentration. The ability of exogenous 
haem to influence erythroblast haem synthesis does nevertheless 
demonstrate that haem arginate can enter developing red cells 
and indicates a potential therapeutic role for haem in the 
treatment of haematological disorders associated with reduced 
haem synthesis. These observations cast doubt over the belief 
that reduced ALA synthase activity is the primary abnormality 
which results in impaired haem synthesis in SA. Reduced ALA 
synthase activity may, in fact, be secondary to the haem 
deficiency.
The primary site(s) of regulation of erythroid haem 
synthesis has not yet been identified. This work has 
demonstrated that erythroid ALA synthase is sensitive to 
intracellular haem levels, particularly in the most immature
erythroid cells. Ferrochelatase in sideroblasts is sensitive 
to haem, but the effect of haem deficiency on ferrochelatase 
is, as yet, unknown.
Control of the haem enzymes is likely to occur at gene 
level. As with ALA synthase, different isoenzymes of PBG 
deaminase have been identified in human liver and erythroid 
tissue (Grandchamp et al, 1987). They are encoded by distinct 
tissue-specific mKNAs but, unlike ALA synthase, are transcribed 
from a single gene (Raich et al, 1986). The genes for 
erythroid and hepatic ALA synthases have been located on 
chromosome X and chromosome 3 respectively (Cox et al, 1990; 
Sutherland et al, 1988). Separate promoters of a single gene 
for PBG deaminase may account for the tissue-specific and 
tissue-nonspecific mRNA transcripts and their respectively 
encoded enzymes (Chretien et al, 1988; Mignotte et al, 1990).
Gene studies will provide clearer understanding of 
erythroid haem synthesis, in the near future, with the cloning 
of all the cDNAs and genes for the haem enzymes. Cloned cDNA 
may be expressed in microorganisms to produce large quantities 
of encoded proteins. This would allow crystallisation and 
subsequent determination of the three-dimensional structure of 
each enzyme. Site-directed mutagenesis can create mutant 
enzymes with altered properties. Analysis of such enzymes may 
then allow a better understanding of enzyme function in
relation to structure.
Determination of DNA sequences responsible for the 
transcriptional regulation of haem enzyme genes may explain 
genetic expression and regulation. The most challenging issue
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is to understand what links erythropoietic differentiation with 
increased expression of the haem enzyme genes. The mammalian 
genes are not clustered and it is therefore likely that some 
common factor(s) coregulate their expression. These factors 
and the DNA sequences that they bind have not been identified.
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APPENDICES
Appendix 1 - General Methods 
Culture Medium
Culture medium contained Eagles MEM, buffered with 20mM 
Hepes to pH 7.4 at 37°C, with glycine ImM. This was prepared 
in 500 ml aliquots; 90 ml was removed from a 500 ml bottle of 
sterile distilled water to which 50 ml Eagles MEM ( x 10 
concentrated), 10 ml Hepes (Gibco) 1M pH 7.3, 4 ml IN NaOH and 
3 ml glycine, 20 mg/ml were added.
Bone Marrow Collecting Medium
Bone marrow samples were collected into culture medium 
containing 25% (v/v) heat inactivated foetal calf serum (Gibco) 
and preservative free heparin 15 U/ml.
Bone Marrow Cell Counts
Cell counts on whole and fractionated bone marrow were 
made using a Coulter Counter Model ZF fitted with a channelyzer 
attachment.
Bone Marrow Cytospin Preparations
Bone marrow cells were washed x 3 in cold culture medium. 
Heat inactivated foetal calf serum, filtered through a 0.22 pm 
micropore filter, was added to the bone marrow cells to achieve 
a final concentration of 2 x 10^ nucleated cells per ml. 0.25 
ml was added to cytospin holders in a Shandon Southern 
cytocentrifuge. Centrifugation was at 600 rpm for 14 minutes. 
Cell morphology was optimally preserved at 5 x 104 nucleated 
cells per slide.
Staining Procedures
Morphological examination of marrow cells was made on
240
cytospin and marrow aspirate preparations stained with Jenner 
Geimsa stain. Cytochemical staining for iron or aspirated bone 
marrow material was made by Peris stain.
ALA. Sythase Assay
(i) Incubation Medium
Incubation medium used was a modification of that 
described by Tikerpae et al (1981) and contained glycine 50 mM, 
sucrose 250 mM, M g C ^  2mM, EDTA 5 mM, Tris 40 mM buffered to pH
7.4 with KH2PO4 50 mM. This was prepared in distilled H 2O 
(N.B. not deionised) in a volume of 1 litre, then stored in 
aliquots of 20 ml at -20°C. On the day of the assay PLP 0.4 
mM, CoA 1.35 mM, succinylacetone 2 mM, succinate thiokinase 
(STK) 1 unit per ml and GTP 5.0 mM were added.
(ii) Radiochemicals
Radiochemicals were purchased from Amersham International 
pic. 2-3-[^C] succinic acid was stored at -20°C in 0.21 ml 
aliquots of 20 mM succinate (specific activity 3.0 Ci/mol) in 
incubation medium.
5-amino 4-[^C] laevulinic acid hydrochloride was stored 
at -20°C in 0.05ml aliquots of 0.25 mM ALA (0.5 pCi/0.05 ml, 
specific activity 40 Ci/m mol).
Modified Ehrlichs Reagent
Modified Erhlichs reagent was prepared fresh daily by 
dissolving lg p-DMAB in 30 ml glacial acetic acid. 8 ml 70% 
perchloric acid was added and the final volume made up to 50 ml 
with glacial acetic acid (Falk, 1964).
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Statistics
Statistical analysis of results was performed using the 
Mann Whitney U test.
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Appendix 2 - Patient Details
Ethical Approval for the studies was obtained from the 
Ethical Committee of Monklands District General Hospital and 
the Western Infirmary, Glasgow.
Normoblastic Marrow
Marrow was aspirated from 15 patients with normoblastic 
erythroid hyperplasia. Hyperplasic marrow is required to 
guarantee satisfactory erythroid fractionation on the percoll 
gradients.
Ten patients had Pernicious Anaemia (PA) with Hb 
concentrations < 8g/dl. Marrow was sampled on day 5 of 
treatment with lOOOpg/day, folic acid 5mg bd and ferrous 
sulphate 200mg tds. Marrow taken on day 0 had in all cases 
shown frank megaloblastic changes. These changes are corrected 
within 48 hours of treatment and by day 5 all appearances were 
hyperplastic but normoblastic. Ferrous sulphate was given to 
prevent the fall in serum iron concentration which follows B-^ 
administration in PA. Stainable iron was demonstrated in the 
marrow reticuloendothelial cells in all cases. Transferrin 
saturation was between 25 and 54% ensuring adequate iron supply 
to erythroblasts. Reticulocyte counts on day 5 were between 18 
and 40% reflecting conversion of ineffective megaloblastic 
erythropoiesis to normoblastic and effective.
Five patients had hereditary haemolytic anaemias - three 
patients had hereditary spherocytosis, one had pyruvate kinase 
deficiency and the fifth had hereditary pyropoiklocytosis. All 
patients had active normoblastic erythropoiesis with
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reticulocyte counts greater than 15%. Haematinic levels 
B^12' ferritin) were normal in all patients.
One patient had autoimmune haemolytic anaemia. Again the 
marrow showed erythroid hyperplasia with normal haematinic 
levels.
One additional patient with autoimmune haemolytic anaemia 
is described in Chapter 6. This patient became unwell prior to 
marrow aspiration requiring treatment with prednisolone 
60mg/day. This steroid treatment started 5 days prior to 
marrow sampling. As such, the results of ALA synthase and 
ferrochelatase activities in this patient are reported 
separately.
Iron Deficient Polycythaemia (IDP)
Ten patients were studied. Eight patients had primary 
polycythaemia i.e. Polycythaemia Rubra Vera. Two patients 
had IDP secondary to chronic obstructive airways disease and 
chronic hypoxia. Serum ferritin concentrations were reduced 
( < lOng/ml) in all caess. Serum iron levels were low and TIBC 
values raised. In all cases transferrin saturation was < 10% 
and no stainable iron was evident in the marrow.
Sideroblastic Patients
Sideroblastic anaemia was established by the demonstration 
of ring sideroblasts in the bone marrow to exceed 30% of. the 
nucleated erythroid cells.
Congenital Sideroblastic Anaemia (CSA)
Three patients with hypochromic microcytic CSA have been 
studied in this work. Two of the patients were children aged 3
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and 4 years with transfusion dependent CSA. Family studies 
were not available as both children lived in England. In 
neither case, however, was there a positive family history. 
Oie child underwent spontaneous remission of his CSA and this 
remission is discussed in detail in Chapter 8.
The third patient with CSA was a 21 year old male student 
studied in Chapter 9. His anaemia was congenital and 
pyridoxine responsive. The mode of inheritance was unclear, 
but did not appear to be X-linked as no abnormal cells were 
seen in the mother (who would be an obligate carrier for an X- 
linked disorder) and five brothers were unaffected. At the 
time of study his Hb concentrations was 8.0g/dl MCV 52 fl. 
Without pyridoxine supplementation he was unable to maintain 
his Hb above 6.0g/dl and was transfusion dependent.
Secondary Sideroblastic Anaemia (SSA)
One woman (aged 24 years) with Secondary Sideroblastic 
Anaemia (SSA) was studied. This woman had Wilson's disease and 
developed sideroblastic erythropoiesis in response to treatment 
with TRIENTENE (a copper chelating agent). She had a mild (Hb 
10.5g/dl) microcytic anaemia (MCV 72f1) with adequate iron 
stores (serum ferritin 70ng/ml) and abundant ring sideroblasts 
( > 30%) in her marrow.
Primary Acquired Sideroblastic Anaemia (PASA)
Eight patients had primary acquired sideroblastic anaemia 
(PASA). Seven patients were long established cases, each of 
more than 3 years duration. These seven cases were all 
significantly anaemic (Hb < 10g/dl). One patient was 
transfusion dependent while the other six were not. All cases
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showed gross erythroid hyperplasia, dyserythropoiesis and > 80% 
ring sideroblasts. One patient was studied within 3 months of 
diagnosis. His Hb was slightly reduced (13.0g/dl) but his 
marrow showed abundant ring sideroblast formation ( > 75%).
Cytogenetic studies were carried out on the six patients 
treated with haem arginate (Chapter 9). All cases showed a 
normal male karyotype. In two patients random loss of 
individual chromosomes was noted.
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